{"PMC7538382": [], "0da30325190e191b9888ad2660f4de0a24fc7053": [["In the case of COVID-19, no previous pandemic had 3 such a big universal impact on societies in the modern history, as a results historic data lacked key 4 information on how people react to such a universal pandemic and how the virus impacts 5 economies and societies.", [["people", "ORGANISM", 175, 181], ["people", "SPECIES", 175, 181], ["COVID", "TEST", 15, 20], ["previous pandemic", "PROBLEM", 28, 45], ["a universal pandemic", "PROBLEM", 196, 216]]], ["Thanks to the technology, we now have an enormous amount of observed 7 data collected by mobile devices amid pandemic.", [["enormous", "OBSERVATION_MODIFIER", 41, 49], ["amount", "OBSERVATION_MODIFIER", 50, 56]]], ["Our research team 10 has utilized a national set of privacy-protected mobile device location data and produced a COVID-11INTRODUCTION19 Impact Analysis Platform to provide comprehensive data and insights on COVID-19's impact 12 on mobility, economy, and society.", [["comprehensive data", "TEST", 172, 190], ["COVID", "TEST", 207, 212]]], ["13 14INTRODUCTIONMobile device location data are becoming popular for studying human behavior, specially mobility 15INTRODUCTIONbehavior.", [["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84]]], ["Earlier studies with mobile device location data were mainly using GPS technology, 16 which is capable of recording accurate information including, location, time, speed, and possibly 17 a measure of data quality 1 .", [["Earlier studies", "TEST", 0, 15], ["GPS technology", "TEST", 67, 81]]], ["Other emerging mobile device 19INTRODUCTIONlocation data sources such as call detail record (CDR) 5-7 , Cellular network data 8 , and social media 20 location-based services 9-13 have also been used by the researchers to study mobility behavior.", [["Cellular network data", "TEST", 104, 125]]], ["Many companies such as Google, Apple, or Cuebiq have already utilized 23 location data to produce valuable information about mobility and economic trends 14-16 .", [["economic trends", "TEST", 138, 153]]], ["24 Researchers have also utilized mobile device location data for studying COVID-19-related 25 behavior 17,18 .", [["COVID-19", "DNA", 75, 83], ["studying COVID", "TEST", 66, 80]]], ["26 27INTRODUCTIONNon-pharmaceutical interventions such as social distancing are important and effective tools for 28 preventing virus spread.", [["27INTRODUCTIONNon-pharmaceutical interventions", "TREATMENT", 3, 49]]], ["One of the most recent studies projected that the recurrent outbreaks might 29 be observed this winter based on pharmaceutical estimates on COVID-19 and other coronaviruses, 30 so prolonged or intermittent social distancing may be required until 2022 without any interventions 31 19 , highlighting the importance of improving our understanding about individual's reaction to 32 social distancing.", [["coronaviruses", "ORGANISM", 159, 172], ["the recurrent outbreaks", "PROBLEM", 46, 69], ["COVID", "TEST", 140, 145], ["other coronaviruses", "PROBLEM", 153, 172], ["individual's reaction", "PROBLEM", 350, 371]]], ["Our current platform utilizes 35 mobile device location data to provide observed data and evidence on social distancing behavior 36 and the impact of COVID-19 on mobility.", [["COVID", "TREATMENT", 150, 155]]], ["We used daily feeds of mobile device location data, 37INTRODUCTIONrepresenting movements of more than 100 Million anonymized devices, integrated with COVID-38 19 case data from John Hopkins University and census population data to monitor the mobility 39 trends in United States and study social distancing behavior 24 .", [["daily feeds", "TREATMENT", 8, 19], ["mobile device", "TREATMENT", 23, 36]]], ["No reuse allowed without permission.INTRODUCTIONwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 120, 123]]], ["1 2 The research team first integrated and cleaned location data from multiple sources representing 3 person and vehicle movements in order to improve the quality of our mobile device location data 4 panel.", [["person", "SPECIES", 102, 108]]], ["We then clustered the location points into activity locations and identified home and work 5 locations at the census block group (CBG) level to protect privacy.", [["CBG", "TEST", 130, 133], ["activity", "OBSERVATION_MODIFIER", 43, 51]]], ["Next, we applied previously developed and validated 8 algorithms 25 to identify all trips from the cleaned data panel, including trip origin, destination, 9 departure time, and arrival time.", [["the cleaned data panel", "TEST", 95, 117]]], ["Additional steps were taken to impute missing trip information 10 for each trip, such as trip purpose (e.g., work, non-work), point-of-interest visited (restaurants, 11METHODOLOGYshops, etc.), travel mode (air, rail, bus, driving, biking, walking, and others), trip distance (airline 12 and actual distance), and socio-demographics of the travelers (income, age, gender, race, etc.) 13 using advanced artificial intelligence and machine learning algorithms.", [["advanced artificial intelligence", "TREATMENT", 392, 424], ["machine learning algorithms", "TREATMENT", 429, 456]]], ["A multi-level weighting procedure expanded the 16 sample to the entire population, using device-level and trip-level weights, so the results are 17METHODOLOGYrepresentative of the entire population in a nation, state, or county.", [["A multi-level weighting procedure", "TREATMENT", 0, 33], ["device", "TEST", 89, 95], ["trip-level weights", "TEST", 106, 124]]], ["The data sources and 18 computational algorithms have been validated based on a variety of independent datasets such as 19METHODOLOGYthe National Household Travel Survey and American Community Survey, and peer reviewed by 20 an external expert panel in a U.S. Department of Transportation Federal Highway Administration's 21METHODOLOGYExploratory Advanced Research Program project, titled \"Data analytics and modeling methods for 22METHODOLOGYtracking and predicting origin-destination travel trends based on mobile device data\" 25 .", [["computational algorithms", "TEST", 24, 48], ["mobile device data", "TEST", 509, 527]]], ["Mobility 23 metrics were then integrated with COVID-19 case data, population data, and other data sources.", [["COVID", "TEST", 46, 51], ["population data", "TEST", 66, 81]]], ["No reuse allowed without permission.METHODOLOGYwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.METHODOLOGYThe copyright holder for this preprint (which this version posted May 5, 2020.", [["med", "ANATOMY", 119, 122]]], ["Trips are the unit of analysis for almost all transportation applications.", [["analysis", "TEST", 22, 30]]], ["Location sightings can be continuously recorded 6 while a device moves, stops, stays static, or starts a new trip.", [["a device moves", "TREATMENT", 56, 70]]], ["Pre-Processing 13 14METHODOLOGYFirst, all device observations are sorted by time.", [["all device observations", "TREATMENT", 38, 61]]], ["19 20METHODOLOGYThe trip identification algorithm has three hyper-parameters: distance threshold, time threshold, 21 and speed threshold.", [["distance threshold", "TEST", 78, 96]]], ["This algorithm checks every point to identify if they belong to the same trip as their previous point.", [["This algorithm checks", "TEST", 0, 21]]], ["If a device is seen 35 in a point with \u2265 \u210e \u210e but is not observed to move there 36 ( < \u210e \u210e ), the point does not belong to the same trip as its previous point.", [["a device", "TREATMENT", 3, 11]]], ["37METHODOLOGYWhen the device is on the move at a point ( \u2265 \u210e \u210e ), the point belongs to 38 the same trip as its previous point; but when the device stops, the algorithm checks the radius and 39 dwell time to identify if the previous trip has ended.", [["the device", "TREATMENT", 18, 28], ["the device", "TREATMENT", 136, 146], ["the algorithm checks", "TEST", 154, 174]]], ["If the device stays at the stop (points should 40 be closer than the distance threshold) for a period of time shorter than the time threshold, the points 41 still belong to the previous trip.", [["the device", "TREATMENT", 3, 13]]], ["When the dwell time reaches above the time threshold, the trip 42 ends, and the next points no longer belong to the same trip.", [["trip 42 ends", "DNA", 58, 70]]], ["44METHODOLOGYThe algorithm may identify a local movement as a trip if the device moves within a stay location.", [["the device", "TREATMENT", 70, 80]]], ["No reuse allowed without permission.METHODOLOGYwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 119, 122]]], ["To filter out such trips, all trips that are within a static cluster and all trips that are shorter than 300 1 meters are removed.", [["such trips", "TREATMENT", 14, 24], ["all trips", "TREATMENT", 26, 35], ["all trips", "TREATMENT", 73, 82], ["filter", "OBSERVATION", 3, 9]]], ["We first identify all activity points. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.METHODOLOGYThe copyright holder for this preprint (which this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.29.20085472 doi: medRxiv preprint non-static clusters based on time and speed checks.", [["speed checks", "TEST", 363, 375], ["med", "ANATOMY", 111, 114]]], ["Home and work CBG Identification 7 8 Figure 5 shows the methodology for home and work CBG identification.", [["CBG", "GENE_OR_GENE_PRODUCT", 86, 89], ["work CBG Identification", "TEST", 9, 32], ["work CBG identification", "TEST", 81, 104]]], ["Instead of setting a fixed 9 time period for each type, e.g., 8pm to 8am as the study period for home CBG identification and 10 the other half day for work CBG identification, the framework examines both temporal and spatial 11METHODOLOGYfeatures for the entire activity location list.", [["the study", "TEST", 76, 85], ["home CBG identification", "TEST", 97, 120], ["work CBG identification", "TEST", 151, 174]]], ["The benefits are two-fold: the results for workers with 12 flexible or opposite work schedules would be more accurate and the employment type for each 13 device could be detected simultaneously.", [["opposite work schedules", "TREATMENT", 71, 94], ["each 13 device", "TREATMENT", 146, 160]]], ["Figure 6 shows the validation of home and work location 14 imputations, by comparing the distance from home to work between longitudinal employer-15 household dynamics (LEHD) data and the imputed locations for a set of mobile device location 16 data for the Baltimore metropolitan area.", [["mobile device location", "TREATMENT", 219, 241]]], ["Home/work CBG imputation methodology 20 21 All rights reserved.", [["methodology", "TEST", 25, 36]]], ["No reuse allowed without permission.METHODOLOGYwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.METHODOLOGYThe copyright holder for this preprint (which this version posted May 5, 2020. to be able to make sufficient generalizations using a multi-layer DNN and capture the exceptions 10 using the wide single-layer model.", [["multi-layer DNN", "CELL_LINE", 319, 334], ["a multi-layer DNN", "TREATMENT", 317, 334], ["the wide single-layer model", "TREATMENT", 371, 398], ["med", "ANATOMY", 119, 122]]], ["The datasets used for training the model were collected from 11 the incenTrip mobile phone app 28 , developed by the authors, where the ground truth information 12 for car, bus, rail, bike, walk, and air trips was collected.", [["training the model", "TEST", 22, 40], ["air trips", "TREATMENT", 200, 209]]], ["Travel mode-specific 14 knowledge is needed to improve the detection accuracy.", [["the detection accuracy", "TEST", 55, 77]]], ["The wide and deep learning method utilized 18 in this study achieved over 95% prediction accuracy for drive, rail, air, and non-motorized, and 19 over 90% for bus modes on test data.", [["this study", "TEST", 49, 59], ["bus modes on test data", "TEST", 159, 181], ["wide", "OBSERVATION_MODIFIER", 4, 8], ["deep", "ANATOMY_MODIFIER", 13, 17], ["air", "ANATOMY", 115, 118]]], ["We have applied the trained algorithms on the location dataset 20 to obtain multimodal trip rosters (see Figure 7 that shows raw location data points by different 21 travel modesLEHD Mobile DeviceAll rights reserved.", [["multimodal trip rosters", "TREATMENT", 76, 99], ["Mobile DeviceAll rights", "TREATMENT", 183, 206]]], ["No reuse allowed without permission.LEHD Mobile Devicewas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.LEHD Mobile DeviceThe copyright holder for this preprint (which this version posted May 5, 2020.", [["Mobile Device", "TREATMENT", 187, 200], ["The copyright holder", "TREATMENT", 200, 220], ["med", "ANATOMY", 126, 129], ["Mobile Device", "OBSERVATION", 187, 200]]], ["In the Home and work CBG Identification, we described how home and work CBGs can be 6LEHD Mobile Deviceidentified.", [["CBG Identification", "TEST", 21, 39]]], ["We have used a popular commercial POI dataset that includes more 8 than forty million records for the U.S. For each trip end, we first filter all POIs that are located 9 within a 200-meter radius of the trip-end.", [["trip-end", "DNA", 203, 211], ["a popular commercial POI dataset", "TREATMENT", 13, 45], ["first filter all POIs", "TREATMENT", 129, 150], ["filter", "OBSERVATION", 135, 141]]], ["Next, we identify the trip purpose by the POI type of the 10 closest POI.", [["POI", "DISEASE", 69, 72]]], ["The state-of-the-practice method is to assign 17 either the census population socio-demographic distribution or the public use microdata sample 18 (PUMS) units to the sample devices within the same geographic area based on the imputed home 19LEHD Mobile Devicelocations.", [["the sample devices", "TREATMENT", 163, 181]]], ["In 22 order to balance the computations and conduct a timely analysis for the pandemic, we have used 23 the state-of-the-practice method and assigned socio-demographic information to the anonymized 24 devices based on the census socio-demographic distribution of their imputed CBG.", [["CBG", "GENE_OR_GENE_PRODUCT", 277, 280], ["a timely analysis", "TEST", 52, 69], ["the anonymized 24 devices", "TREATMENT", 183, 208], ["their imputed CBG", "TEST", 263, 280]]], ["Five-year 25LEHD Mobile DeviceAmerican Community Survey (ACS) estimates for 2014 to 2018 from the U.S. Census Bureau can 26 be used to obtain median income, age distribution, gender distribution, and race distribution for 27 each U.S. CBG 29 .", [["CBG", "TEST", 235, 238]]], ["For each device, we used Monte-Carlo simulation 30 to draw from the age, 28 gender, and race distribution at the device's imputed home CBG.", [["each device", "TREATMENT", 4, 15], ["Monte-Carlo simulation", "TREATMENT", 25, 47], ["home CBG", "TEST", 130, 138]]], ["We also assigned the CBG's 1 median income to the device.", [["the CBG", "TEST", 17, 24], ["the device", "TREATMENT", 46, 56]]], ["Weighting 4 5LEHD Mobile DeviceThe sample data needs to be weighted to represent population-level statistics.", [["Weighting", "TEST", 0, 9], ["Mobile Device", "TREATMENT", 18, 31], ["The sample data", "TEST", 31, 46]]], ["First, the devices 6 available in our dataset are a sample of all individuals in the population, so we need to apply 7 device-level weights.", [["the devices", "TREATMENT", 7, 18], ["7 device-level weights", "TREATMENT", 117, 139]]], ["Second, for an observed device, only a sample of all trips may be recorded, 8 so trip-level weights are also needed.", [["an observed device", "TREATMENT", 12, 30]]], ["For the sake of timeliness, we have applied simple weighting 9 methods to obtain county-level device weights and state-level trip weights.", [["simple weighting 9 methods", "TREATMENT", 44, 70], ["level device weights", "TREATMENT", 88, 108]]], ["In order to obtain 10 device-level weights, we have used the home county, obtained from the imputed home CBG 11LEHD Mobile Deviceinformation. research findings available to other researchers, agencies, non-profits, media, and the general 28 public.", [["research findings", "TEST", 142, 159]]], ["The platform will evolve and expand over time as new data and impact metrics are 29 computed and additional visualizations are developed.", [["impact metrics", "TEST", 62, 76]]], ["No reuse allowed without permission.LEHD Mobile Devicewas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.LEHD Mobile DeviceThe copyright holder for this preprint (which this version posted May 5, 2020.", [["Mobile Device", "TREATMENT", 187, 200], ["The copyright holder", "TREATMENT", 200, 220], ["med", "ANATOMY", 126, 129], ["Mobile Device", "OBSERVATION", 187, 200]]], ["The Integrated dataset compiled by our research team shows how the nation and different states 6 and counties are impacted by the COVID-19 and how the communities are conforming with the 7 social distancing and stay-at-home orders issued to prevent the spread of the virus.", [["the virus", "PROBLEM", 263, 272]]], ["The platform 8 utilizes privacy-protected anonymized mobile device location data integrated with healthcare 9 system data and population data to assign a social distancing score to each state and county based 10 on derived information such as percentage of people who are staying home, average number of 11 trips per person and average distance traveled by each person.", [["people", "ORGANISM", 257, 263], ["people", "SPECIES", 257, 263], ["person", "SPECIES", 317, 323], ["person", "SPECIES", 362, 368]]], ["As the next steps, the research team 12 is integrating socio-demographic and economic data into the platform to study the multifaceted 13LEHD Mobile Deviceimpact of COVID-19 on our mobility, health, economy, and society.", [["COVID", "TEST", 165, 170]]], ["No reuse allowed without permission.LEHD Mobile Devicewas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.LEHD Mobile DeviceThe copyright holder for this preprint (which this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.29.20085472 doi: medRxiv preprint", [["Mobile Device", "TREATMENT", 187, 200], ["The copyright holder", "TREATMENT", 200, 220], ["medRxiv", "TREATMENT", 330, 337], ["med", "ANATOMY", 126, 129], ["Mobile Device", "OBSERVATION", 187, 200]]]], "PMC7189005": [["Allergen-Immuntherapie (AIT)Die Allergen-Immuntherapie (AIT) ist die einzige urs\u00e4chlich wirksame Therapie, f\u00fcr die ein langfristiger klinischer Nutzen bei allergischen Atemwegserkrankungen, zum Beispiel bei allergischem Asthma bronchiale oder allergischer Rhinokonjunktivitis und anderen allergischen Erkrankungen, gezeigt werden konnte [1].", [["Allergen-Immuntherapie (AIT)Die Allergen-Immuntherapie (AIT) ist die einzige urs\u00e4chlich wirksame Therapie, f\u00fcr die ein langfristiger klinischer Nutzen bei allergischen Atemwegserkrankungen, zum Beispiel bei allergischem Asthma bronchiale oder allergischer Rhinokonjunktivitis und anderen allergischen Erkrankungen, gezeigt werden konnte", "SPECIES", 0, 336], ["Allergen-Immuntherapie (AIT)", "TREATMENT", 0, 28], ["Asthma", "PROBLEM", 220, 226], ["Rhinokonjunktivitis", "PROBLEM", 256, 275]]], ["Seit ihrer Erstbeschreibung vor \u00fcber einhundert Jahren (1911 [2]) ist die AIT ein etabliertes und international anerkanntes Verfahren zur Behandlung von allergischen Soforttypreaktionen (Typ-I-Allergie) und assoziierten Erkrankungen.Allergen-Immuntherapie (AIT)Die AIT induziert eine Immuntoleranz gegen ein spezifisches, individuell relevantes Allergen [3].", [["Seit ihrer Erstbeschreibung vor \u00fcber einhundert Jahren (1911 [2]) ist die AIT ein etabliertes und international anerkanntes Verfahren zur Behandlung von allergischen Soforttypreaktionen (Typ-I-Allergie) und assoziierten Erkrankungen", "SPECIES", 0, 232], ["Soforttypreaktionen (Typ-I-Allergie)", "TREATMENT", 166, 202], ["Allergen-Immuntherapie (AIT", "TREATMENT", 233, 260]]], ["Systematische Metaanalysen haben best\u00e4tigt, dass die AIT Symptome der allergischen Erkrankung und die Menge notwendiger antisymptomatischer Medikamente bei Patienten mit allergischem Asthma [4] und allergischer Rhinokonjunktivitis [5] signifikant reduziert.Allergen-Immuntherapie (AIT)Dies gilt sowohl f\u00fcr die subkutane Immuntherapie (SCIT) [6, 7] als auch f\u00fcr die sublinguale Immuntherapie (SLIT) [8].Allergen-Immuntherapie (AIT)Das Risiko von Patienten mit allergischer Rhinitis, ein Asthma zu entwickeln, wird durch eine AIT reduziert [9, 10].", [["Rhinitis", "DISEASE", 472, 480], ["Systematische", "TREATMENT", 0, 13], ["Asthma", "PROBLEM", 183, 189], ["Allergen-Immuntherapie (AIT)", "TREATMENT", 257, 285], ["Rhinitis", "PROBLEM", 472, 480], ["ein Asthma", "PROBLEM", 482, 492]]], ["Die AIT ist auch bei Patienten mit einer IgE-vermittelten Nahrungsmittelallergie [11, 12] und Insektengiftallergie [13] wirksam.", [["IgE", "PROTEIN", 41, 44], ["Die AIT ist auch bei Patienten mit einer IgE-vermittelten Nahrungsmittelallergie", "SPECIES", 0, 80]]], ["Zudem wurde der kosteneinsparende Effekt dieser krankheitsmodifizierenden Therapieoption [14, 15, 16] gezeigt.Allergen-Immuntherapie (AIT)Wissenschaftliche Studien \u00fcber den Zusammenhang zwischen allergischen Atemwegserkrankungen und viralen Atemwegsinfektionen zeigen uneinheitliche Ergebnisse; \u00fcber Einfl\u00fcsse von AIT auf respiratorische Virusinfektionen und umgekehrt ist wenig bekannt [17].Allergen-Immuntherapie (AIT)In einer prospektiven und vergleichenden klinischen Studie fanden Ahmetaji et al. keinen signifikanten Unterschied in der Wirksamkeit oder in der Verbesserung der Symptome allergischer Asthmapatienten unter SCIT mit oder ohne Influenza-\u00e4hnlichen Virusinfektionen.", [["Zudem wurde der kosteneinsparende Effekt dieser krankheitsmodifizierenden Therapieoption", "SPECIES", 0, 88], ["\u00fcber den Zusammenhang zwischen allergischen Atemwegserkrankungen und viralen Atemwegsinfektionen zeigen uneinheitliche Ergebnisse; \u00fcber Einfl\u00fcsse von AIT auf respiratorische Virusinfektionen und umgekehrt ist wenig bekannt", "SPECIES", 164, 386], ["Allergen", "TEST", 110, 118], ["Immuntherapie (AIT", "TREATMENT", 119, 137], ["Wissenschaftliche", "TREATMENT", 138, 155], ["Studien", "TEST", 156, 163], ["allergischen Atemwegserkrankungen", "TREATMENT", 195, 228], ["Influenza", "PROBLEM", 646, 655], ["\u00e4hnlichen Virusinfektionen", "TREATMENT", 656, 682]]], ["Auch die laborchemischen und h\u00e4matologischen Standardparameter und verschiedenen Zytokine w\u00e4hrend der Behandlung und einer einj\u00e4hrigen Nachbeobachtung nach SCIT waren nicht unterschiedlich [18].", [["Auch die laborchemischen", "TREATMENT", 0, 24], ["Standardparameter", "TREATMENT", 45, 62], ["Zytokine", "TREATMENT", 81, 89]]], ["Diese vorl\u00e4ufigen Daten deuten darauf hin, dass eine SCIT bei Influenza-infizierten Patienten sicher und gut vertr\u00e4glich ist.Allergen-Immuntherapie (AIT)Iemoli et al. untersuchten die Sicherheit und klinische Wirksamkeit einer sublingualen Grastabletten-Immuntherapie bei einer Gruppe von HIV-positiven Patienten mit allergischer Rhinitis unter antiretroviraler Therapie.", [["Rhinitis", "DISEASE", 330, 338], ["Sicherheit und klinische Wirksamkeit einer sublingualen Grastabletten-Immuntherapie bei einer Gruppe von HIV-positiven Patienten mit allergischer Rhinitis unter antiretroviraler Therapie", "SPECIES", 184, 370], ["Grastabletten", "TEST", 240, 253], ["Rhinitis", "PROBLEM", 330, 338], ["antiretroviraler Therapie", "TREATMENT", 345, 370]]], ["Die HIV-Infektion wurde als relative Kontraindikation f\u00fcr die AIT angesehen.", [["Die HIV-Infektion wurde als relative Kontraindikation f\u00fcr die AIT angesehen", "SPECIES", 0, 75]]], ["Eine hochaktive antiretrovirale Behandlung hat die Immunfunktion und die Lebenserwartung bei HIV-infizierten Patienten inzwischen aber so verbessert, dass ein Therapieversuch vertretbar erscheint, zumal die Inzidenz allergischer Atemwegserkrankungen bei HIV-Infizierten mit jener der Allgemeinbev\u00f6lkerung vergleichbar ist [19].", [["Eine hochaktive antiretrovirale Behandlung hat die Immunfunktion und die Lebenserwartung bei HIV-infizierten Patienten inzwischen aber so verbessert, dass ein Therapieversuch vertretbar erscheint, zumal die Inzidenz allergischer Atemwegserkrankungen bei HIV-Infizierten mit jener der Allgemeinbev\u00f6lkerung vergleichbar ist [19", "SPECIES", 0, 325]]], ["Die Daten zur klinischen Wirksamkeit zeigten bei den SLIT-behandelten Patienten im Vergleich zu den Kontrollen eine signifikante Verbesserung, aber keine wesentliche Ver\u00e4nderung in der Zahl peripherer CD4-positiver T-Zellen (CD4, \"cluster of differentiation 4\"; Glykoprotein an der Oberfl\u00e4che von Zellen des Immunsystems) und der HIV-Viruslast in beiden Gruppen.", [["CD4", "PROTEIN", 201, 204], ["CD4", "PROTEIN", 225, 228], ["Die Daten zur klinischen Wirksamkeit zeigten bei den SLIT-behandelten Patienten im Vergleich zu den Kontrollen eine signifikante Verbesserung", "SPECIES", 0, 141], ["CD4", "TEST", 201, 204], ["T", "TEST", 215, 216], ["Zellen", "PROBLEM", 217, 223], ["Glykoprotein an der Oberfl\u00e4che von Zellen des Immunsystems", "TREATMENT", 262, 320]]], ["Diese Daten zeigen, dass die SLIT-Therapie bei viro-immunologisch kontrollierten HIV-positiven Patienten wirksam, sicher und gut vertr\u00e4glich sein kann.Allergen-Immuntherapie (AIT)Es konnte zudem gezeigt werden, dass Zytomegalieviren (CMV) das allergene Potenzial von ansonsten schwach allergenen Umweltallergenen in einem Atemwegsepithel-Mausmodell bei Koexposition gegen\u00fcber CMV und Ovalbumin (OVA) verst\u00e4rken [20].Allergen-Immuntherapie (AIT)Im Gegensatz dazu k\u00f6nnen virus\u00e4hnliche Partikel (VLPs) als moderne Impfplattformen in naher Zukunft sogar als AIT f\u00fcr Inhalations- und Nahrungsmittelallergene (Erdnuss) eingesetzt werden [21, 22].Coronavirus disease 2019 (Covid-19)Die Weltgesundheitsorganisation (WHO) erkl\u00e4rte am 11.", [["Coronavirus disease", "DISEASE", 640, 659], ["CMV", "ORGANISM", 234, 237], ["Diese Daten zeigen, dass die SLIT-Therapie bei viro-immunologisch kontrollierten HIV-positiven Patienten wirksam, sicher und gut vertr\u00e4glich sein kann", "SPECIES", 0, 150], ["einem Atemwegsepithel-Mausmodell bei Koexposition gegen\u00fcber CMV und Ovalbumin (OVA) verst\u00e4rken", "SPECIES", 316, 410], ["Coronavirus disease 2019 (Covid-19)Die Weltgesundheitsorganisation (WHO) erkl\u00e4rte am 11", "SPECIES", 640, 727], ["Allergen-Immuntherapie (AIT)", "TREATMENT", 151, 179], ["Es konnte zudem gezeigt", "TREATMENT", 179, 202], ["dass Zytomegalieviren (CMV)", "TREATMENT", 211, 238], ["Potenzial von ansonsten schwach", "TREATMENT", 253, 284], ["Umweltallergenen in einem Atemwegsepithel", "TREATMENT", 296, 337], ["Mausmodell bei Koexposition", "TREATMENT", 338, 365], ["CMV und Ovalbumin (OVA)", "TREATMENT", 376, 399], ["Allergen", "TEST", 416, 424], ["Immuntherapie (AIT", "TREATMENT", 425, 443], ["Im Gegensatz dazu k\u00f6nnen virus\u00e4hnliche Partikel (VLPs) als moderne Impfplattformen", "TREATMENT", 444, 526], ["Zukunft sogar als AIT", "TREATMENT", 536, 557], ["Inhalations- und Nahrungsmittelallergene (Erdnuss)", "TREATMENT", 562, 612], ["Coronavirus disease", "PROBLEM", 640, 659], ["Covid", "TEST", 666, 671]]], ["M\u00e4rz 2020 die Pandemie einer Infektionskrankheit, die k\u00fcrzlich als \"Coronavirus-Krankheit 2019\" (Covid-19) definiert wurde.", [["Coronavirus", "PROBLEM", 68, 79], ["Covid", "TEST", 97, 102]]], ["Gegenw\u00e4rtig breitet sich Covid-19 pandemisch \u00fcber den Globus aus.", [["Gegenw\u00e4rtig", "TEST", 0, 11], ["Covid", "TEST", 25, 30], ["Globus aus", "OBSERVATION", 54, 64]]], ["Covid-19 wird durch einen neuartigen Stamm menschlicher Coronaviren verursacht, der vom Internationalen Komitee f\u00fcr die Taxonomie von Viren (ICTV) als SARS-CoV-2 (\"severe acute respiratory syndrome coronavirus 2\") benannt wurde.", [["acute respiratory syndrome coronavirus", "DISEASE", 171, 209], ["der vom Internationalen Komitee f\u00fcr die Taxonomie von Viren (ICTV) als SARS-CoV-2 (\"severe acute respiratory syndrome coronavirus", "SPECIES", 80, 209], ["Covid", "TEST", 0, 5], ["wird durch einen neuartigen", "TREATMENT", 9, 36], ["Coronaviren verursacht", "TREATMENT", 56, 78], ["als SARS", "PROBLEM", 147, 155], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 164, 209], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["respiratory syndrome", "OBSERVATION", 177, 197]]], ["SARS-CoV-2 wurde erstmals bei einer Gruppe von Patienten mit Lungenentz\u00fcndung im Dezember 2019 in Wuhan, China entdeckt und identifiziert [23, 24].", [["SARS", "DISEASE", 0, 4]]], ["SARS-CoV-2 ist ein Betacoronavirus der Untergattung Sarbecovirus und der Unterfamilie Orthocoronavirinae.", [["SARS", "DISEASE", 0, 4], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8]]], ["Es kann aus menschlichen Proben isoliert werden, die aus Atemwegssekreten, Nasen- und Rachenabstrichen gewonnen und anschlie\u00dfend aus Zellkulturen isoliert werden [23, 24].", [["Nasen- und Rachenabstrichen gewonnen", "TREATMENT", 75, 111]]], ["SARS-CoV-2 ist das siebente Mitglied der Familie der Coronaviridae, das den Menschen infizieren kann.", [["SARS", "DISEASE", 0, 4]]], ["Es ist umh\u00fcllt von einer Lipidmembran, die durch Detergenzien zerst\u00f6rt werden kann und unterscheidet sich vom Coronavirus des Mittleren Ostens (MERS-CoV), vom Coronavirus des schweren akuten Atemwegssyndroms (SARS-CoV) und von den f\u00fcr die Erk\u00e4ltung verantwortlichen Viren (229E, OC43, NL63 und HKU1) [25].", [["SARS-CoV)", "DISEASE", 209, 218], ["Es ist umh\u00fcllt von einer Lipidmembran, die durch Detergenzien zerst\u00f6rt werden kann und unterscheidet sich vom Coronavirus des Mittleren Ostens (MERS-CoV", "SPECIES", 0, 152], ["Coronavirus des schweren akuten Atemwegssyndroms (SARS-CoV) und von den f\u00fcr die Erk\u00e4ltung verantwortlichen Viren (229E, OC43, NL63 und HKU1)", "SPECIES", 159, 299], ["zerst\u00f6rt", "TREATMENT", 62, 70], ["sich", "PROBLEM", 101, 105], ["Coronavirus des Mittleren Ostens", "PROBLEM", 110, 142], ["vom Coronavirus des", "PROBLEM", 155, 174], ["akuten Atemwegssyndroms", "PROBLEM", 184, 207], ["Viren", "TEST", 266, 271], ["OC43", "TEST", 279, 283]]], ["Coronaviren sind zoonotisch, das hei\u00dft, sie werden zwischen Tier und Mensch \u00fcbertragen.Coronavirus disease 2019 (Covid-19)Covid-19 Infektionen k\u00f6nnen klinisch asymptomatisch verlaufen, leichte Erkrankungen mit oder ohne Lungenbeteiligung bis hin zu schwersten Formen von Pneumonie und Multiorganversagen verursachen [26].Coronavirus disease 2019 (Covid-19)H\u00e4ufige Symptome von Covid-19-Infektionen sind Fieber, Husten, Kurzatmigkeit und Atembeschwerden sowie Riech- und Schmeckst\u00f6rungen.", [["Coronavirus disease", "DISEASE", 87, 106], ["Coronavirus disease", "DISEASE", 321, 340], ["Coronavirus disease 2019 (Covid-19)Covid-19 Infektionen k\u00f6nnen klinisch asymptomatisch verlaufen, leichte Erkrankungen mit oder ohne Lungenbeteiligung bis hin zu schwersten Formen von Pneumonie und Multiorganversagen verursachen", "SPECIES", 87, 315], ["Coronavirus disease 2019 (Covid-19)H\u00e4ufige Symptome von Covid-19-Infektionen sind Fieber, Husten, Kurzatmigkeit und Atembeschwerden sowie Riech- und Schmeckst\u00f6rungen", "SPECIES", 321, 486], ["Coronavirus disease", "PROBLEM", 87, 106], ["Covid", "TEST", 113, 118], ["Covid", "TEST", 122, 127], ["Infektionen", "TEST", 131, 142], ["k\u00f6nnen", "TEST", 143, 149], ["klinisch", "TEST", 150, 158], ["asymptomatisch", "TEST", 159, 173], ["verlaufen", "TEST", 174, 183], ["Coronavirus disease", "PROBLEM", 321, 340], ["Covid", "TEST", 347, 352], ["Covid", "TEST", 377, 382]]], ["Weitere Anzeichen einer viralen Atemwegsinfektion k\u00f6nnen nasale Symptome und Halsschmerzen sein.", [["Anzeichen einer viralen Atemwegsinfektion k\u00f6nnen nasale Symptome und Halsschmerzen sein", "SPECIES", 8, 95], ["Anzeichen einer viralen", "TREATMENT", 8, 31]]], ["In schwereren F\u00e4llen kann eine Infektion mit Covid-19 zu Pneumonie, schwerem akuten Atemwegssyndrom, Nierenversagen und zum Tod f\u00fchren [26, 27, 28, 29, 30].", [["schwereren F\u00e4llen kann eine Infektion mit Covid-19 zu Pneumonie, schwerem akuten Atemwegssyndrom, Nierenversagen und zum Tod f\u00fchren", "SPECIES", 3, 134], ["Covid", "TEST", 45, 50]]], ["In der ver\u00f6ffentlichten wissenschaftlichen Literatur zu Covid-19 werden h\u00f6heres Alter und Komorbidit\u00e4ten wie chronische Atemwegserkrankungen, Diabetes mellitus, koronare Herzkrankheit und Immunschw\u00e4che unterschiedlichen Ursprungs als Risikofaktoren f\u00fcr einen schweren Verlauf, Krankenhausaufenthalte, Intubationspflicht und Tod aufgef\u00fchrt [26, 27, 28, 30].Coronavirus disease 2019 (Covid-19)Prinzipiell kann bei jeder viralen Atemwegserkrankung eine Asthmaexazerbation ausgel\u00f6st werden.", [["Diabetes mellitus", "DISEASE", 142, 159], ["Coronavirus disease", "DISEASE", 356, 375], ["der ver\u00f6ffentlichten wissenschaftlichen Literatur zu Covid-19 werden h\u00f6heres Alter und Komorbidit\u00e4ten wie chronische Atemwegserkrankungen, Diabetes mellitus, koronare Herzkrankheit und Immunschw\u00e4che unterschiedlichen Ursprungs als Risikofaktoren f\u00fcr einen schweren Verlauf, Krankenhausaufenthalte, Intubationspflicht und Tod aufgef\u00fchrt", "SPECIES", 3, 338], ["Coronavirus disease 2019 (Covid-19", "SPECIES", 356, 390], ["Diabetes mellitus", "PROBLEM", 142, 159], ["koronare Herzkrankheit", "PROBLEM", 161, 183], ["Coronavirus disease", "PROBLEM", 356, 375], ["Covid", "TEST", 382, 387], ["Prinzipiell", "TREATMENT", 391, 402]]], ["Kindern und Erwachsenen mit Asthma bronchiale wird angesichts der aktuellen SARS-CoV-2-Infektionsgefahr empfohlen, ihre verordnete Dauertherapie mit inhalativen Glukokortikoiden konsequent durchzuf\u00fchren, um eine m\u00f6glichst optimale Asthmakontrolle zu erhalten beziehungsweise zu erreichen.", [["Asthma bronchiale wird angesichts der aktuellen SARS-CoV-2-Infektionsgefahr empfohlen, ihre verordnete Dauertherapie mit inhalativen Glukokortikoiden konsequent durchzuf\u00fchren, um eine m\u00f6glichst optimale Asthmakontrolle zu erhalten beziehungsweise zu erreichen", "SPECIES", 28, 287], ["Asthma", "PROBLEM", 28, 34], ["bronchiale wird angesichts", "PROBLEM", 35, 61], ["CoV", "TEST", 81, 84], ["Infektionsgefahr empfohlen", "TREATMENT", 87, 113]]], ["Laufende Therapien sollten aktuell nicht reduziert oder abgesetzt werden.Coronavirus disease 2019 (Covid-19)Da Covid-19 durch einen neu identifizierten Virusstamm verursacht wird, stehen bislang keine in kontrollierten Studien gepr\u00fcften, spezifischen antiviralen Substanzen oder Impfstoffe zur Verf\u00fcgung, und es wird vermutet, dass in der Bev\u00f6lkerung keine pr\u00e4existente Immunit\u00e4t besteht [31].", [["Coronavirus disease", "DISEASE", 73, 92], ["Coronavirus disease 2019 (Covid-19)Da Covid-19 durch einen neu identifizierten Virusstamm verursacht wird, stehen bislang keine in kontrollierten Studien gepr\u00fcften, spezifischen antiviralen Substanzen oder Impfstoffe zur Verf\u00fcgung, und es wird vermutet", "SPECIES", 73, 325], ["Laufende Therapien", "TREATMENT", 0, 18], ["Coronavirus disease", "PROBLEM", 73, 92], ["Covid", "TEST", 99, 104], ["Da", "TEST", 108, 110], ["Covid", "TEST", 111, 116]]], ["In den meisten F\u00e4llen werden Coronaviren durch gro\u00dfe Sekrettr\u00f6pfchen von Mensch zu Mensch, durch Einatmen oder Ablagerung auf der Schleimhautoberfl\u00e4che, \u00fcbertragen.", [["\u00fcbertragen", "TREATMENT", 153, 163]]], ["Andere Infektionswege sind die \u00dcbertragung von Coronaviren durch Kontakt mit kontaminierten Oberfl\u00e4chen, durch direkten Mensch-zu-Mensch-Kontakt und durch die Inhalation von Aerosolen, die durch Niesen oder Husten oder auch bei zahn\u00e4rztlichen Behandlungen entstehen [32].", [["Andere Infektionswege sind die \u00dcbertragung von Coronaviren durch Kontakt mit kontaminierten Oberfl\u00e4chen, durch direkten Mensch-zu-Mensch-Kontakt und durch die Inhalation von Aerosolen, die durch Niesen oder Husten oder auch bei zahn\u00e4rztlichen Behandlungen entstehen", "SPECIES", 0, 265], ["mit kontaminierten Oberfl\u00e4chen", "TREATMENT", 73, 103], ["durch direkten Mensch", "TREATMENT", 105, 126], ["zu-Mensch", "TREATMENT", 127, 136]]], ["Das SARS-CoV-2-Virus wurde in Atemwegs-, Kot- und Blutproben nachgewiesen [32].Coronavirus disease 2019 (Covid-19)Das h\u00f6chste Risiko einer \u00dcbertragung f\u00fcr medizinisches Personal besteht, wenn keine Standardvorkehrungen getroffen werden, wenn keine Ma\u00dfnahmen zur Prim\u00e4rinfektionspr\u00e4vention und -kontrolle von Atemwegsinfektionen getroffen werden und wenn Patienten ohne Verwendung von Schutzma\u00dfnahmen behandelt werden, deren Covid-19-Diagnose noch nicht bekannt ist.", [["Coronavirus disease", "DISEASE", 79, 98], ["Virus", "ORGANISM", 15, 20], ["Atemwegs", "SIMPLE_CHEMICAL", 30, 38], ["Coronavirus disease 2019 (Covid-19)Das h\u00f6chste Risiko einer \u00dcbertragung f\u00fcr medizinisches Personal besteht, wenn keine Standardvorkehrungen getroffen werden, wenn keine Ma\u00dfnahmen zur Prim\u00e4rinfektionspr\u00e4vention und -kontrolle von Atemwegsinfektionen getroffen werden und wenn Patienten ohne Verwendung von Schutzma\u00dfnahmen behandelt werden, deren Covid-19-Diagnose noch nicht bekannt", "SPECIES", 79, 460], ["Das SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["Virus wurde", "TEST", 15, 26], ["Atemwegs", "TEST", 30, 38], ["Kot", "TEST", 41, 44], ["Coronavirus disease", "PROBLEM", 79, 98], ["Covid", "TEST", 105, 110], ["Personal besteht", "TREATMENT", 169, 185], ["Covid", "TEST", 424, 429]]], ["Wegen der m\u00f6glichen \u00dcbertragung durch Aerosole [33, 34] bei der Vielzahl der Atemwegserkrankten wird eine umsichtige Vorgehensweise auch in der Allergologie empfohlen [35], wo Lungenfunktionsmessung, Atemtests und nasale Provokation beispielsweise ein Standardverfahren sind.Coronavirus disease 2019 (Covid-19)Weitere Hintergrundinformationen \u00fcber Covid-19 sind online beim Europ\u00e4ischen Zentrum f\u00fcr die Pr\u00e4vention und Kontrolle von Krankheiten (ECDC) [36], der WHO [37] und in den 'Rapid Risk Assessments' des ECDC [31] erh\u00e4ltlich.Coronavirus disease 2019 (Covid-19)Angesichts der begrenzten klinischen Daten, die bisher verf\u00fcgbar sind, gibt es keinen Hinweis darauf, dass Patienten mit allergischer Rhinitis zus\u00e4tzliche Symptome oder schwerere Verl\u00e4ufe entwickeln als andere Patienten [26, 35].", [["Coronavirus disease", "DISEASE", 275, 294], ["Coronavirus disease", "DISEASE", 531, 550], ["Coronavirus disease 2019 (Covid-19)Weitere Hintergrundinformationen \u00fcber Covid-19 sind online beim Europ\u00e4ischen Zentrum f\u00fcr die Pr\u00e4vention und Kontrolle von Krankheiten (ECDC)", "SPECIES", 275, 450], ["Coronavirus disease 2019 (Covid-19", "SPECIES", 531, 565], ["Wegen der m\u00f6glichen \u00dcbertragung durch Aerosole", "TREATMENT", 0, 46], ["Coronavirus disease", "PROBLEM", 275, 294], ["Covid", "TEST", 301, 306], ["Covid", "TEST", 348, 353], ["Coronavirus disease", "PROBLEM", 531, 550], ["Covid", "TEST", 557, 562], ["Rhinitis", "PROBLEM", 700, 708]]], ["Allergische Kinder zeigten einen milden Verlauf, \u00e4hnlich wie andere Kinder [26].Immunmechanismen bei AIT und Covid-19 - Unterschiede und \u00c4hnlichkeitenEine AIT zielt darauf ab, bei Allergiepatienten eine allergenspezifische Immuntoleranz zu induzieren, indem Wirkungen auf mehrere Immunmechanismen genutzt werden (Tab.", [["Immunmechanismen bei AIT und Covid-19 - Unterschiede und \u00c4hnlichkeitenEine AIT zielt darauf ab, bei Allergiepatienten eine allergenspezifische Immuntoleranz zu induzieren, indem Wirkungen auf mehrere Immunmechanismen genutzt werden", "SPECIES", 80, 311], ["Allergische", "TREATMENT", 0, 11], ["Immunmechanismen", "TEST", 80, 96], ["AIT", "TEST", 101, 104], ["Covid", "TEST", 109, 114], ["darauf ab", "TREATMENT", 165, 174], ["Immuntoleranz zu induzieren", "TREATMENT", 223, 250]]], ["1), darunter T-Zellen, B-Zellen, angeborene lymphatische Zellen (ILC) und Effektorzellen wie Eosinophile, Mastzellen und Basophile [15, 38].", [["T", "TEST", 13, 14], ["Zellen", "TEST", 15, 21]]], ["Eine der wichtigsten Ver\u00e4nderungen durch die AIT ist die Entwicklung einer T- und B-regulatorischen Zellantwort und ihrer suppressiven Zytokine wie IL(Interleukin)-10 und TGF (\"transformig growth factor\") und Oberfl\u00e4chenmolek\u00fclen wie CTLA-4 (\"cytotoxic T-lymphocyte-associated Protein 4\") und PD-1 (\"programmed cell death protein\"), die alle ein suppressives Milieu bilden [15, 38].", [["cell", "ANATOMY", 311, 315], ["TGF", "GENE_OR_GENE_PRODUCT", 171, 174], ["CTLA-4", "CELL", 234, 240], ["T-lymphocyte-associated Protein 4", "GENE_OR_GENE_PRODUCT", 253, 286], ["PD-1", "GENE_OR_GENE_PRODUCT", 293, 297], ["cell", "CELL", 311, 315], ["Interleukin", "PROTEIN", 151, 162], ["TGF", "PROTEIN", 171, 174], ["cytotoxic T-lymphocyte-associated Protein 4", "PROTEIN", 243, 286], ["PD-1", "PROTEIN", 293, 297], ["Eine der wichtigsten Ver\u00e4nderungen durch die AIT ist die Entwicklung einer T- und B-regulatorischen Zellantwort und ihrer suppressiven Zytokine wie", "SPECIES", 0, 147], ["regulatorischen Zellantwort", "TREATMENT", 84, 111], ["Zytokine wie IL(Interleukin)", "TREATMENT", 135, 163], ["Oberfl\u00e4chenmolek\u00fclen", "TEST", 209, 229], ["CTLA", "TEST", 234, 238], ["cytotoxic T", "TEST", 243, 254], ["lymphocyte", "TEST", 255, 265], ["Protein", "TEST", 277, 284]]], ["Diese immunregulatorische Antwort findet in gezielten antigen-/allergenspezifischen T- und B-Zellen statt, betrifft aber nicht das gesamte Immunsystem und verursacht vor allem keine systemische Immunschw\u00e4che.", [["gezielten antigen", "TEST", 44, 61]]], ["T-Zell-Reaktionen bei schwerem Covid-19 sind mit einer Lymphopenie verbunden, die haupts\u00e4chlich T-Ged\u00e4chtnis-Lymphozyten betrifft.", [["T-Zell-Reaktionen bei schwerem Covid-19 sind mit einer Lymphopenie verbunden, die haupts\u00e4chlich T-Ged\u00e4chtnis-Lymphozyten betrifft", "SPECIES", 0, 129], ["T", "TEST", 0, 1], ["Zell", "TEST", 2, 6], ["Lymphozyten betrifft", "TREATMENT", 109, 129]]], ["Sowohl CD4- als auch CD8+-T-Zellen nehmen ab, wobei diese Ver\u00e4nderung bei CD8+-T-Zellen st\u00e4rker ausgepr\u00e4gt ist [15, 38].", [["CD4", "PROTEIN", 7, 10], ["CD8", "PROTEIN", 21, 24], ["Sowohl", "TEST", 0, 6], ["CD4", "TEST", 7, 10], ["CD8", "TEST", 21, 24], ["T-", "TEST", 26, 28], ["Zellen", "TEST", 28, 34], ["nehmen", "TEST", 35, 41], ["ab", "TEST", 42, 44], ["wobei", "TEST", 46, 51], ["diese", "TEST", 52, 57], ["T", "TEST", 79, 80], ["CD4", "OBSERVATION", 7, 10]]], ["Zytotoxische CD8+-T-Lymphozyten und NK(nat\u00fcrliche Killer-)-Zellen bei Patienten, die mit SARS-CoV-2 infiziert sind, sind f\u00fcr eine angemessene antivirale Reaktion unerl\u00e4sslich [39].", [["NK", "ANATOMY", 36, 38], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["CD8", "PROTEIN", 13, 16], ["Zytotoxische", "TEST", 0, 12], ["CD8", "TEST", 13, 16], ["Lymphozyten", "TEST", 20, 31], ["NK", "TEST", 36, 38], ["(nat\u00fcrliche Killer", "TREATMENT", 38, 56], ["CoV", "TEST", 94, 97]]], ["Eine k\u00fcrzlich durchgef\u00fchrte Studie deutet darauf hin, dass Patienten eine funktionelle Ersch\u00f6pfung der zytotoxischen CD8+-T-Lymphozyten in Verbindung mit einer SARS-CoV-2-Infektion zeigen [39].", [["Verbindung mit einer SARS-CoV-2-Infektion zeigen", "SPECIES", 139, 187], ["Lymphozyten", "TEST", 124, 135], ["CoV", "TEST", 165, 168]]], ["Die Gesamtzahl der NK- und CD8+-T-Zellen war bei Patienten mit einer SARS-CoV-2-Infektion deutlich verringert [39].", [["NK", "ANATOMY", 19, 21], ["Die Gesamtzahl der NK- und CD8+-T-Zellen war bei Patienten mit einer SARS-CoV-2-Infektion deutlich verringert", "SPECIES", 0, 109], ["Zellen", "TEST", 34, 40], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77]]], ["Dies kann zu einer St\u00f6rung der antiviralen Immunit\u00e4t f\u00fchren und eine Rolle bei der Pathogenese und dem Schweregrad von Covid-19 spielen.Immunmechanismen bei AIT und Covid-19 - Unterschiede und \u00c4hnlichkeitenDie AIT vermindert signifikant sehr selektiv die allergenspezifischen Th2-Zellen im Blutkreislauf und reduziert die allgemeine Typ-2-Reaktion.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITWir empfehlen die Anwendung der Ma\u00dfnahmen zur Infektionspr\u00e4vention und -kontrolle bei Behandlung von allen Patienten, die sich einer AIT unterziehen, gem\u00e4\u00df ECDC und WHO.", [["kann zu einer St\u00f6rung der antiviralen Immunit\u00e4t f\u00fchren und eine Rolle bei der Pathogenese und dem Schweregrad von Covid-19 spielen", "SPECIES", 5, 135], ["Immunmechanismen bei AIT und Covid-19 - Unterschiede und \u00c4hnlichkeiten", "SPECIES", 136, 206], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITWir empfehlen die Anwendung der Ma\u00dfnahmen zur Infektionspr\u00e4vention und -kontrolle bei Behandlung von allen Patienten, die sich einer AIT unterziehen", "SPECIES", 373, 580], ["Covid", "TEST", 119, 124], ["Immunmechanismen", "TEST", 136, 152], ["Covid", "TEST", 165, 170], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 348, 369], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen", "TREATMENT", 373, 424]]], ["In einzelnen Regionen oder L\u00e4ndern k\u00f6nnen diese Ma\u00dfnahmen unterschiedlich ausgelegt und angewendet werden, weshalb zur Infektionspr\u00e4vention alle regionalen und nationalen Vorgaben befolgt werden sollten, einschlie\u00dflich der in diesem Dokument enthaltenen Ma\u00dfnahmen und der Verfahren zur Meldung und \u00dcberf\u00fchrung von untersuchten Personen und von wahrscheinlichen/best\u00e4tigten Covid-19-F\u00e4llen.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITPersonen, die sich mit typischen Atemwegssymptomen krank f\u00fchlen, sollte eine telefonische Konsultation oder eine Beratung per E-Health/Telemedizin/online angeraten werden und keine pers\u00f6nliche Vorstellung in Praxis oder Allergiezentrum [36, 40] (Triage).", [["Ma\u00dfnahmen unterschiedlich ausgelegt und angewendet werden, weshalb zur Infektionspr\u00e4vention alle regionalen und nationalen Vorgaben befolgt werden sollten, einschlie\u00dflich der in diesem Dokument enthaltenen Ma\u00dfnahmen und der Verfahren zur Meldung und \u00dcberf\u00fchrung von untersuchten Personen und von wahrscheinlichen/best\u00e4tigten Covid-19-F\u00e4llen", "SPECIES", 48, 388], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITPersonen, die sich mit typischen Atemwegssymptomen krank f\u00fchlen, sollte eine telefonische Konsultation oder eine Beratung per E-Health/Telemedizin/online angeraten werden und keine pers\u00f6nliche", "SPECIES", 414, 665], ["Covid", "TEST", 373, 378], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITPersonen", "TREATMENT", 414, 481]]], ["Dadurch wird die Zahl der Personen mit Symptomen von Covid-19, die Kontakt mit dem Personal des Allergiezentrums haben, verringert.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITDas Personal, einschlie\u00dflich \u00c4rzte, Medizinische Fachangestellte (MFA), \u00d6kotrophologen, Pflege- und Verwaltungspersonal und alle sonstigen Mitarbeiter der Einrichtung mit Patientenkontakt, sollten informiert sein \u00fcber: A.die aktuelle epidemiologische Situation von Covid-19 in Deutschland beziehungsweise \u00d6sterreich beziehungsweise in der Schweiz und weltweit; B.bekannte Risikofaktoren f\u00fcr Infektionen; C.klinische Symptome und Anzeichen von Covid-19; D.empfohlene Ma\u00dfnahmen zur Pr\u00e4vention und Eind\u00e4mmung von Infektionen in ihrer Region oder ihrem Land, einschlie\u00dflich der in diesem Dokument genannten; E.Verfahren zur Meldung und Verlegung von Personen, die untersucht werden, und von wahrscheinlichen/best\u00e4tigten F\u00e4llen mit den entsprechenden regionalen Regelungen und Besonderheiten [36, 40].Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITSie sollten weiterhin regelm\u00e4\u00dfig unterwiesen werden in den aktuellen, speziell f\u00fcr medizinisches Personal empfohlenen Ma\u00dfnahmen im Falle der Entwicklung von Symptomen oder bei Kontakt mit SARS-CoV-2-positiven Personen.", [["Dadurch wird die Zahl der Personen mit Symptomen von Covid-19, die Kontakt mit dem Personal des Allergiezentrums haben", "SPECIES", 0, 118], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITDas Personal, einschlie\u00dflich \u00c4rzte, Medizinische Fachangestellte (MFA), \u00d6kotrophologen, Pflege- und Verwaltungspersonal und alle sonstigen Mitarbeiter der Einrichtung mit Patientenkontakt, sollten informiert sein \u00fcber: A.die aktuelle epidemiologische Situation von Covid-19 in Deutschland beziehungsweise \u00d6sterreich beziehungsweise in der Schweiz und weltweit; B.bekannte Risikofaktoren f\u00fcr Infektionen; C.klinische Symptome und Anzeichen von Covid-19; D.empfohlene Ma\u00dfnahmen zur Pr\u00e4vention und Eind\u00e4mmung von Infektionen in ihrer Region oder ihrem Land, einschlie\u00dflich der in diesem Dokument genannten; E.Verfahren zur Meldung und Verlegung von Personen, die untersucht werden, und von wahrscheinlichen/best\u00e4tigten F\u00e4llen mit den entsprechenden regionalen Regelungen und Besonderheiten", "SPECIES", 156, 1001], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITSie sollten weiterhin regelm\u00e4\u00dfig unterwiesen werden in den aktuellen, speziell f\u00fcr medizinisches Personal empfohlenen Ma\u00dfnahmen im Falle der Entwicklung von Symptomen oder bei Kontakt mit SARS-CoV-2-positiven Personen", "SPECIES", 1036, 1312], ["Allergiezentren und -praxen sowie", "TREATMENT", 156, 189], ["einschlie\u00dflich \u00c4rzte", "TREATMENT", 229, 249], ["\u00d6kotrophologen", "TREATMENT", 287, 301], ["Pflege", "TREATMENT", 303, 309], ["Covid", "TEST", 480, 485], ["Infektionen", "TREATMENT", 606, 617], ["Covid", "TEST", 658, 663], ["D.empfohlene Ma\u00dfnahmen zur Pr\u00e4vention", "TREATMENT", 668, 705], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 1011, 1032], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen", "TREATMENT", 1036, 1087], ["CoV", "TEST", 1288, 1291]]], ["Geeignete pers\u00f6nliche Schutzausr\u00fcstung (PSA) sollte vor Ort f\u00fcr das gesamte Personal am Behandlungsort verf\u00fcgbar sein, um Standard-, Kontakt- und Tr\u00f6pfchenschutz zu gew\u00e4hrleisten.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITIn jeder Allergieeinrichtung sollte ein Mitarbeiter (z.", [["Ort f\u00fcr das gesamte Personal am Behandlungsort verf\u00fcgbar sein, um Standard-, Kontakt- und Tr\u00f6pfchenschutz zu gew\u00e4hrleisten", "SPECIES", 56, 178], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 179, 200], ["Allergiezentren und -praxen sowie", "TREATMENT", 204, 237], ["Kontrollma\u00dfnahmen bei AITIn", "TREATMENT", 238, 265]]], ["B. leitender Arzt/Krankenschwester/MFA) die Covid-19-Pr\u00e4ventionsma\u00dfnahmen leiten und die entsprechenden Richtlinien f\u00fcr Infrastruktur und Kontrollma\u00dfnahmen umsetzen.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITAn allen Eingangst\u00fcren sollten Schilder angebracht werden, auf denen die Hauptsymptome, die auf eine Covid-19-Infektion hindeuten k\u00f6nnen (Fieber, Husten und Atemnot etc.), aufgef\u00fchrt sind und Besucher mit einem dieser Symptome darauf hingewiesen werden, die Praxis/Allergieabteilung nicht zu betreten (Abb.", [["B. leitender Arzt/Krankenschwester/MFA) die Covid-19-Pr\u00e4ventionsma\u00dfnahmen leiten und die entsprechenden Richtlinien f\u00fcr Infrastruktur und Kontrollma\u00dfnahmen umsetzen", "SPECIES", 0, 164], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITAn allen Eingangst\u00fcren sollten Schilder angebracht werden, auf denen die Hauptsymptome, die auf eine Covid-19-Infektion hindeuten k\u00f6nnen (Fieber, Husten und Atemnot etc.), aufgef\u00fchrt sind und Besucher mit einem dieser Symptome darauf hingewiesen werden, die Praxis/Allergieabteilung nicht zu betreten", "SPECIES", 190, 549], ["Covid", "TEST", 44, 49], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 165, 186], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen", "TREATMENT", 190, 241], ["Covid", "TEST", 350, 355]]], ["1).Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITAlle Mitarbeiter und alle Personen, die eine Praxis/Allergieabteilung betreten, sollten geeignete Ma\u00dfnahmen zur Handhygiene ergreifen und dabei Seife und Wasser oder ein alkoholisches H\u00e4ndedesinfektionsmittel mit Virenwirksamkeit verwenden.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITAuf der Grundlage einer fallweisen Risikobewertung sollte die Verwendung von pers\u00f6nlicher Schutzausr\u00fcstung (PSA) f\u00fcr die AIT in Betracht gezogen werden.", [["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITAlle Mitarbeiter und alle Personen, die eine Praxis/Allergieabteilung betreten, sollten geeignete Ma\u00dfnahmen zur Handhygiene ergreifen und dabei Seife und Wasser oder ein alkoholisches H\u00e4ndedesinfektionsmittel mit Virenwirksamkeit verwenden", "SPECIES", 28, 326], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 3, 24], ["Allergiezentren und -praxen sowie", "TREATMENT", 28, 61], ["Kontrollma\u00dfnahmen bei AITAlle Mitarbeiter", "TREATMENT", 62, 103], ["Allergieabteilung betreten", "TREATMENT", 139, 165], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 327, 348], ["Allergiezentren und -praxen sowie", "TREATMENT", 352, 385], ["Kontrollma\u00dfnahmen bei AITAuf der Grundlage einer fallweisen", "TREATMENT", 386, 445]]], ["Mit dem derzeitigen Wissen \u00fcber die \u00dcbertragung von Covid-19, bei der gr\u00f6\u00dfere Fl\u00fcssigkeitstr\u00f6pfchen eine bedeutende Rolle zu spielen scheinen (obwohl eine \u00dcbertragung \u00fcber die Luft zum jetzigen Zeitpunkt nicht ausgeschlossen werden kann), und unter Ber\u00fccksichtigung des m\u00f6glichen Mangels an PSA im Gesundheitswesen aufgrund der steigenden Zahl von Covid-19-Patienten, kann das vorgeschlagene PSA-Set f\u00fcr Tr\u00f6pfchen-, Kontakt- und Luft\u00fcbertragung (Handschuhe, Schutzbrille, Kittel und FFP2/FFP3-Atemschutzger\u00e4t) f\u00fcr die klinische Beurteilung von Covid-19-Verdachtsf\u00e4llen angepasst werden.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITBei Verf\u00fcgbarkeit sollte eine Mund-Nase-Maske (\"Operationsmaske\" beziehungsweise chirurgischer Mund- und Nasenschutz) f\u00fcr Patienten mit Atemwegsbeschwerden (z.", [["Mit dem derzeitigen Wissen \u00fcber die \u00dcbertragung von Covid-19, bei der gr\u00f6\u00dfere Fl\u00fcssigkeitstr\u00f6pfchen eine bedeutende", "SPECIES", 0, 115], ["Rolle zu spielen scheinen (obwohl eine \u00dcbertragung \u00fcber die Luft zum jetzigen Zeitpunkt nicht ausgeschlossen werden kann), und unter Ber\u00fccksichtigung des m\u00f6glichen Mangels an PSA im Gesundheitswesen aufgrund der steigenden Zahl von Covid-19-Patienten, kann das vorgeschlagene PSA-Set f\u00fcr Tr\u00f6pfchen-, Kontakt- und Luft\u00fcbertragung (Handschuhe, Schutzbrille, Kittel und FFP2/FFP3-Atemschutzger\u00e4t) f\u00fcr die klinische Beurteilung von Covid-19-Verdachtsf\u00e4llen angepasst werden", "SPECIES", 116, 585], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITBei Verf\u00fcgbarkeit sollte eine Mund-Nase-Maske (\"Operationsmaske\" beziehungsweise chirurgischer Mund- und Nasenschutz) f\u00fcr Patienten mit Atemwegsbeschwerden", "SPECIES", 611, 825], ["Mit dem derzeitigen", "TREATMENT", 0, 19], ["an PSA", "TEST", 288, 294], ["Covid", "TEST", 348, 353], ["PSA", "TEST", 392, 395], ["Tr\u00f6pfchen", "TEST", 404, 413], ["Kontakt", "TEST", 416, 423], ["Covid", "TEST", 544, 549], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 586, 607], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen", "TREATMENT", 611, 662]]], ["B. Husten) zur Verf\u00fcgung gestellt werden [41].Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITIm Falle der Kinder- und Jugendmedizin sollten Kinder und Jugendliche lediglich von einer Person begleitet werden, f\u00fcr die alle hygienischen Ma\u00dfnahmen ebenso gelten.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITMitarbeiter, die aerosolerzeugende Untersuchungen durchf\u00fchren, zum Beispiel Provokationstestungen [41], sollten das vorgeschlagene PSA-Set zur Verhinderung von Tr\u00f6pfchen-, Kontakt- und Luft\u00fcbertragung tragen (Handschuhe, Schutzbrille, Kittel und FFP2/FFP3-Atemschutzmaske) [42], ansonsten sollten diese Tests aktuell sicherheitshalber unterbleiben.Vorbeugende Ma\u00dfnahmen in Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITUm die Verwendung von PSA bei unzureichender Versorgung zu maximieren, sollte Personal f\u00fcr die Durchf\u00fchrung von Verfahren oder einer Prozedur in speziell daf\u00fcr vorgesehenen Bereichen eingesetzt werden [43].Organisation der AIT w\u00e4hrend der Covid-19-PandemieDie AIT ist eine Behandlung, die einen wiederkehrenden Arzt-/MFA-/Krankenschwester-/Patientenkontakt \u00fcber einen l\u00e4ngeren Zeitraum, zum Beispiel drei Jahre, erfordert.Organisation der AIT w\u00e4hrend der Covid-19-PandemieBei der SCIT werden Injektionen in t\u00e4glichen, w\u00f6chentlichen (Aufdosierungsphase) oder vier- bis achtw\u00f6chentlichen (Fortsetzungsphase) Abst\u00e4nden verabreicht.Organisation der AIT w\u00e4hrend der Covid-19-PandemieBei der SLIT wird die Einleitung in allergologischen Praxen oder Allergiezentren vorgenommen, w\u00e4hrend die Fortsetzung von den Patienten selbst durchgef\u00fchrt wird, die im Rahmen von regelm\u00e4\u00dfigen Verlaufskontrollen von den behandelnden \u00c4rzten kontrolliert wird.Organisation der AIT w\u00e4hrend der Covid-19-PandemieDas Inverkehrbringen jedes SCIT- oder SLIT-Produkts muss von der zust\u00e4ndigen Beh\u00f6rde mit Anwendungshinweisen in der Fach-/Gebrauchsinformation genehmigt werden.", [["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITIm Falle der Kinder- und Jugendmedizin sollten Kinder und Jugendliche lediglich von einer Person begleitet werden, f\u00fcr die alle hygienischen Ma\u00dfnahmen ebenso gelten", "SPECIES", 71, 294], ["sollten das vorgeschlagene PSA-Set zur Verhinderung von Tr\u00f6pfchen-, Kontakt- und Luft\u00fcbertragung tragen (Handschuhe, Schutzbrille, Kittel und FFP2/FFP3-Atemschutzmaske)", "SPECIES", 483, 651], ["Allergiezentren und -praxen sowie Kontrollma\u00dfnahmen bei AITUm die Verwendung von PSA bei unzureichender Versorgung zu maximieren", "SPECIES", 752, 880], ["Organisation der AIT w\u00e4hrend der Covid-19-PandemieDie AIT ist eine Behandlung, die einen wiederkehrenden Arzt-/MFA-/Krankenschwester-/Patientenkontakt \u00fcber einen l\u00e4ngeren", "SPECIES", 1017, 1187], ["Organisation der AIT w\u00e4hrend der Covid-19-PandemieBei der SLIT wird die Einleitung in allergologischen Praxen oder Allergiezentren vorgenommen, w\u00e4hrend die Fortsetzung von den Patienten selbst durchgef\u00fchrt wird, die im Rahmen von regelm\u00e4\u00dfigen Verlaufskontrollen von den behandelnden \u00c4rzten kontrolliert wird", "SPECIES", 1439, 1746], ["Allergiezentren und -praxen sowie", "TREATMENT", 71, 104], ["PSA", "TEST", 510, 513], ["Tr\u00f6pfchen", "TEST", 539, 548], ["Kontakt", "TEST", 551, 558], ["Vorbeugende Ma\u00dfnahmen", "TREATMENT", 727, 748], ["Allergiezentren und -praxen sowie", "TREATMENT", 752, 785], ["Covid", "TEST", 1266, 1271], ["PandemieBei der SCIT", "TREATMENT", 1275, 1295], ["w\u00f6chentlichen (Aufdosierungsphase)", "TREATMENT", 1329, 1363], ["bis achtw\u00f6chentlichen (Fortsetzungsphase)", "TREATMENT", 1375, 1416], ["PandemieBei der SLIT wird", "TREATMENT", 1481, 1506], ["Covid", "TEST", 1780, 1785]]], ["Diese enth\u00e4lt Informationen \u00fcber die Anwendung des AIT-Produkts f\u00fcr Patienten, \u00c4rzte/Allergologen und Fachpersonal.", [["Diese enth\u00e4lt Informationen \u00fcber die Anwendung des AIT-Produkts f\u00fcr Patienten, \u00c4rzte/Allergologen und Fachpersonal", "SPECIES", 0, 114]]], ["Wir empfehlen, w\u00e4hrend der aktuellen Covid-19-Pandemie \u00e4hnliche Ma\u00dfnahmen zu ergreifen.", [["w\u00e4hrend der aktuellen Covid-19-Pandemie \u00e4hnliche Ma\u00dfnahmen zu ergreifen", "SPECIES", 15, 86], ["Covid", "TEST", 37, 42], ["Pandemie", "TREATMENT", 46, 54]]], ["Bei best\u00e4tigten F\u00e4llen sollte die AIT - sowohl die SCIT als auch die SLIT - unabh\u00e4ngig vom Schweregrad der Erkrankung unterbrochen werden, bis die Symptome vollst\u00e4ndig abgeklungen sind.Organisation der AIT w\u00e4hrend der Covid-19-PandemieDer Beginn einer AIT bei Allergikern ohne bekannte SARS-CoV-2-Exposition, die in Bezug auf Covid-19 asymptomatisch sind, deren aktueller SARS-CoV-2-Infektions- und Immunstatus jedoch nicht bekannt sind, erfordert eine besonders gr\u00fcndliche Untersuchung auf Infektionszeichen mit SARS-CoV-2 im Rahmen der Verschreibung der AIT, die bei Beginn der AIT wiederholt werden soll.", [["Bei best\u00e4tigten F\u00e4llen sollte die AIT - sowohl die SCIT als auch die SLIT - unabh\u00e4ngig vom Schweregrad der Erkrankung unterbrochen werden, bis die Symptome vollst\u00e4ndig abgeklungen", "SPECIES", 0, 179], ["Organisation der AIT w\u00e4hrend der Covid-19-PandemieDer Beginn einer AIT bei Allergikern ohne bekannte SARS-CoV-2-Exposition, die in Bezug auf Covid-19 asymptomatisch sind, deren aktueller SARS-CoV-2-Infektions- und Immunstatus jedoch nicht bekannt sind, erfordert eine besonders gr\u00fcndliche Untersuchung auf Infektionszeichen mit SARS-CoV-2 im Rahmen der Verschreibung der AIT, die bei Beginn der AIT wiederholt werden soll", "SPECIES", 185, 606], ["Covid", "TEST", 218, 223], ["PandemieDer", "TREATMENT", 227, 238], ["Covid", "TEST", 326, 331], ["SARS", "TEST", 372, 376], ["CoV", "TEST", 377, 380], ["Infektions", "TEST", 383, 393]]], ["Lieferzeiten der AIT-Pr\u00e4parate sowie das Infektionsrisiko durch das aktuelle pers\u00f6nliche und berufliche Umfeld des Patienten sind hierbei zu ber\u00fccksichtigen.Organisation der AIT w\u00e4hrend der Covid-19-PandemieEine SLIT bietet einerseits die M\u00f6glichkeit, nach der ersten Einnahme in der Praxis/Allergieabteilung, das Allergenpr\u00e4parat in der Folge ohne \u00e4rztliche Aufsicht zu Hause einzunehmen, wodurch die Notwendigkeit vermieden wird, zum wiederholten Male in einer Praxis/Allergieabteilung vorstellig werden zu m\u00fcssen, denn auch der Arztbesuch ist prinzipiell mit einem Infektionsrisiko verbunden.", [["Lieferzeiten der AIT-Pr\u00e4parate sowie das Infektionsrisiko durch das aktuelle pers\u00f6nliche und berufliche Umfeld des Patienten sind hierbei zu ber\u00fccksichtigen", "SPECIES", 0, 156], ["nach der ersten Einnahme in der Praxis/Allergieabteilung, das Allergenpr\u00e4parat in der Folge ohne \u00e4rztliche Aufsicht zu Hause einzunehmen, wodurch die Notwendigkeit vermieden wird, zum wiederholten Male in einer Praxis/Allergieabteilung vorstellig werden zu m\u00fcssen, denn auch der Arztbesuch ist prinzipiell mit einem Infektionsrisiko verbunden", "SPECIES", 252, 594], ["PandemieEine SLIT bietet einerseits", "TREATMENT", 199, 234]]], ["Andererseits kann die Notwendigkeit einer Unterbrechung der AIT besser von einem Arzt beurteilt werden, da Patienten gegebenenfalls ihre Symptome nicht richtig einsch\u00e4tzen und/oder Covid-19 nicht zuordnen k\u00f6nnen.", [["Andererseits kann die Notwendigkeit einer Unterbrechung der AIT besser von einem Arzt beurteilt werden, da Patienten gegebenenfalls ihre Symptome nicht richtig einsch\u00e4tzen und/oder Covid-19 nicht zuordnen k\u00f6nnen", "SPECIES", 0, 211]]], ["Subklinische/oligosymptomatische Infektionsverl\u00e4ufe stellen f\u00fcr den Patienten eine besondere Herausforderung bei der Selbstmedikation dar.", [["Subklinische/oligosymptomatische Infektionsverl\u00e4ufe stellen f\u00fcr den Patienten eine besondere Herausforderung bei der Selbstmedikation dar", "SPECIES", 0, 137]]], ["Patienten, die eine SLIT zu Hause einnehmen, sollten daher angehalten werden, sich bei Anzeichen eines Infektes vor der n\u00e4chsten Einnahme mit dem behandelnden Arzt in Verbindung zu setzen.Organisation der AIT w\u00e4hrend der Covid-19-PandemieDie M\u00f6glichkeit, die Injektionsintervalle in der Fortsetzungsphase zu verl\u00e4ngern, kann bei SCIT-Pr\u00e4paraten genutzt werden.", [["Organisation der AIT w\u00e4hrend der Covid-19-PandemieDie M\u00f6glichkeit, die Injektionsintervalle in der Fortsetzungsphase zu verl\u00e4ngern, kann bei SCIT-Pr\u00e4paraten genutzt werden", "SPECIES", 188, 359], ["kann bei SCIT", "TREATMENT", 320, 333]]], ["Bei Patienten, die sich von Covid-19 erholt haben oder bei denen eine ausreichende SARS-CoV-2-Antik\u00f6rperreaktion nach einer (eventuell auch asymptomatischen) Erkrankung [37] festgestellt wird, kann die AIT wie geplant begonnen oder fortgesetzt werden [35].", [["CoV", "TEST", 88, 91], ["Antik\u00f6rperreaktion nach einer", "TREATMENT", 94, 123]]], ["Die AIT kann auch bei Patienten ohne klinische Symptome und Anzeichen von Covid-19 oder anderen Infektionen und ohne Reisen in Gebiete mit Covid-19-F\u00e4llen (Hochrisikogebiete) innerhalb der letzten 14 Tage wie gewohnt fortgesetzt werden.", [["Die AIT kann auch bei Patienten ohne klinische Symptome und Anzeichen von Covid-19 oder anderen Infektionen und ohne Reisen in Gebiete mit Covid-19-F\u00e4llen (Hochrisikogebiete) innerhalb der letzten 14 Tage wie gewohnt fortgesetzt werden", "SPECIES", 0, 235], ["Covid", "TEST", 74, 79], ["Covid", "TEST", 139, 144], ["F\u00e4llen (Hochrisikogebiete) innerhalb der letzten", "TREATMENT", 148, 196]]]], "d3f7a1144e32e496eb542188448b074047f7c3e0": [["12 March 2020, WHO declared it a pandemic, with the virus having spread to every continent (123 countries), affecting broad and localised areas (132,758 confirmed cases, 4,955 deaths; Puliatti et al., 2020) .", [["deaths", "DISEASE", 176, 182], ["a pandemic", "PROBLEM", 31, 41], ["the virus", "PROBLEM", 48, 57], ["broad", "OBSERVATION_MODIFIER", 118, 123], ["localised", "OBSERVATION_MODIFIER", 128, 137]]], ["The first case was transmitted from animal to human, but now human-human transmission occurs through respiratory droplets from coughing and sneezing, with symptomatic individuals being the main vehicle for its spread.", [["respiratory droplets", "ANATOMY", 101, 121], ["coughing", "DISEASE", 127, 135], ["sneezing", "DISEASE", 140, 148], ["human", "ORGANISM", 46, 51], ["human", "ORGANISM", 61, 66], ["human", "ORGANISM", 67, 72], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 67, 72], ["respiratory droplets", "PROBLEM", 101, 121], ["coughing", "PROBLEM", 127, 135], ["sneezing", "PROBLEM", 140, 148], ["symptomatic individuals", "PROBLEM", 155, 178]]]], "PMC7422802": [["IntroductionNeprilysin (NEP) is a neutral endopeptidase.", [["Neprilysin", "CHEMICAL", 12, 22], ["Neprilysin", "CHEMICAL", 12, 22], ["Neprilysin", "GENE_OR_GENE_PRODUCT", 12, 22], ["NEP", "GENE_OR_GENE_PRODUCT", 24, 27], ["Neprilysin", "PROTEIN", 12, 22], ["NEP", "PROTEIN", 24, 27], ["IntroductionNeprilysin (NEP)", "TREATMENT", 0, 28], ["a neutral endopeptidase", "TREATMENT", 32, 55]]], ["It is also known by different functional names such as common acute lymphoblastic leukemia antigen (CALLA), the cluster of differentiation 10 (CD10), endoprotease 24.11, endopeptidase 24.11, and membrane metalloendopeptidase.", [["acute lymphoblastic leukemia", "ANATOMY", 62, 90], ["membrane", "ANATOMY", 195, 203], ["acute lymphoblastic leukemia", "DISEASE", 62, 90], ["acute lymphoblastic leukemia", "CANCER", 62, 90], ["CALLA", "GENE_OR_GENE_PRODUCT", 100, 105], ["cluster of differentiation 10", "GENE_OR_GENE_PRODUCT", 112, 141], ["CD10", "GENE_OR_GENE_PRODUCT", 143, 147], ["endoprotease 24.11", "GENE_OR_GENE_PRODUCT", 150, 168], ["endopeptidase 24.11", "GENE_OR_GENE_PRODUCT", 170, 189], ["membrane", "CELLULAR_COMPONENT", 195, 203], ["common acute lymphoblastic leukemia antigen", "PROTEIN", 55, 98], ["CALLA", "PROTEIN", 100, 105], ["cluster of differentiation 10", "PROTEIN", 112, 141], ["CD10", "PROTEIN", 143, 147], ["endoprotease 24.11", "PROTEIN", 150, 168], ["endopeptidase 24.11", "PROTEIN", 170, 189], ["membrane metalloendopeptidase", "PROTEIN", 195, 224], ["common acute lymphoblastic leukemia antigen", "PROBLEM", 55, 98], ["CD10", "TEST", 143, 147], ["endoprotease", "TEST", 150, 162], ["endopeptidase", "TEST", 170, 183], ["membrane metalloendopeptidase", "TREATMENT", 195, 224], ["common", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["lymphoblastic leukemia", "OBSERVATION", 68, 90]]], ["NEP is a member of M13 family of zinc peptidase [1].", [["zinc", "CHEMICAL", 33, 37], ["NEP", "GENE_OR_GENE_PRODUCT", 0, 3], ["M13", "GENE_OR_GENE_PRODUCT", 19, 22], ["zinc peptidase", "GENE_OR_GENE_PRODUCT", 33, 47], ["NEP", "PROTEIN", 0, 3], ["M13 family", "PROTEIN", 19, 29], ["zinc peptidase", "PROTEIN", 33, 47], ["zinc peptidase", "TREATMENT", 33, 47]]], ["In the body, NEP cleaves many peptides such as atrial natriuretic peptides, B-type natriuretic peptides, angiotensins (I, II, II, IX), bradykinin, substance P, endothelin I & II, amyloid-\u03b2 (A\u03b2), endorphin, neurotensin, vasopressin, etc. [2][3][4].", [["body", "ANATOMY", 7, 11], ["bradykinin", "CHEMICAL", 135, 145], ["amyloid-\u03b2", "CHEMICAL", 179, 188], ["neurotensin", "CHEMICAL", 206, 217], ["vasopressin", "CHEMICAL", 219, 230], ["bradykinin", "CHEMICAL", 135, 145], ["body", "ORGANISM_SUBDIVISION", 7, 11], ["NEP", "GENE_OR_GENE_PRODUCT", 13, 16], ["atrial natriuretic peptides", "GENE_OR_GENE_PRODUCT", 47, 74], ["B-type natriuretic peptides", "GENE_OR_GENE_PRODUCT", 76, 103], ["angiotensins", "GENE_OR_GENE_PRODUCT", 105, 117], ["I, II, II", "GENE_OR_GENE_PRODUCT", 119, 128], ["IX", "GENE_OR_GENE_PRODUCT", 130, 132], ["bradykinin", "SIMPLE_CHEMICAL", 135, 145], ["substance P", "SIMPLE_CHEMICAL", 147, 158], ["endothelin I & II", "GENE_OR_GENE_PRODUCT", 160, 177], ["amyloid-\u03b2", "GENE_OR_GENE_PRODUCT", 179, 188], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 190, 192], ["endorphin", "GENE_OR_GENE_PRODUCT", 195, 204], ["neurotensin", "GENE_OR_GENE_PRODUCT", 206, 217], ["vasopressin", "GENE_OR_GENE_PRODUCT", 219, 230], ["[2][3][4", "SIMPLE_CHEMICAL", 237, 245], ["NEP", "PROTEIN", 13, 16], ["IX", "PROTEIN", 130, 132], ["endothelin I & II", "PROTEIN", 160, 177], ["A\u03b2", "PROTEIN", 190, 192], ["NEP cleaves many peptides", "TREATMENT", 13, 38], ["atrial natriuretic peptides", "TEST", 47, 74], ["B-type natriuretic peptides", "TREATMENT", 76, 103], ["angiotensins", "PROBLEM", 105, 117], ["bradykinin", "PROBLEM", 135, 145], ["amyloid", "TEST", 179, 186], ["endorphin", "TREATMENT", 195, 204], ["neurotensin", "TREATMENT", 206, 217], ["vasopressin", "TREATMENT", 219, 230], ["body", "ANATOMY", 7, 11]]], ["The progression of various pathological conditions such as kidney and heart disease [4], obesity [5], diabetes [6][7], few malignancies such as colon cancer, lung cancer and melanomas [8][9][10][11], etc. is associated the peptidase activity of NEP.", [["kidney", "ANATOMY", 59, 65], ["heart", "ANATOMY", 70, 75], ["malignancies", "ANATOMY", 123, 135], ["colon cancer", "ANATOMY", 144, 156], ["lung cancer", "ANATOMY", 158, 169], ["melanomas", "ANATOMY", 174, 183], ["kidney and heart disease", "DISEASE", 59, 83], ["obesity", "DISEASE", 89, 96], ["diabetes", "DISEASE", 102, 110], ["malignancies", "DISEASE", 123, 135], ["colon cancer", "DISEASE", 144, 156], ["lung cancer", "DISEASE", 158, 169], ["melanomas", "DISEASE", 174, 183], ["8][9][10][11]", "CHEMICAL", 185, 198], ["kidney", "ORGAN", 59, 65], ["heart", "ORGAN", 70, 75], ["malignancies", "CANCER", 123, 135], ["colon cancer", "CANCER", 144, 156], ["lung cancer", "CANCER", 158, 169], ["melanomas", "CANCER", 174, 183], ["[8][9][10][11]", "SIMPLE_CHEMICAL", 184, 198], ["NEP", "GENE_OR_GENE_PRODUCT", 245, 248], ["peptidase", "PROTEIN", 223, 232], ["NEP", "PROTEIN", 245, 248], ["various pathological conditions", "PROBLEM", 19, 50], ["kidney and heart disease", "PROBLEM", 59, 83], ["obesity", "PROBLEM", 89, 96], ["diabetes", "PROBLEM", 102, 110], ["few malignancies", "PROBLEM", 119, 135], ["colon cancer", "PROBLEM", 144, 156], ["lung cancer", "PROBLEM", 158, 169], ["melanomas", "PROBLEM", 174, 183], ["progression", "OBSERVATION_MODIFIER", 4, 15], ["various", "OBSERVATION_MODIFIER", 19, 26], ["pathological conditions", "OBSERVATION", 27, 50], ["kidney", "ANATOMY", 59, 65], ["heart", "ANATOMY", 70, 75], ["disease", "OBSERVATION", 76, 83], ["few", "OBSERVATION_MODIFIER", 119, 122], ["malignancies", "OBSERVATION", 123, 135], ["colon", "ANATOMY", 144, 149], ["cancer", "OBSERVATION", 150, 156], ["lung", "ANATOMY", 158, 162], ["cancer", "OBSERVATION", 163, 169]]], ["In 2015, the U.S. Food and Drug Administration (FDA) approved sacubitril/valsartan, combination of a neprilysin inhibitor and an angiotensin receptor blocker (ARB) respectively, commonly known as angiotensin receptor Neprilysin inhibitor (ARNi), for heart failure with reduced ejection fraction [12].", [["heart", "ANATOMY", 250, 255], ["sacubitril/valsartan", "CHEMICAL", 62, 82], ["angiotensin", "CHEMICAL", 129, 140], ["ARB", "CHEMICAL", 159, 162], ["angiotensin", "CHEMICAL", 196, 207], ["ARNi", "CHEMICAL", 239, 243], ["heart failure", "DISEASE", 250, 263], ["sacubitril", "CHEMICAL", 62, 72], ["valsartan", "CHEMICAL", 73, 82], ["sacubitril", "SIMPLE_CHEMICAL", 62, 72], ["valsartan", "SIMPLE_CHEMICAL", 73, 82], ["neprilysin", "GENE_OR_GENE_PRODUCT", 101, 111], ["angiotensin receptor blocker", "SIMPLE_CHEMICAL", 129, 157], ["ARB", "SIMPLE_CHEMICAL", 159, 162], ["angiotensin receptor Neprilysin", "GENE_OR_GENE_PRODUCT", 196, 227], ["ARNi", "SIMPLE_CHEMICAL", 239, 243], ["heart", "ORGAN", 250, 255], ["Drug Administration", "TREATMENT", 27, 46], ["sacubitril", "TREATMENT", 62, 72], ["valsartan", "TREATMENT", 73, 82], ["a neprilysin inhibitor", "TREATMENT", 99, 121], ["an angiotensin receptor blocker", "TREATMENT", 126, 157], ["ARB", "TREATMENT", 159, 162], ["angiotensin receptor Neprilysin inhibitor", "TREATMENT", 196, 237], ["heart failure", "PROBLEM", 250, 263], ["reduced ejection fraction", "PROBLEM", 269, 294], ["heart", "ANATOMY", 250, 255], ["failure", "OBSERVATION", 256, 263], ["reduced", "OBSERVATION_MODIFIER", 269, 276], ["ejection fraction", "OBSERVATION", 277, 294]]], ["Further, in 2017, clinical trials involving sacubitril/valsartan treatment groups performed well in the renal failure population as compared to treatment with an ARB (Valsartan) alone [13].", [["renal", "ANATOMY", 104, 109], ["sacubitril/", "CHEMICAL", 44, 55], ["valsartan", "CHEMICAL", 55, 64], ["renal failure", "DISEASE", 104, 117], ["ARB", "CHEMICAL", 162, 165], ["Valsartan", "CHEMICAL", 167, 176], ["sacubitril", "CHEMICAL", 44, 54], ["valsartan", "CHEMICAL", 55, 64], ["Valsartan", "CHEMICAL", 167, 176], ["sacubitril", "SIMPLE_CHEMICAL", 44, 54], ["valsartan", "SIMPLE_CHEMICAL", 55, 64], ["renal", "ORGAN", 104, 109], ["ARB", "SIMPLE_CHEMICAL", 162, 165], ["Valsartan", "SIMPLE_CHEMICAL", 167, 176], ["sacubitril", "TREATMENT", 44, 54], ["valsartan treatment groups", "TREATMENT", 55, 81], ["the renal failure population", "PROBLEM", 100, 128], ["an ARB (Valsartan)", "TREATMENT", 159, 177], ["renal", "ANATOMY", 104, 109], ["failure", "OBSERVATION", 110, 117]]], ["Therefore, NEP has gained considerable attention in the last decade for its peptide degrading property, and whose inhibition has therapeutic potential in multiple diseases.", [["NEP", "GENE_OR_GENE_PRODUCT", 11, 14], ["NEP", "PROTEIN", 11, 14], ["its peptide", "TREATMENT", 72, 83], ["multiple diseases", "PROBLEM", 154, 171], ["multiple", "OBSERVATION_MODIFIER", 154, 162], ["diseases", "OBSERVATION", 163, 171]]], ["But the known and available NEP inhibitors are limited.", [["NEP", "GENE_OR_GENE_PRODUCT", 28, 31], ["available NEP inhibitors", "TREATMENT", 18, 42]]], ["Hence, drug repurposing using different in-silico tools can aid in speeding up the process of drug discovery for the development of new NEP inhibitors.IntroductionThe role of NEP has been extensively studied in various diseases.", [["NEP", "GENE_OR_GENE_PRODUCT", 136, 139], ["NEP", "GENE_OR_GENE_PRODUCT", 175, 178], ["NEP", "PROTEIN", 175, 178], ["drug repurposing", "TREATMENT", 7, 23], ["new NEP inhibitors", "TREATMENT", 132, 150], ["various diseases", "PROBLEM", 211, 227], ["various", "OBSERVATION_MODIFIER", 211, 218], ["diseases", "OBSERVATION", 219, 227]]], ["The study report of the PARADIGM trial highlighted the role of NEP inhibitors in the population of heart failure with reduced ejection fraction [14].", [["heart", "ANATOMY", 99, 104], ["heart failure", "DISEASE", 99, 112], ["NEP", "GENE_OR_GENE_PRODUCT", 63, 66], ["heart", "ORGAN", 99, 104], ["The study", "TEST", 0, 9], ["the PARADIGM trial", "TREATMENT", 20, 38], ["NEP inhibitors", "TREATMENT", 63, 77], ["heart failure", "PROBLEM", 99, 112], ["reduced ejection fraction", "PROBLEM", 118, 143], ["heart", "ANATOMY", 99, 104], ["failure", "OBSERVATION", 105, 112], ["reduced", "OBSERVATION_MODIFIER", 118, 125], ["ejection fraction", "OBSERVATION", 126, 143]]], ["In an in-vivo study of subtotal nephrectomy, the renoprotective effect of sacubitril/valsartan was found to be stronger as compared to valsartan alone [15].", [["sacubitril", "CHEMICAL", 74, 84], ["valsartan", "CHEMICAL", 85, 94], ["valsartan", "CHEMICAL", 135, 144], ["sacubitril", "CHEMICAL", 74, 84], ["valsartan", "CHEMICAL", 85, 94], ["valsartan", "CHEMICAL", 135, 144], ["sacubitril", "SIMPLE_CHEMICAL", 74, 84], ["valsartan", "SIMPLE_CHEMICAL", 85, 94], ["valsartan", "SIMPLE_CHEMICAL", 135, 144], ["subtotal nephrectomy", "TREATMENT", 23, 43], ["sacubitril", "TREATMENT", 74, 84], ["valsartan", "TREATMENT", 85, 94], ["valsartan", "TREATMENT", 135, 144], ["subtotal", "OBSERVATION_MODIFIER", 23, 31], ["nephrectomy", "OBSERVATION", 32, 43]]], ["According to the result of the U.K. HARP-III trial, the combination of sacubitril/valsartan is effective and is well-tolerated in the chronic kidney disease population [16].", [["kidney", "ANATOMY", 142, 148], ["sacubitril", "CHEMICAL", 71, 81], ["valsartan", "CHEMICAL", 82, 91], ["chronic kidney disease", "DISEASE", 134, 156], ["sacubitril", "CHEMICAL", 71, 81], ["valsartan", "CHEMICAL", 82, 91], ["sacubitril", "SIMPLE_CHEMICAL", 71, 81], ["valsartan", "SIMPLE_CHEMICAL", 82, 91], ["kidney", "ORGAN", 142, 148], ["sacubitril", "TREATMENT", 71, 81], ["valsartan", "TREATMENT", 82, 91], ["the chronic kidney disease population", "PROBLEM", 130, 167], ["chronic", "OBSERVATION_MODIFIER", 134, 141], ["kidney", "ANATOMY", 142, 148], ["disease", "OBSERVATION", 149, 156]]], ["Similarly, various studies are focussed on the importance of NEP on chronic kidney and cardiovascular diseases.", [["kidney", "ANATOMY", 76, 82], ["cardiovascular", "ANATOMY", 87, 101], ["chronic kidney and cardiovascular diseases", "DISEASE", 68, 110], ["NEP", "GENE_OR_GENE_PRODUCT", 61, 64], ["kidney", "ORGAN", 76, 82], ["cardiovascular", "ANATOMICAL_SYSTEM", 87, 101], ["NEP", "PROTEIN", 61, 64], ["various studies", "TEST", 11, 26], ["chronic kidney", "PROBLEM", 68, 82], ["cardiovascular diseases", "PROBLEM", 87, 110], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["kidney", "ANATOMY", 76, 82], ["cardiovascular", "ANATOMY", 87, 101], ["diseases", "OBSERVATION", 102, 110]]], ["NEP inhibition in streptozotocin-induced diabetic mice, improved outcomes of cardiac function for heart failure with reduced ejection fraction.", [["cardiac", "ANATOMY", 77, 84], ["heart", "ANATOMY", 98, 103], ["streptozotocin", "CHEMICAL", 18, 32], ["diabetic", "DISEASE", 41, 49], ["heart failure", "DISEASE", 98, 111], ["streptozotocin", "CHEMICAL", 18, 32], ["NEP", "GENE_OR_GENE_PRODUCT", 0, 3], ["streptozotocin", "SIMPLE_CHEMICAL", 18, 32], ["mice", "ORGANISM", 50, 54], ["cardiac", "ORGAN", 77, 84], ["heart", "ORGAN", 98, 103], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["NEP inhibition", "TREATMENT", 0, 14], ["streptozotocin", "TREATMENT", 18, 32], ["diabetic mice", "PROBLEM", 41, 54], ["heart failure", "PROBLEM", 98, 111], ["reduced ejection fraction", "PROBLEM", 117, 142], ["diabetic mice", "OBSERVATION", 41, 54], ["cardiac", "ANATOMY", 77, 84], ["heart", "ANATOMY", 98, 103], ["failure", "OBSERVATION", 104, 111], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["ejection fraction", "OBSERVATION", 125, 142]]], ["In diabetic nephropathy, the combination of the NEP inhibitor thiorphan, with an angiotensin receptor blocker and an angiotensin-converting enzyme II activator showed significant improvement in the condition, by modulating components of the renin-angiotensin system and natriuretic peptide system [6].", [["diabetic nephropathy", "DISEASE", 3, 23], ["thiorphan", "CHEMICAL", 62, 71], ["angiotensin", "CHEMICAL", 81, 92], ["angiotensin", "CHEMICAL", 117, 128], ["angiotensin", "CHEMICAL", 247, 258], ["thiorphan", "CHEMICAL", 62, 71], ["NEP", "GENE_OR_GENE_PRODUCT", 48, 51], ["thiorphan", "SIMPLE_CHEMICAL", 62, 71], ["angiotensin-converting enzyme II", "GENE_OR_GENE_PRODUCT", 117, 149], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 241, 258], ["angiotensin-converting enzyme II", "PROTEIN", 117, 149], ["renin", "PROTEIN", 241, 246], ["diabetic nephropathy", "PROBLEM", 3, 23], ["the NEP inhibitor thiorphan", "TREATMENT", 44, 71], ["an angiotensin receptor blocker", "TREATMENT", 78, 109], ["an angiotensin", "TREATMENT", 114, 128], ["converting enzyme II activator", "TEST", 129, 159], ["the renin-angiotensin system", "TREATMENT", 237, 265], ["natriuretic peptide system", "TREATMENT", 270, 296], ["diabetic", "OBSERVATION_MODIFIER", 3, 11], ["nephropathy", "OBSERVATION", 12, 23], ["significant", "OBSERVATION_MODIFIER", 167, 178], ["improvement", "OBSERVATION_MODIFIER", 179, 190]]], ["The activation of the leptin-aldosterone-neprilysin axis contributes to the pathogenesis of cardiac complications in obese patients [17].", [["cardiac", "ANATOMY", 92, 99], ["aldosterone", "CHEMICAL", 29, 40], ["cardiac complications", "DISEASE", 92, 113], ["aldosterone", "CHEMICAL", 29, 40], ["leptin", "GENE_OR_GENE_PRODUCT", 22, 28], ["aldosterone", "GENE_OR_GENE_PRODUCT", 29, 40], ["neprilysin", "GENE_OR_GENE_PRODUCT", 41, 51], ["cardiac", "ORGAN", 92, 99], ["patients", "ORGANISM", 123, 131], ["neprilysin", "PROTEIN", 41, 51], ["patients", "SPECIES", 123, 131], ["the leptin", "TREATMENT", 18, 28], ["aldosterone-neprilysin axis", "TREATMENT", 29, 56], ["cardiac complications", "PROBLEM", 92, 113], ["cardiac", "ANATOMY", 92, 99], ["complications", "OBSERVATION", 100, 113]]], ["In obesity and type 2 diabetes, NEP inhibition showed improvement in insulin sensitivity and glycaemic control.", [["obesity", "DISEASE", 3, 10], ["type 2 diabetes", "DISEASE", 15, 30], ["NEP", "GENE_OR_GENE_PRODUCT", 32, 35], ["insulin", "GENE_OR_GENE_PRODUCT", 69, 76], ["NEP", "PROTEIN", 32, 35], ["obesity", "PROBLEM", 3, 10], ["type 2 diabetes", "PROBLEM", 15, 30], ["NEP inhibition", "TEST", 32, 46], ["insulin sensitivity", "TREATMENT", 69, 88], ["glycaemic control", "TREATMENT", 93, 110], ["obesity", "OBSERVATION", 3, 10], ["type 2", "OBSERVATION_MODIFIER", 15, 21], ["diabetes", "OBSERVATION", 22, 30], ["improvement", "OBSERVATION_MODIFIER", 54, 65], ["insulin sensitivity", "OBSERVATION", 69, 88]]], ["The inhibition results in modulation of several peptides with glucoregulatory properties such as bradykinin, cholecystokinin, glycogen like peptide, glucose-dependent insulinotropic peptide, secretin, and vasoactive intestinal polypeptide, leading to improved glucose homeostasis and weight loss [18].", [["bradykinin", "CHEMICAL", 97, 107], ["cholecystokinin", "CHEMICAL", 109, 124], ["glycogen", "CHEMICAL", 126, 134], ["glucose", "CHEMICAL", 149, 156], ["glucose", "CHEMICAL", 260, 267], ["weight loss", "DISEASE", 284, 295], ["bradykinin", "CHEMICAL", 97, 107], ["glucose", "CHEMICAL", 149, 156], ["glucose", "CHEMICAL", 260, 267], ["bradykinin", "SIMPLE_CHEMICAL", 97, 107], ["cholecystokinin", "GENE_OR_GENE_PRODUCT", 109, 124], ["glycogen like peptide", "SIMPLE_CHEMICAL", 126, 147], ["glucose", "SIMPLE_CHEMICAL", 149, 156], ["-dependent insulinotropic peptide", "SIMPLE_CHEMICAL", 156, 189], ["secretin", "GENE_OR_GENE_PRODUCT", 191, 199], ["vasoactive intestinal polypeptide", "GENE_OR_GENE_PRODUCT", 205, 238], ["glucose", "SIMPLE_CHEMICAL", 260, 267], ["glucoregulatory properties", "TREATMENT", 62, 88], ["bradykinin", "TEST", 97, 107], ["cholecystokinin", "TEST", 109, 124], ["glycogen like peptide", "TREATMENT", 126, 147], ["glucose-dependent insulinotropic peptide", "TREATMENT", 149, 189], ["secretin", "TREATMENT", 191, 199], ["vasoactive intestinal polypeptide", "TREATMENT", 205, 238], ["improved glucose homeostasis", "PROBLEM", 251, 279], ["weight loss", "PROBLEM", 284, 295], ["intestinal", "ANATOMY", 216, 226], ["glucose homeostasis", "OBSERVATION", 260, 279]]], ["A study conducted to evaluate the effect of NEP on nociception, concluded that NEP inhibition can be a good strategy for pain management [19].", [["pain", "DISEASE", 121, 125], ["NEP", "GENE_OR_GENE_PRODUCT", 44, 47], ["NEP", "GENE_OR_GENE_PRODUCT", 79, 82], ["A study", "TEST", 0, 7], ["NEP on nociception", "TREATMENT", 44, 62], ["NEP inhibition", "TREATMENT", 79, 93], ["pain management", "TREATMENT", 121, 136]]], ["In cancers, such as colon cancer [9][10], lung cancer [11][20], and melanomas [8], the increased levels of NEP is correlated with neoplastic progression.", [["cancers", "ANATOMY", 3, 10], ["colon cancer", "ANATOMY", 20, 32], ["lung cancer", "ANATOMY", 42, 53], ["melanomas", "ANATOMY", 68, 77], ["neoplastic", "ANATOMY", 130, 140], ["cancers", "DISEASE", 3, 10], ["colon cancer", "DISEASE", 20, 32], ["lung cancer", "DISEASE", 42, 53], ["melanomas", "DISEASE", 68, 77], ["cancers", "CANCER", 3, 10], ["colon cancer", "CANCER", 20, 32], ["lung cancer", "CANCER", 42, 53], ["melanomas", "CANCER", 68, 77], ["NEP", "GENE_OR_GENE_PRODUCT", 107, 110], ["NEP", "PROTEIN", 107, 110], ["cancers", "PROBLEM", 3, 10], ["colon cancer", "PROBLEM", 20, 32], ["lung cancer", "PROBLEM", 42, 53], ["melanomas", "PROBLEM", 68, 77], ["the increased levels of NEP", "PROBLEM", 83, 110], ["neoplastic progression", "PROBLEM", 130, 152], ["cancers", "OBSERVATION", 3, 10], ["colon", "ANATOMY", 20, 25], ["cancer", "OBSERVATION", 26, 32], ["lung", "ANATOMY", 42, 46], ["cancer", "OBSERVATION", 47, 53], ["melanomas", "OBSERVATION", 68, 77], ["neoplastic", "OBSERVATION", 130, 140]]], ["The peptidase activity of NEP and its interaction with Akt/ focal adhesion kinase is assumed to contribute to the pathogenesis of colon cancer [21].", [["colon cancer", "ANATOMY", 130, 142], ["colon cancer", "DISEASE", 130, 142], ["NEP", "GENE_OR_GENE_PRODUCT", 26, 29], ["Akt", "GENE_OR_GENE_PRODUCT", 55, 58], ["focal adhesion kinase", "GENE_OR_GENE_PRODUCT", 60, 81], ["colon cancer", "CANCER", 130, 142], ["NEP", "PROTEIN", 26, 29], ["Akt", "PROTEIN", 55, 58], ["focal adhesion kinase", "PROTEIN", 60, 81], ["The peptidase activity of NEP", "TREATMENT", 0, 29], ["Akt/ focal adhesion kinase", "PROBLEM", 55, 81], ["colon cancer", "PROBLEM", 130, 142], ["focal", "OBSERVATION_MODIFIER", 60, 65], ["adhesion kinase", "OBSERVATION", 66, 81], ["colon", "ANATOMY", 130, 135], ["cancer", "OBSERVATION", 136, 142]]], ["In aggressive melanomas, CD10 (NEP) is the biomarker [8] for detection.", [["melanomas", "ANATOMY", 14, 23], ["melanomas", "DISEASE", 14, 23], ["melanomas", "CANCER", 14, 23], ["CD10", "GENE_OR_GENE_PRODUCT", 25, 29], ["NEP", "GENE_OR_GENE_PRODUCT", 31, 34], ["CD10", "PROTEIN", 25, 29], ["NEP", "PROTEIN", 31, 34], ["aggressive melanomas", "PROBLEM", 3, 23], ["the biomarker", "TEST", 39, 52], ["aggressive", "OBSERVATION_MODIFIER", 3, 13], ["melanomas", "OBSERVATION", 14, 23]]], ["The recent finding, also highlighted the role of ARNi to enhance anti-inflammatory and natriuretic peptide system in COVID-19 patients [22][23].", [["ARNi", "SIMPLE_CHEMICAL", 49, 53], ["patients", "ORGANISM", 126, 134], ["ARNi", "PROTEIN", 49, 53], ["patients", "SPECIES", 126, 134], ["anti-inflammatory and natriuretic peptide system", "TREATMENT", 65, 113], ["COVID", "TEST", 117, 122]]], ["Additionally, the use of ARNi is also recommended for patients suffering from COVID-19 [24].", [["ARNi", "CHEMICAL", 25, 29], ["COVID-19", "CHEMICAL", 78, 86], ["ARNi", "SIMPLE_CHEMICAL", 25, 29], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["COVID", "TEST", 78, 83]]], ["All these findings highlighted the need for designing novel NEP inhibitors.", [["NEP", "GENE_OR_GENE_PRODUCT", 60, 63], ["designing novel NEP inhibitors", "TREATMENT", 44, 74]]], ["Hence, drug discovery by repurposing the existing drugs can be an attractive strategy, with the benefit of with reduced developmental risk, especially in the case of NEP inhibitors.IntroductionThe computation repurposing is known as \u2018in-silico drug repurposing\u2019.", [["NEP", "GENE_OR_GENE_PRODUCT", 166, 169], ["repurposing the existing drugs", "TREATMENT", 25, 55], ["an attractive strategy", "TREATMENT", 63, 85], ["reduced developmental risk", "PROBLEM", 112, 138], ["NEP inhibitors", "TREATMENT", 166, 180]]], ["In 2019, in the U.S., approximately 30% of drugs approved was through the drug repurposing approach [25].", [["drugs", "TREATMENT", 43, 48], ["the drug repurposing approach", "TREATMENT", 70, 99]]], ["The concept of drug repurposing has been already practiced in cardiovascular disease, cancer, obesity, erectile dysfunction, smoking cessation, stress, psychosis, etc. [26].", [["cardiovascular", "ANATOMY", 62, 76], ["cancer", "ANATOMY", 86, 92], ["erectile", "ANATOMY", 103, 111], ["cardiovascular disease", "DISEASE", 62, 84], ["cancer", "DISEASE", 86, 92], ["obesity", "DISEASE", 94, 101], ["erectile dysfunction", "DISEASE", 103, 123], ["smoking", "CHEMICAL", 125, 132], ["psychosis", "DISEASE", 152, 161], ["cardiovascular", "ANATOMICAL_SYSTEM", 62, 76], ["cancer", "CANCER", 86, 92], ["erectile", "TISSUE", 103, 111], ["cardiovascular disease", "PROBLEM", 62, 84], ["cancer", "PROBLEM", 86, 92], ["obesity", "PROBLEM", 94, 101], ["erectile dysfunction", "PROBLEM", 103, 123], ["stress", "PROBLEM", 144, 150], ["psychosis", "PROBLEM", 152, 161], ["drug repurposing", "OBSERVATION", 15, 31], ["cardiovascular", "ANATOMY", 62, 76], ["disease", "OBSERVATION", 77, 84], ["cancer", "OBSERVATION", 86, 92], ["obesity", "OBSERVATION", 94, 101], ["erectile dysfunction", "OBSERVATION", 103, 123]]], ["Drug repurposing using already approved drugs reduces the time and money on preliminary screening, toxicity studies, clinical trials, bulk manufacturing and formulation development.", [["toxicity", "DISEASE", 99, 107], ["Drug repurposing", "TREATMENT", 0, 16], ["already approved drugs", "TREATMENT", 23, 45], ["preliminary screening", "TEST", 76, 97], ["toxicity studies", "TEST", 99, 115], ["bulk manufacturing", "TREATMENT", 134, 152]]], ["A good example is the case of allopurinol which was originally approved for cancer and is now available for the treatment of gout [25].IntroductionIn this context, we decided to find out a series of inhibitors for NEP using in-silico drug repurposing.", [["cancer", "ANATOMY", 76, 82], ["allopurinol", "CHEMICAL", 30, 41], ["cancer", "DISEASE", 76, 82], ["gout", "DISEASE", 125, 129], ["allopurinol", "CHEMICAL", 30, 41], ["allopurinol", "SIMPLE_CHEMICAL", 30, 41], ["cancer", "CANCER", 76, 82], ["NEP", "GENE_OR_GENE_PRODUCT", 214, 217], ["NEP", "PROTEIN", 214, 217], ["allopurinol", "TREATMENT", 30, 41], ["cancer", "PROBLEM", 76, 82], ["gout", "PROBLEM", 125, 129], ["a series of inhibitors", "TREATMENT", 187, 209], ["NEP", "TREATMENT", 214, 217], ["gout", "OBSERVATION", 125, 129]]], ["The protein structure of the extracellular domain of NEP with sacubitralat (the active metabolite of sacubitril) was used in the current study.", [["extracellular", "ANATOMY", 29, 42], ["sacubitralat", "CHEMICAL", 62, 74], ["sacubitril", "CHEMICAL", 101, 111], ["sacubitralat", "CHEMICAL", 62, 74], ["sacubitril", "CHEMICAL", 101, 111], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["NEP", "GENE_OR_GENE_PRODUCT", 53, 56], ["sacubitralat", "SIMPLE_CHEMICAL", 62, 74], ["sacubitril", "SIMPLE_CHEMICAL", 101, 111], ["extracellular domain", "PROTEIN", 29, 49], ["NEP", "PROTEIN", 53, 56], ["sacubitralat", "TREATMENT", 62, 74], ["the active metabolite of sacubitril)", "TREATMENT", 76, 112], ["the current study", "TEST", 125, 142], ["protein structure", "OBSERVATION", 4, 21]]], ["The inhibitor binding pocket in the protein structure of the extracellular domain of human NEP (PDB ID: 5JMY) has already been revealed by Schiering, Nikolaus, et al. [27].", [["extracellular", "ANATOMY", 61, 74], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["human", "ORGANISM", 85, 90], ["NEP", "GENE_OR_GENE_PRODUCT", 91, 94], ["PDB ID: 5JMY", "GENE_OR_GENE_PRODUCT", 96, 108], ["extracellular domain", "PROTEIN", 61, 81], ["human NEP", "PROTEIN", 85, 94], ["5JMY", "PROTEIN", 104, 108], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["The inhibitor binding pocket", "PROBLEM", 0, 28], ["pocket", "OBSERVATION_MODIFIER", 22, 28]]], ["The inhibitor binding pocket contains the catalytically essential triad of HIS583, HIS587, and GLU646.", [["HIS583", "CHEMICAL", 75, 81], ["HIS587", "CHEMICAL", 83, 89], ["GLU646", "CHEMICAL", 95, 101], ["HIS583", "SIMPLE_CHEMICAL", 75, 81], ["HIS587", "SIMPLE_CHEMICAL", 83, 89], ["GLU646", "GENE_OR_GENE_PRODUCT", 95, 101], ["HIS583", "PROTEIN", 75, 81], ["HIS587", "PROTEIN", 83, 89], ["GLU646", "PROTEIN", 95, 101], ["The inhibitor binding pocket", "PROBLEM", 0, 28], ["HIS587", "TEST", 83, 89], ["GLU646", "TEST", 95, 101]]], ["For our drug repurposing study, the structures of 2934 FDA approved drugs were downloaded from the Zinc 12 database.", [["Zinc 12", "CHEMICAL", 99, 106], ["our drug repurposing study", "TEST", 4, 30], ["drugs", "TREATMENT", 68, 73], ["the Zinc 12 database", "TEST", 95, 115]]], ["Based on the binding pocket of NEP inhibitors, the high throughput virtual screening of existing FDA approved drugs was done to find out new series of NEP inhibitors.", [["NEP", "GENE_OR_GENE_PRODUCT", 31, 34], ["NEP", "GENE_OR_GENE_PRODUCT", 151, 154], ["NEP inhibitors", "TREATMENT", 31, 45], ["existing FDA approved drugs", "TREATMENT", 88, 115], ["NEP inhibitors", "TREATMENT", 151, 165]]], ["To the best of our knowledge, this is the first study based on drug repurposing approach that is being reported and employed for the development of NEP inhibitors using receptor-inhibitor complex.Protein preparation and grid generation ::: Materials and methodsX-ray crystallographic structure of an extracellular domain of human NEP (PDB ID: 5JMY) was downloaded from the RCSB protein data bank.", [["extracellular", "ANATOMY", 300, 313], ["NEP", "GENE_OR_GENE_PRODUCT", 148, 151], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 300, 313], ["human", "ORGANISM", 324, 329], ["NEP", "GENE_OR_GENE_PRODUCT", 330, 333], ["receptor-inhibitor complex", "PROTEIN", 169, 195], ["extracellular domain", "PROTEIN", 300, 320], ["human NEP", "PROTEIN", 324, 333], ["PDB ID", "PROTEIN", 335, 341], ["5JMY", "PROTEIN", 343, 347], ["RCSB", "PROTEIN", 373, 377], ["human", "SPECIES", 324, 329], ["human", "SPECIES", 324, 329], ["the first study", "TEST", 38, 53], ["drug repurposing approach", "TREATMENT", 63, 88], ["NEP inhibitors", "TREATMENT", 148, 162], ["receptor-inhibitor complex", "TREATMENT", 169, 195], ["Protein preparation", "TREATMENT", 196, 215], ["methodsX", "TEST", 254, 262]]], ["Prior to docking and simulation studies, the biological unit of protein was prepared using \u2018Protein Preparation Wizard\u2019 in Schrodinger suite [28].", [["simulation studies", "TEST", 21, 39], ["the biological unit of protein", "TREATMENT", 41, 71]]], ["During the process of protein preparation, the protein was subjected to import and refine, review and modify, and minimize processes.", [["protein preparation", "TREATMENT", 22, 41]]], ["In protein preparation wizard, missing side chains and residues were filled using the Prime tool.", [["protein preparation wizard", "TREATMENT", 3, 29], ["missing side chains", "TREATMENT", 31, 50]]], ["The active site and catalytically important residues were retained in the protein structure.", [["protein structure", "PROTEIN", 74, 91], ["The active site", "PROBLEM", 0, 15], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION_MODIFIER", 11, 15], ["protein structure", "OBSERVATION", 74, 91]]], ["The non-protein water molecules beyond 5 \u00c5 were deleted and stages were generated for hetero atoms.", [["hetero atoms", "SIMPLE_CHEMICAL", 86, 98], ["non-protein water molecules", "PROTEIN", 4, 31], ["The non-protein water molecules", "TREATMENT", 0, 31]]], ["To generate low energy state protein, energy minimization was done using OPLS3e (Optimized potential for liquid stimulation) force field and the prepared protein was used for molecular modelling.", [["low energy state protein", "PROBLEM", 12, 36], ["energy minimization", "TREATMENT", 38, 57], ["OPLS3e", "TREATMENT", 73, 79], ["liquid stimulation) force field", "TREATMENT", 105, 136], ["the prepared protein", "TREATMENT", 141, 161], ["molecular modelling", "PROBLEM", 175, 194], ["low energy", "OBSERVATION_MODIFIER", 12, 22]]], ["To generate a grid around ligand, the receptor grid generation workflow was used by keeping all functional residues in the grid [29].Ligand preparation ::: Materials and methodsThe structures of 2934 FDA approved drugs from Zinc 12 database were downloaded [30].", [["Zinc", "CHEMICAL", 224, 228], ["Zinc 12", "CHEMICAL", 224, 231], ["a grid around ligand", "TREATMENT", 12, 32], ["the receptor grid generation workflow", "TREATMENT", 34, 71], ["Zinc 12 database", "TEST", 224, 240], ["functional residues", "OBSERVATION", 96, 115]]], ["For ligand preparation, the LigPrep tool was employed.", [["ligand preparation", "TREATMENT", 4, 22]]], ["The lowest energy 3D structures with correlated chiralities were generated at pH 7.0 \u00b1 2.0 under the OPLS3e force field.", [["pH", "TEST", 78, 80]]], ["In this process, all the ligands were pre-processed, which includes generation of tautomers, ionization state at pH 7.0 \u00b1 2.0 using Epik, addition of hydrogen bond, charged group neutralization, and ligand geometry were optimized [29].Ligand docking ::: Materials and methodsAll the molecular docking studies were carried out by using the ligand docking tool GLIDE (Grid-based Ligand Docking with Energetics) module.", [["hydrogen", "CHEMICAL", 150, 158], ["ionization state", "TEST", 93, 109], ["pH", "TEST", 113, 115], ["hydrogen bond", "TREATMENT", 150, 163], ["charged group neutralization", "TREATMENT", 165, 193], ["All the molecular docking studies", "TEST", 275, 308], ["Grid-based Ligand Docking with Energetics) module", "TREATMENT", 366, 415]]], ["The GLIDE module was used for predicting ligand-protein binding modes and ranking.", [["GLIDE module", "DNA", 4, 16], ["The GLIDE module", "TREATMENT", 0, 16], ["GLIDE module", "OBSERVATION", 4, 16]]], ["First, all drugs were docked with HTVS mode.", [["all drugs", "TREATMENT", 7, 16], ["HTVS mode", "TREATMENT", 34, 43]]], ["But computationally, HTVS docking does not use descriptor and explicit water technology as used in the XP mode.", [["water technology", "TREATMENT", 71, 87]]], ["Hence to avoid false-positive results, based on the HTVS dock score, few drugs were reanalyzed using SP and XP modes [31][32].Free ligand binding energy calculation ::: Materials and methodsThe prime module was used to determine absolute ligand-binding affinities to protein using MM/GBSA (Molecular mechanics energies generalized Born and surface area continuum Solvation) method.", [["SP", "PROTEIN", 101, 103], ["few drugs", "TREATMENT", 69, 78], ["MM/GBSA (Molecular mechanics energies generalized Born and surface area continuum Solvation) method", "TREATMENT", 281, 380]]], ["The MM/GBSA assay of top eight XP docked drugs was performed using pose viewer file of GLIDE XP mode.", [["The MM/GBSA assay", "TEST", 0, 17], ["XP docked drugs", "TREATMENT", 31, 46], ["GLIDE XP mode", "TREATMENT", 87, 100]]], ["The prime MM/GBSA method is dependent on the VSGB solvation model that uses a variable-dielectric generalized Born model and water as a solvent under the OPLS3e force field to calculate binding energy [33].ADME analysis ::: Materials and methodsFor the assessment of the ADME profile, the QikProp tool from the maestro modeling platform was used [33].", [["The prime MM/GBSA method", "TEST", 0, 24], ["a variable-dielectric generalized Born model", "TREATMENT", 76, 120], ["the assessment", "TEST", 249, 263], ["the ADME profile", "TEST", 267, 283], ["the QikProp tool", "TEST", 285, 301], ["the maestro modeling platform", "TEST", 307, 336]]], ["The QikProp tool helps in the prediction of the druggable property of best four hits based on ADME analysis.", [["The QikProp tool", "TEST", 0, 16], ["ADME analysis", "TEST", 94, 107]]], ["During this process, various descriptors such as molecular weight, cardiotoxicity (QPlogHERG), predicted octanol/water partition coefficient (QPlogPo/w), permeability (QPPCaco), polar surface area (PSA), percentage human oral absorption (% Oral Absorption), and Lipinski rule of five were calculated.Induced fit docking (IFD)-SP ::: Materials and methodsIFD-SP was carried out using the induced-fit docking module from Maestro molecular modelling platform [34].", [["surface", "ANATOMY", 184, 191], ["oral", "ANATOMY", 221, 225], ["cardiotoxicity", "DISEASE", 67, 81], ["octanol", "CHEMICAL", 105, 112], ["octanol", "CHEMICAL", 105, 112], ["octanol", "SIMPLE_CHEMICAL", 105, 112], ["human", "ORGANISM", 215, 220], ["oral", "ORGANISM_SUBDIVISION", 221, 225], ["PSA", "PROTEIN", 198, 201], ["SP", "PROTEIN", 326, 328], ["methodsIFD", "PROTEIN", 347, 357], ["SP", "PROTEIN", 358, 360], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["cardiotoxicity", "PROBLEM", 67, 81], ["octanol/water partition coefficient", "TREATMENT", 105, 140], ["permeability (QPPCaco)", "TREATMENT", 154, 176], ["PSA", "TEST", 198, 201], ["percentage human oral absorption (% Oral Absorption)", "TREATMENT", 204, 256], ["Lipinski rule", "TEST", 262, 275], ["methodsIFD", "TEST", 347, 357], ["polar", "ANATOMY_MODIFIER", 178, 183]]], ["Based on the XP GLIDE docking score, binding energy, crucial residues involved and ADME analysis, four (ZINC000000001427, ZINC000001533877, ZINC000000601283, and ZINC000003831594) drugs were selected for IFD\u2013 SP docking.", [["ZINC000000001427", "CHEMICAL", 104, 120], ["ZINC000001533877", "CHEMICAL", 122, 138], ["ZINC000000601283", "CHEMICAL", 140, 156], ["ZINC000003831594", "CHEMICAL", 162, 178], ["the XP GLIDE docking score", "TEST", 9, 35], ["binding energy", "PROBLEM", 37, 51], ["ADME analysis", "TEST", 83, 96], ["drugs", "TREATMENT", 180, 185], ["SP docking", "TREATMENT", 209, 219]]], ["In IFD, based on the B-factor, side chains were trimmed with receptor and Vander Waals scaling of 0.70 and 0.50 respectively and a maximum of 20 poses were set for each ligand.", [["IFD", "DISEASE", 3, 6], ["B-factor", "GENE_OR_GENE_PRODUCT", 21, 29], ["B-factor", "PROTEIN", 21, 29], ["side chains", "TREATMENT", 31, 42], ["receptor", "TEST", 61, 69], ["Vander Waals scaling", "TEST", 74, 94]]], ["Further prime side-chain prediction and minimization were performed in which refinement of all residues within 5\u00c5 of the ligands pose and side chains were performed [35].", [["Further prime side-chain prediction", "TREATMENT", 0, 35], ["all residues", "TREATMENT", 91, 103], ["the ligands pose and side chains", "TREATMENT", 117, 149]]], ["The ligands and residues are minimized.", [["ligands", "OBSERVATION", 4, 11]]], ["In induced-fit protein structure, all the ligands were rigorously docked and IFD score for each was calculated using the formula:Induced fit docking (IFD)-SP ::: Materials and methodsIFD Score: 1.0GLIDE Score + 1.428*GLIDE_EcoulMolecular dynamics (MD) simulation ::: Materials and methodsThe flexibility of the receptor is restricted in grid-based docking systems like XP and IFD.", [["IFD", "DISEASE", 376, 379], ["SP", "PROTEIN", 155, 157], ["IFD score", "TEST", 77, 86], ["methodsIFD Score", "TEST", 176, 192], ["GLIDE Score", "TEST", 197, 208], ["XP", "PROBLEM", 369, 371], ["IFD", "PROBLEM", 376, 379], ["-fit", "OBSERVATION_MODIFIER", 10, 14], ["protein structure", "OBSERVATION", 15, 32], ["restricted", "OBSERVATION_MODIFIER", 323, 333], ["IFD", "OBSERVATION", 376, 379]]], ["These do not mimic the actual biological systems, where the protein and drug are solvated in water.", [["water", "SIMPLE_CHEMICAL", 93, 98]]], ["Hence to tackle this problem, MD simulation was performed.", [["MD simulation", "TEST", 30, 43]]], ["Based on the GLIDE docking score, free binding energy, and IFD score, four drugs were selected for MD simulation for 20ns.", [["the GLIDE docking score", "TEST", 9, 32], ["free binding energy", "PROBLEM", 34, 53], ["IFD score", "TEST", 59, 68], ["four drugs", "TREATMENT", 70, 80]]], ["The docked complex of protein and ligand were selected, and the system model was made by predefined SPC solvent under orthorhombic boundary conditions.", [["docked complex", "PROTEIN", 4, 18], ["orthorhombic boundary conditions", "TREATMENT", 118, 150], ["complex", "OBSERVATION_MODIFIER", 11, 18]]], ["Next, the system model was subjected to energy minimization until a gradient threshold reached 25 kcal/mol/\u00c5, balanced at 300 K temperature, and 1 bar pressure via NPT ensemble.", [["energy minimization", "TREATMENT", 40, 59], ["a gradient threshold", "TEST", 66, 86], ["K temperature", "TEST", 126, 139], ["1 bar pressure", "TEST", 145, 159]]], ["In the final step, Minimized ligand-protein complex were subjected to MD simulation [36].Bioisostere replacement ::: Materials and methodsFor optimization of ADME and biological properties of top two selected compounds (ZINC000000601283 and ZINC000003831594), the bioisostere replacement of functional group was performed.", [["ZINC000000601283", "CHEMICAL", 220, 236], ["ZINC000000601283", "CHEMICAL", 220, 236], ["ZINC000003831594", "CHEMICAL", 241, 257], ["bioisostere", "SIMPLE_CHEMICAL", 264, 275], ["Minimized ligand-protein complex", "PROTEIN", 19, 51], ["the bioisostere replacement of functional group", "TREATMENT", 260, 307], ["replacement", "OBSERVATION", 101, 112]]], ["The bioisosteric replacement tool from Maestro molecular modelling platform was employed to create bioisosteric structures of better potency and ADME profile.", [["The bioisosteric replacement tool", "TREATMENT", 0, 33], ["Maestro molecular modelling platform", "TREATMENT", 39, 75], ["bioisosteric replacement", "OBSERVATION", 4, 28], ["bioisosteric structures", "OBSERVATION", 99, 122]]], ["Further, the results of the generated bioisosteres were analysed through interaction of ligands with crucial amino acid residue, XP GLIDE docking score, binding energy, and ADME analysis [37].Ligand docking ::: ResultsAround 2934 ligands from Zinc 12 database were screened with HTVS docking mode of GLIDE panel.", [["amino acid", "CHEMICAL", 109, 119], ["Zinc", "CHEMICAL", 243, 247], ["amino acid", "CHEMICAL", 109, 119], ["Zinc 12", "CHEMICAL", 243, 250], ["amino acid", "AMINO_ACID", 109, 119], ["crucial amino acid residue", "PROBLEM", 101, 127], ["XP GLIDE docking score", "TEST", 129, 151], ["binding energy", "TEST", 153, 167], ["ADME analysis", "TEST", 173, 186], ["Zinc 12 database", "TEST", 243, 259], ["GLIDE panel", "TEST", 300, 311]]], ["HTVS docking mode utilizes a small period to a large set of drugs by reducing the final torsional refinement and comprehensive sampling.", [["a large set of drugs", "TREATMENT", 45, 65], ["the final torsional refinement", "TREATMENT", 78, 108], ["comprehensive sampling", "TEST", 113, 135]]], ["Hence a total of 281 drugs with dock scores less than -5 Kcal/mole were filtered and reanalyzed in SP docking mode.", [["SP", "PROTEIN", 99, 101], ["a total of 281 drugs", "TREATMENT", 6, 26], ["dock scores", "TEST", 32, 43]]], ["After performing SP docking, around 100 drugs were subjected to an extensive XP docking mode of GLIDE panel.", [["SP", "PROTEIN", 17, 19], ["SP docking", "TREATMENT", 17, 27], ["GLIDE panel", "TEST", 96, 107]]], ["XP docking mode is more accurate, avoids the possibility of false-positive results and gives an appropriate correlation between a good pose of drugs and a good dock score.", [["false-positive results", "PROBLEM", 60, 82], ["drugs", "TREATMENT", 143, 148]]], ["Finally, based on XP dock score and pivotal interactions, eight active drugs (ZINC000001533877, ZINC000000001427, ZINC000001851195, ZINC000000402909, ZINC000000601283, ZINC000000000797, ZINC000003831594, ZINC000028973441) were identified for further screening.", [["ZINC000001533877", "CHEMICAL", 78, 94], ["ZINC000000001427", "CHEMICAL", 96, 112], ["ZINC000001851195", "CHEMICAL", 114, 130], ["ZINC000000402909", "CHEMICAL", 132, 148], ["ZINC000000601283", "CHEMICAL", 150, 166], ["XP dock score", "TEST", 18, 31], ["further screening", "TEST", 242, 259]]], ["The docking score of co-crystalized ligand sacubitralat was found to be -15.685.", [["sacubitralat", "CHEMICAL", 43, 55], ["sacubitralat", "CHEMICAL", 43, 55], ["co-crystalized ligand sacubitralat", "SIMPLE_CHEMICAL", 21, 55], ["The docking score", "TEST", 0, 17], ["co-crystalized ligand sacubitralat", "TEST", 21, 55]]], ["All the eight selected drugs showed the docking score between -14.041 to -8.392 (given in table 1).Ligand docking ::: ResultsAll the eight drugs showed similar interaction as compared to sacubitrilat.", [["sacubitrilat", "CHEMICAL", 187, 199], ["sacubitrilat", "CHEMICAL", 187, 199], ["sacubitrilat", "SIMPLE_CHEMICAL", 187, 199], ["the docking score", "TEST", 36, 53]]], ["Schiering, Nikolaus, et al. had reported that the hydrophobic interaction of sacubitrilat with PHE544 was towards the shallow S1 pocket of NEP protein [27].", [["sacubitrilat", "CHEMICAL", 77, 89], ["PHE544", "CHEMICAL", 95, 101], ["sacubitrilat", "CHEMICAL", 77, 89], ["PHE544", "CHEMICAL", 95, 101], ["sacubitrilat", "SIMPLE_CHEMICAL", 77, 89], ["PHE544", "SIMPLE_CHEMICAL", 95, 101], ["NEP", "GENE_OR_GENE_PRODUCT", 139, 142], ["shallow S1 pocket", "PROTEIN", 118, 135], ["NEP protein", "PROTEIN", 139, 150], ["PHE544", "TREATMENT", 95, 101], ["NEP protein", "TEST", 139, 150]]], ["The charge positive interaction with ARG717 and polar interaction with ASN542 were found to be common in sacubitrilat and selected eight drugs.", [["ARG717", "CHEMICAL", 37, 43], ["ASN542", "CHEMICAL", 71, 77], ["sacubitrilat", "CHEMICAL", 105, 117], ["ARG717", "CHEMICAL", 37, 43], ["ASN542", "CHEMICAL", 71, 77], ["sacubitrilat", "CHEMICAL", 105, 117], ["ARG717", "SIMPLE_CHEMICAL", 37, 43], ["ASN542", "SIMPLE_CHEMICAL", 71, 77], ["sacubitrilat", "SIMPLE_CHEMICAL", 105, 117], ["ASN542", "TREATMENT", 71, 77], ["positive", "OBSERVATION", 11, 19]]], ["Even in this study, all the eight drugs showed hydrophobic interactions with PHE544.", [["PHE544", "CHEMICAL", 77, 83], ["PHE544", "CHEMICAL", 77, 83], ["PHE544", "SIMPLE_CHEMICAL", 77, 83], ["this study", "TEST", 8, 18], ["hydrophobic interactions", "PROBLEM", 47, 71], ["PHE544", "TREATMENT", 77, 83]]], ["Sacubitrilat also showed interactions with ASN542, ARG717, ARG110, and ARG102.", [["Sacubitrilat", "CHEMICAL", 0, 12], ["ASN542", "CHEMICAL", 43, 49], ["Sacubitrilat", "CHEMICAL", 0, 12], ["ASN542", "CHEMICAL", 43, 49], ["ARG717", "CHEMICAL", 51, 57], ["ARG110", "CHEMICAL", 59, 65], ["ARG102", "CHEMICAL", 71, 77], ["Sacubitrilat", "SIMPLE_CHEMICAL", 0, 12], ["ASN542", "SIMPLE_CHEMICAL", 43, 49], ["ARG717", "SIMPLE_CHEMICAL", 51, 57], ["ARG110", "GENE_OR_GENE_PRODUCT", 59, 65], ["ARG102", "GENE_OR_GENE_PRODUCT", 71, 77], ["ARG102", "TREATMENT", 71, 77]]], ["In-silico docking studies also showed that all the eight drugs showed interaction with HIS711 which then formed a hydrogen bond with zinc, causing the stabilization of zinc transition state [38].", [["HIS711", "CHEMICAL", 87, 93], ["zinc", "CHEMICAL", 133, 137], ["zinc", "CHEMICAL", 168, 172], ["HIS711", "CHEMICAL", 87, 93], ["hydrogen", "CHEMICAL", 114, 122], ["zinc", "CHEMICAL", 133, 137], ["zinc", "CHEMICAL", 168, 172], ["HIS711", "SIMPLE_CHEMICAL", 87, 93], ["zinc", "SIMPLE_CHEMICAL", 133, 137], ["silico docking studies", "TEST", 3, 25], ["a hydrogen bond with zinc", "TREATMENT", 112, 137], ["zinc transition state", "PROBLEM", 168, 189]]], ["This interaction with zinc and its stabilization might result in decreased catalytic activity of NEP, as it is a zinc dependent endopeptidase.Ligand docking ::: ResultsNEP degrades various peptide substrates at the amino sides of hydrophobic amino acids.", [["zinc", "CHEMICAL", 22, 26], ["zinc", "CHEMICAL", 113, 117], ["ResultsNEP", "CHEMICAL", 161, 171], ["amino acids", "CHEMICAL", 242, 253], ["zinc", "CHEMICAL", 22, 26], ["zinc", "CHEMICAL", 113, 117], ["amino", "CHEMICAL", 215, 220], ["amino acids", "CHEMICAL", 242, 253], ["zinc", "SIMPLE_CHEMICAL", 22, 26], ["NEP", "GENE_OR_GENE_PRODUCT", 97, 100], ["ResultsNEP", "SIMPLE_CHEMICAL", 161, 171], ["amino", "AMINO_ACID", 215, 220], ["hydrophobic", "AMINO_ACID", 230, 241], ["amino acids", "AMINO_ACID", 242, 253], ["NEP", "PROTEIN", 97, 100], ["zinc dependent endopeptidase", "PROTEIN", 113, 141], ["ResultsNEP", "PROTEIN", 161, 171], ["zinc", "TREATMENT", 22, 26], ["decreased catalytic activity of NEP", "PROBLEM", 65, 100], ["a zinc dependent endopeptidase", "PROBLEM", 111, 141], ["various peptide substrates", "PROBLEM", 181, 207], ["hydrophobic amino acids", "TREATMENT", 230, 253], ["amino acids", "OBSERVATION", 242, 253]]], ["According to the reports, the protein structure of NEP consists of a large hydrophobic pocket, containing the side chains ALA543, ILE558, PHE563, MET579, VAL580, HIS583, VAL692 and, TRP693 [39].", [["ALA543", "CHEMICAL", 122, 128], ["ILE558", "CHEMICAL", 130, 136], ["PHE563", "CHEMICAL", 138, 144], ["MET579", "CHEMICAL", 146, 152], ["HIS583", "CHEMICAL", 162, 168], ["VAL692", "CHEMICAL", 170, 176], ["TRP693", "CHEMICAL", 182, 188], ["NEP", "GENE_OR_GENE_PRODUCT", 51, 54], ["ILE558", "GENE_OR_GENE_PRODUCT", 130, 136], ["PHE563", "GENE_OR_GENE_PRODUCT", 138, 144], ["MET579", "GENE_OR_GENE_PRODUCT", 146, 152], ["VAL580", "GENE_OR_GENE_PRODUCT", 154, 160], ["HIS583", "GENE_OR_GENE_PRODUCT", 162, 168], ["NEP", "PROTEIN", 51, 54], ["a large hydrophobic pocket", "PROBLEM", 67, 93], ["ILE558", "TEST", 130, 136], ["PHE563", "TEST", 138, 144], ["MET579", "TEST", 146, 152], ["VAL580", "TEST", 154, 160], ["HIS583", "TEST", 162, 168], ["VAL692", "TEST", 170, 176], ["TRP693", "TEST", 182, 188], ["large", "OBSERVATION_MODIFIER", 69, 74], ["hydrophobic pocket", "OBSERVATION", 75, 93], ["side", "ANATOMY_MODIFIER", 110, 114], ["chains", "ANATOMY_MODIFIER", 115, 121]]], ["The co-crystalized ligand, sacubitrilat showed hydrophobic interaction with ALA543, ILE558, PHE563, MET579, VAL580, VAL692 and, TRP693.", [["sacubitrilat", "CHEMICAL", 27, 39], ["ALA543", "CHEMICAL", 76, 82], ["sacubitrilat", "CHEMICAL", 27, 39], ["ALA543", "CHEMICAL", 76, 82], ["ILE558", "CHEMICAL", 84, 90], ["PHE563", "CHEMICAL", 92, 98], ["MET579", "CHEMICAL", 100, 106], ["VAL580", "CHEMICAL", 108, 114], ["VAL692", "CHEMICAL", 116, 122], ["TRP693", "CHEMICAL", 128, 134], ["sacubitrilat", "SIMPLE_CHEMICAL", 27, 39], ["ALA543", "SIMPLE_CHEMICAL", 76, 82], ["ILE558", "SIMPLE_CHEMICAL", 84, 90], ["PHE563", "SIMPLE_CHEMICAL", 92, 98], ["MET579", "SIMPLE_CHEMICAL", 100, 106], ["VAL580", "SIMPLE_CHEMICAL", 108, 114], ["TRP693", "GENE_OR_GENE_PRODUCT", 128, 134], ["The co-crystalized ligand", "TEST", 0, 25], ["ALA543", "TEST", 76, 82], ["ILE558", "TEST", 84, 90], ["PHE563", "TEST", 92, 98], ["MET579", "TEST", 100, 106], ["VAL580", "TEST", 108, 114], ["VAL692", "TEST", 116, 122], ["hydrophobic interaction", "OBSERVATION", 47, 70]]], ["The eight selected drugs also showed hydrophobic interaction with ALA543, ILE558, PHE563, MET579, VAL580, VAL692 and, TRP693.", [["ALA543", "CHEMICAL", 66, 72], ["ALA543", "CHEMICAL", 66, 72], ["ILE558", "CHEMICAL", 74, 80], ["PHE563", "CHEMICAL", 82, 88], ["MET579", "CHEMICAL", 90, 96], ["VAL580", "CHEMICAL", 98, 104], ["VAL692", "CHEMICAL", 106, 112], ["TRP693", "CHEMICAL", 118, 124], ["ALA543", "SIMPLE_CHEMICAL", 66, 72], ["ILE558", "SIMPLE_CHEMICAL", 74, 80], ["PHE563", "SIMPLE_CHEMICAL", 82, 88], ["MET579", "SIMPLE_CHEMICAL", 90, 96], ["VAL580", "GENE_OR_GENE_PRODUCT", 98, 104], ["VAL692", "GENE_OR_GENE_PRODUCT", 106, 112], ["TRP693", "GENE_OR_GENE_PRODUCT", 118, 124], ["ALA543", "TEST", 66, 72], ["PHE563", "TEST", 82, 88], ["MET579", "TEST", 90, 96], ["VAL580", "TEST", 98, 104], ["VAL692", "TEST", 106, 112]]], ["But, the hydrophobic interaction with ILE558, MET594 and, TRP693 were missing in interactions of ZINC000000402909, ZINC000003831594, and ZINC000000001427 respectively.", [["ILE558", "CHEMICAL", 38, 44], ["MET594", "CHEMICAL", 46, 52], ["TRP693", "CHEMICAL", 58, 64], ["ZINC000000402909", "CHEMICAL", 97, 113], ["ZINC000003831594", "CHEMICAL", 115, 131], ["ZINC000000001427", "CHEMICAL", 137, 153], ["ILE558", "GENE_OR_GENE_PRODUCT", 38, 44], ["MET594", "SIMPLE_CHEMICAL", 46, 52], ["TRP693", "GENE_OR_GENE_PRODUCT", 58, 64], ["ILE558", "PROTEIN", 38, 44], ["TRP693", "PROTEIN", 58, 64]]], ["Sacubitrilat and the selected eight drugs showed polar, Pi-Pi stacking and cation interaction with HIS583.", [["Sacubitrilat", "CHEMICAL", 0, 12], ["Pi-Pi", "CHEMICAL", 56, 61], ["HIS583", "CHEMICAL", 99, 105], ["Sacubitrilat", "CHEMICAL", 0, 12], ["Pi-Pi", "CHEMICAL", 56, 61], ["HIS583", "CHEMICAL", 99, 105], ["Sacubitrilat", "SIMPLE_CHEMICAL", 0, 12], ["Pi-Pi", "SIMPLE_CHEMICAL", 56, 61], ["cation", "SIMPLE_CHEMICAL", 75, 81], ["HIS583", "SIMPLE_CHEMICAL", 99, 105], ["Sacubitrilat", "TREATMENT", 0, 12], ["polar, Pi-Pi stacking and cation interaction", "TREATMENT", 49, 93], ["HIS583", "TREATMENT", 99, 105], ["polar", "ANATOMY_MODIFIER", 49, 54], ["Pi-Pi stacking", "OBSERVATION", 56, 70], ["cation interaction", "OBSERVATION", 75, 93]]], ["The interactions with side chains of ALA543, ILE558, PHE563, MET579, VAL580, HIS583, VAL692, and TRP693 may contribute to inhibition of peptidase activity of NEP in various disease.", [["TRP693", "CHEMICAL", 97, 103], ["ALA543", "CHEMICAL", 37, 43], ["ILE558", "CHEMICAL", 45, 51], ["PHE563", "CHEMICAL", 53, 59], ["MET579", "CHEMICAL", 61, 67], ["VAL580", "CHEMICAL", 69, 75], ["HIS583", "CHEMICAL", 77, 83], ["VAL692", "CHEMICAL", 85, 91], ["TRP693", "CHEMICAL", 97, 103], ["ALA543", "SIMPLE_CHEMICAL", 37, 43], ["ILE558", "SIMPLE_CHEMICAL", 45, 51], ["PHE563", "SIMPLE_CHEMICAL", 53, 59], ["MET579", "GENE_OR_GENE_PRODUCT", 61, 67], ["VAL580", "GENE_OR_GENE_PRODUCT", 69, 75], ["HIS583", "GENE_OR_GENE_PRODUCT", 77, 83], ["VAL692", "GENE_OR_GENE_PRODUCT", 85, 91], ["TRP693", "GENE_OR_GENE_PRODUCT", 97, 103], ["NEP", "GENE_OR_GENE_PRODUCT", 158, 161], ["peptidase", "PROTEIN", 136, 145], ["NEP", "PROTEIN", 158, 161], ["ALA543", "TEST", 37, 43], ["PHE563", "TEST", 53, 59], ["VAL580", "TEST", 69, 75], ["HIS583", "TEST", 77, 83], ["VAL692", "TEST", 85, 91], ["peptidase activity of NEP in various disease", "PROBLEM", 136, 180], ["various disease", "OBSERVATION", 165, 180]]], ["According to previous reports, amino acid residue GLU584 is important for peptidase activity [40] and amino acid residues such as ALA543 and ASN542 are important for NEP inhibitor [39].", [["amino acid", "CHEMICAL", 31, 41], ["GLU584", "CHEMICAL", 50, 56], ["amino acid", "CHEMICAL", 102, 112], ["ALA543", "CHEMICAL", 130, 136], ["ASN542", "CHEMICAL", 141, 147], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 102, 112], ["ALA543", "CHEMICAL", 130, 136], ["ASN542", "CHEMICAL", 141, 147], ["amino acid", "AMINO_ACID", 31, 41], ["residue", "AMINO_ACID", 42, 49], ["GLU584", "AMINO_ACID", 50, 56], ["amino acid", "AMINO_ACID", 102, 112], ["ALA543", "GENE_OR_GENE_PRODUCT", 130, 136], ["ASN542", "SIMPLE_CHEMICAL", 141, 147], ["NEP", "GENE_OR_GENE_PRODUCT", 166, 169], ["NEP", "PROTEIN", 166, 169], ["amino acid residue GLU584", "TREATMENT", 31, 56], ["peptidase activity", "TEST", 74, 92], ["amino acid residues", "TREATMENT", 102, 121], ["ASN542", "TREATMENT", 141, 147], ["NEP inhibitor", "TREATMENT", 166, 179]]], ["In the current study, all eight selected drugs possess interaction with GLU584, ASN542, and ALA543.", [["GLU584", "CHEMICAL", 72, 78], ["ASN542", "CHEMICAL", 80, 86], ["ALA543", "CHEMICAL", 92, 98], ["GLU584", "SIMPLE_CHEMICAL", 72, 78], ["ASN542", "SIMPLE_CHEMICAL", 80, 86], ["ALA543", "SIMPLE_CHEMICAL", 92, 98], ["the current study", "TEST", 3, 20], ["GLU584", "TEST", 72, 78]]], ["All the eight drugs showed stability in the docked pose with \u0394G binding energy > -34 Kcal/mol (Described in Table 1).", [["\u0394G binding energy", "TREATMENT", 61, 78], ["stability", "OBSERVATION", 27, 36]]], ["The \u0394G binding energy of co-crystallized drug sacubitrilat was found to be -96.51Kcal/mol.", [["sacubitrilat", "CHEMICAL", 46, 58], ["sacubitrilat", "CHEMICAL", 46, 58], ["sacubitrilat", "SIMPLE_CHEMICAL", 46, 58], ["co-crystallized drug sacubitrilat", "TEST", 25, 58]]], ["This finding indicates that, selected drug may act as NEP inhibitor.Induced fit docking (IFD)-SP ::: ResultsAfter the virtual docking studies, based on the ligand interaction and binding energy of the eight drugs, four ligands showing good values were taken forward for induced fit docking (IFD).", [["NEP", "GENE_OR_GENE_PRODUCT", 54, 57], ["SP", "PROTEIN", 94, 96], ["NEP inhibitor", "TREATMENT", 54, 67], ["the virtual docking studies", "TEST", 114, 141], ["the eight drugs", "TREATMENT", 197, 212]]], ["In virtual docking protocol, the interactions occur between the binding site of the rigid protein and the flexible ligand.", [["binding site", "PROTEIN", 64, 76], ["rigid protein", "PROTEIN", 84, 97], ["virtual docking protocol", "TREATMENT", 3, 27], ["rigid protein", "OBSERVATION", 84, 97], ["flexible ligand", "OBSERVATION", 106, 121]]], ["But, this is not the case with the actual ligand-protein interactions in the body, where the target protein undergoes backbone or side-chain movements after binding with ligands which induces alteration in binding sites of the protein.", [["body", "ANATOMY", 77, 81], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["binding sites", "PROTEIN", 206, 219], ["binding with ligands", "PROBLEM", 157, 177], ["alteration in binding sites", "PROBLEM", 192, 219], ["body", "ANATOMY", 77, 81]]], ["Also, in the body, the ligand binding site on the proteins conforms to the ligand shape and binding mode.", [["body", "ANATOMY", 13, 17], ["body", "ORGANISM_SUBDIVISION", 13, 17], ["ligand binding site", "PROTEIN", 23, 42], ["the ligand binding site", "PROBLEM", 19, 42], ["body", "ANATOMY_MODIFIER", 13, 17], ["ligand", "OBSERVATION", 23, 29], ["binding site", "OBSERVATION", 30, 42]]], ["IFD was conducted to resolve the shortcomings of rigid docking protocols.", [["IFD", "DISEASE", 0, 3], ["IFD", "PROBLEM", 0, 3], ["rigid docking protocols", "TREATMENT", 49, 72]]], ["IFD has two main applications, first is it generates the most accurate active complex structure of ligand, which is not possible in virtual molecular docking with rigid protein structure.", [["IFD", "DISEASE", 0, 3], ["IFD", "PROBLEM", 0, 3], ["rigid protein structure", "PROBLEM", 163, 186], ["two", "OBSERVATION_MODIFIER", 8, 11], ["main", "OBSERVATION_MODIFIER", 12, 16], ["active", "OBSERVATION_MODIFIER", 71, 77], ["complex", "OBSERVATION", 78, 85], ["ligand", "ANATOMY", 99, 105], ["not possible", "UNCERTAINTY", 116, 128], ["rigid protein structure", "OBSERVATION", 163, 186]]], ["Second, IFD avoids false-negative results of virtual docking.", [["virtual docking", "TREATMENT", 45, 60]]], ["In virtual docking screening of the ligands was done with the single conformation of ligands.", [["virtual docking screening of the ligands", "TEST", 3, 43]]], ["However, in IFD, 20 confirmers were generated for each ligand.", [["IFD", "DISEASE", 12, 15], ["IFD", "TEST", 12, 15]]], ["Hence IFD-SP was carried for ZINC000000001427, ZINC000001533877, ZINC000000601283, and ZINC000003831594 and a maximum of 20 conformers were generated for each ligand based on molecular docking and binding energy.", [["ZINC000000001427", "CHEMICAL", 29, 45], ["ZINC000001533877", "CHEMICAL", 47, 63], ["ZINC000000601283", "CHEMICAL", 65, 81], ["ZINC000003831594", "CHEMICAL", 87, 103], ["ZINC000000001427", "CHEMICAL", 29, 45], ["ZINC000001533877", "CHEMICAL", 47, 63], ["ZINC000000601283", "CHEMICAL", 65, 81], ["ZINC000003831594", "CHEMICAL", 87, 103], ["ZINC000000001427", "SIMPLE_CHEMICAL", 29, 45], ["ZINC000003831594", "TREATMENT", 87, 103]]], ["Further, the IFD score and ligand interaction were analyzed for selected drugs.", [["the IFD score", "TEST", 9, 22], ["selected drugs", "TREATMENT", 64, 78]]], ["The IFD score and 3D ligand interactions are given in Figure 1.Induced fit docking (IFD)-SP ::: ResultsZINC000000001427 showed similar non-bonding interactions as predicted in XP docking.", [["The IFD score", "TEST", 0, 13], ["3D ligand interactions", "TREATMENT", 18, 40]]], ["The ZINC000001533877 exhibits a new H-bond interaction with HIS711 with similar non-bonding interactions as observed in XP docking.", [["ZINC000001533877", "CHEMICAL", 4, 20], ["HIS711", "CHEMICAL", 60, 66], ["ZINC000001533877", "CHEMICAL", 4, 20], ["H", "CHEMICAL", 36, 37], ["HIS711", "CHEMICAL", 60, 66], ["ZINC000001533877", "SIMPLE_CHEMICAL", 4, 20], ["HIS711", "SIMPLE_CHEMICAL", 60, 66], ["HIS711", "TREATMENT", 60, 66]]], ["In ligand interactions of ZINC000000601283, the new H-bond interaction was observed with HIS711 and lost with GLU584.", [["ZINC000000601283", "CHEMICAL", 26, 42], ["GLU584", "CHEMICAL", 110, 116], ["ZINC000000601283", "CHEMICAL", 26, 42], ["H", "CHEMICAL", 52, 53], ["HIS711", "CHEMICAL", 89, 95], ["GLU584", "CHEMICAL", 110, 116], ["ZINC000000601283", "SIMPLE_CHEMICAL", 26, 42], ["HIS711", "SIMPLE_CHEMICAL", 89, 95], ["GLU584", "SIMPLE_CHEMICAL", 110, 116], ["HIS711", "PROTEIN", 89, 95], ["GLU584", "PROTEIN", 110, 116], ["GLU584", "TEST", 110, 116]]], ["The hydrophobic interaction with ALA543, VAL580, MET579, PHE689, VAL692, TRP693, PHE563, and PHE106 was also lost.", [["TRP693", "CHEMICAL", 73, 79], ["PHE563", "CHEMICAL", 81, 87], ["PHE106", "CHEMICAL", 93, 99], ["ALA543", "CHEMICAL", 33, 39], ["VAL580", "CHEMICAL", 41, 47], ["MET579", "CHEMICAL", 49, 55], ["PHE689", "CHEMICAL", 57, 63], ["VAL692", "CHEMICAL", 65, 71], ["TRP693", "CHEMICAL", 73, 79], ["PHE563", "CHEMICAL", 81, 87], ["PHE106", "CHEMICAL", 93, 99], ["ALA543", "SIMPLE_CHEMICAL", 33, 39], ["VAL580", "SIMPLE_CHEMICAL", 41, 47], ["TRP693", "GENE_OR_GENE_PRODUCT", 73, 79], ["PHE563", "GENE_OR_GENE_PRODUCT", 81, 87], ["PHE106", "SIMPLE_CHEMICAL", 93, 99], ["ALA543", "TEST", 33, 39], ["VAL580", "TEST", 41, 47], ["PHE689", "TEST", 57, 63], ["VAL692", "TEST", 65, 71], ["TRP693", "TEST", 73, 79], ["PHE563", "TEST", 81, 87], ["PHE106", "TEST", 93, 99]]], ["Similarly, new hydrophobic interaction was observed with ILE718 and lost with ILE558 and PHE544.", [["ILE718", "CHEMICAL", 57, 63], ["ILE558", "CHEMICAL", 78, 84], ["PHE544", "CHEMICAL", 89, 95], ["ILE718", "CHEMICAL", 57, 63], ["ILE558", "CHEMICAL", 78, 84], ["PHE544", "CHEMICAL", 89, 95], ["ILE718", "SIMPLE_CHEMICAL", 57, 63], ["ILE558", "SIMPLE_CHEMICAL", 78, 84], ["PHE544", "SIMPLE_CHEMICAL", 89, 95], ["new hydrophobic interaction", "PROBLEM", 11, 38], ["new", "OBSERVATION_MODIFIER", 11, 14], ["hydrophobic interaction", "OBSERVATION", 15, 38]]], ["The new Pi-Pi stacking interactions were observed with TRP693 and PHE106 and missing with amino acid residue HIS583.", [["TRP693", "CHEMICAL", 55, 61], ["PHE106", "CHEMICAL", 66, 72], ["amino acid", "CHEMICAL", 90, 100], ["HIS583", "CHEMICAL", 109, 115], ["Pi-Pi", "CHEMICAL", 8, 13], ["TRP693", "CHEMICAL", 55, 61], ["PHE106", "CHEMICAL", 66, 72], ["amino acid", "CHEMICAL", 90, 100], ["HIS583", "CHEMICAL", 109, 115], ["Pi-Pi", "SIMPLE_CHEMICAL", 8, 13], ["TRP693", "SIMPLE_CHEMICAL", 55, 61], ["PHE106", "SIMPLE_CHEMICAL", 66, 72], ["amino acid", "AMINO_ACID", 90, 100], ["TRP693", "PROTEIN", 55, 61], ["PHE106", "PROTEIN", 66, 72], ["The new Pi-Pi stacking interactions", "PROBLEM", 0, 35], ["TRP693", "TEST", 55, 61], ["PHE106", "TEST", 66, 72], ["amino acid residue", "TEST", 90, 108], ["new", "OBSERVATION_MODIFIER", 4, 7], ["Pi-Pi stacking", "OBSERVATION", 8, 22]]], ["The Pi-Pi cation interaction with ARG717 is retained and lost ARG110 as predicted in XP docking.", [["Pi-Pi", "CHEMICAL", 4, 9], ["ARG717", "CHEMICAL", 34, 40], ["Pi-Pi", "CHEMICAL", 4, 9], ["Pi-Pi cation", "SIMPLE_CHEMICAL", 4, 16], ["ARG717", "SIMPLE_CHEMICAL", 34, 40], ["ARG110", "GENE_OR_GENE_PRODUCT", 62, 68], ["ARG717", "PROTEIN", 34, 40], ["ARG110", "PROTEIN", 62, 68], ["The Pi-Pi cation interaction", "TREATMENT", 0, 28]]], ["The last ligand, ZINC000003831594 retained H-bond interaction with HIS711 and GLU584, showed new H-bond interaction with TRP693, and lost H-bond interaction with ARG717.", [["ZINC000003831594", "CHEMICAL", 17, 33], ["HIS711", "CHEMICAL", 67, 73], ["GLU584", "CHEMICAL", 78, 84], ["ARG717", "CHEMICAL", 162, 168], ["ZINC000003831594", "CHEMICAL", 17, 33], ["H", "CHEMICAL", 43, 44], ["HIS711", "CHEMICAL", 67, 73], ["GLU584", "CHEMICAL", 78, 84], ["H", "CHEMICAL", 97, 98], ["TRP693", "CHEMICAL", 121, 127], ["H", "CHEMICAL", 138, 139], ["ARG717", "CHEMICAL", 162, 168], ["ZINC000003831594", "SIMPLE_CHEMICAL", 17, 33], ["HIS711", "SIMPLE_CHEMICAL", 67, 73], ["GLU584", "SIMPLE_CHEMICAL", 78, 84], ["TRP693", "SIMPLE_CHEMICAL", 121, 127], ["ARG717", "SIMPLE_CHEMICAL", 162, 168], ["TRP693", "PROTEIN", 121, 127], ["ARG717", "PROTEIN", 162, 168], ["HIS711", "TEST", 67, 73], ["GLU584", "TEST", 78, 84], ["new H-bond interaction", "PROBLEM", 93, 115]]], ["The new Pi-Pi stacking interaction was observed with PHE106.", [["Pi-Pi", "CHEMICAL", 8, 13], ["PHE106", "CHEMICAL", 53, 59], ["Pi-Pi", "CHEMICAL", 8, 13], ["PHE106", "CHEMICAL", 53, 59], ["Pi-Pi", "SIMPLE_CHEMICAL", 8, 13], ["PHE106", "SIMPLE_CHEMICAL", 53, 59], ["The new Pi-Pi stacking interaction", "PROBLEM", 0, 34], ["PHE106", "TREATMENT", 53, 59], ["new", "OBSERVATION_MODIFIER", 4, 7], ["Pi-Pi stacking", "OBSERVATION", 8, 22]]], ["ZINC000003831594 also showed new hydrophobic interaction with PHE689 and MET579, with hydrophobic interaction missing with TYR545.", [["ZINC000003831594", "CHEMICAL", 0, 16], ["PHE689", "CHEMICAL", 62, 68], ["MET579", "CHEMICAL", 73, 79], ["TYR545", "CHEMICAL", 123, 129], ["ZINC000003831594", "CHEMICAL", 0, 16], ["PHE689", "CHEMICAL", 62, 68], ["MET579", "CHEMICAL", 73, 79], ["TYR545", "CHEMICAL", 123, 129], ["ZINC000003831594", "SIMPLE_CHEMICAL", 0, 16], ["PHE689", "SIMPLE_CHEMICAL", 62, 68], ["MET579", "SIMPLE_CHEMICAL", 73, 79], ["TYR545", "SIMPLE_CHEMICAL", 123, 129], ["MET579", "PROTEIN", 73, 79], ["TYR545", "PROTEIN", 123, 129]]], ["It also showed similar hydrophobic interaction patterns with other amino acid residues as predicted in XP docking.", [["amino acid", "CHEMICAL", 67, 77], ["amino acid", "CHEMICAL", 67, 77], ["amino acid", "AMINO_ACID", 67, 77], ["other amino acid residues", "PROBLEM", 61, 86], ["XP docking", "TREATMENT", 103, 113], ["similar", "OBSERVATION_MODIFIER", 15, 22], ["hydrophobic interaction", "OBSERVATION", 23, 46], ["amino acid residues", "OBSERVATION", 67, 86]]]], "PMC7403122": [], "PMC7270404": [["IntroductionCOVID-19 is a respiratory disease whose aetiologic agent is a novel beta coronavirus (CoV) called Severe Acute Respiratory Syndrome (SARS)-CoV-2/2019-nCov.", [["respiratory", "ANATOMY", 26, 37], ["respiratory disease", "DISEASE", 26, 45], ["Acute Respiratory Syndrome", "DISEASE", 117, 143], ["SARS", "DISEASE", 145, 149], ["beta coronavirus", "ORGANISM", 80, 96], ["CoV", "ORGANISM", 98, 101], ["Severe Acute Respiratory", "ORGANISM", 110, 134], ["beta coronavirus", "SPECIES", 80, 96], ["CoV", "SPECIES", 98, 101], ["Severe Acute Respiratory Syndrome (SARS)-CoV-2/2019-nCov", "SPECIES", 110, 166], ["IntroductionCOVID", "TEST", 0, 17], ["a respiratory disease", "PROBLEM", 24, 45], ["a novel beta coronavirus", "PROBLEM", 72, 96], ["Severe Acute Respiratory Syndrome", "PROBLEM", 110, 143], ["CoV", "TEST", 151, 154], ["nCov", "TREATMENT", 162, 166], ["respiratory disease", "OBSERVATION", 26, 45], ["Severe", "OBSERVATION_MODIFIER", 110, 116], ["Acute", "OBSERVATION_MODIFIER", 117, 122], ["Respiratory Syndrome", "OBSERVATION", 123, 143]]], ["Indeed, on May 12, 2020, 4.5 million worldwide cases were confirmed (probably a significant under-estimation given the number of untested asymptomatic subjects), with a death toll exceeding 286,000.", [["death", "DISEASE", 169, 174]]], ["Before the SARS-CoV-2 outbreak, two related highly pathogenic CoVs viruses, Middle east respiratory syndrome (MERS)-CoV (1) and SARS-CoV (2), provoked catastrophic epidemics and pandemics, respectively.", [["SARS", "DISEASE", 11, 15], ["Middle east respiratory syndrome", "DISEASE", 76, 108], ["SARS", "DISEASE", 128, 132], ["CoVs", "ORGANISM", 62, 66], ["MERS)-CoV", "ORGANISM", 110, 119], ["SARS-CoV", "ORGANISM", 128, 136], ["SARS-CoV", "SPECIES", 11, 19], ["Middle east respiratory syndrome (MERS)-CoV", "SPECIES", 76, 119], ["SARS-CoV", "SPECIES", 128, 136], ["the SARS", "PROBLEM", 7, 15], ["highly pathogenic CoVs viruses", "PROBLEM", 44, 74], ["Middle east respiratory syndrome", "PROBLEM", 76, 108], ["SARS", "PROBLEM", 128, 132], ["provoked catastrophic epidemics", "PROBLEM", 142, 173], ["pandemics", "PROBLEM", 178, 187], ["pathogenic CoVs viruses", "OBSERVATION", 51, 74], ["Middle", "ANATOMY_MODIFIER", 76, 82], ["respiratory syndrome", "OBSERVATION", 88, 108], ["catastrophic", "OBSERVATION_MODIFIER", 151, 163], ["epidemics", "OBSERVATION", 164, 173]]], ["Unfortunately, no drugs nor vaccines have currently been approved to prevent or treat these viral episodes.", [["drugs", "TREATMENT", 18, 23], ["vaccines", "TREATMENT", 28, 36], ["these viral episodes", "PROBLEM", 86, 106]]], ["The first anatomical/histological reports from the lungs of severely SARS-CoV-2-affected patients experiencing acute respiratory disease syndrome (ARDS) revealed excessive inflammatory activation and destruction of the bronchial and alveolar epithelium, features already observed during the first SARS pandemics in 2003 (3, 4).", [["lungs", "ANATOMY", 51, 56], ["respiratory", "ANATOMY", 117, 128], ["bronchial", "ANATOMY", 219, 228], ["alveolar epithelium", "ANATOMY", 233, 252], ["SARS", "DISEASE", 69, 73], ["acute respiratory disease syndrome", "DISEASE", 111, 145], ["ARDS", "DISEASE", 147, 151], ["SARS pandemics", "DISEASE", 297, 311], ["lungs", "ORGAN", 51, 56], ["SARS-CoV-2", "ORGANISM", 69, 79], ["patients", "ORGANISM", 89, 97], ["bronchial", "MULTI-TISSUE_STRUCTURE", 219, 228], ["alveolar epithelium", "TISSUE", 233, 252], ["patients", "SPECIES", 89, 97], ["severely SARS", "PROBLEM", 60, 73], ["CoV", "TEST", 74, 77], ["acute respiratory disease syndrome", "PROBLEM", 111, 145], ["ARDS", "PROBLEM", 147, 151], ["excessive inflammatory activation", "PROBLEM", 162, 195], ["destruction of the bronchial and alveolar epithelium", "PROBLEM", 200, 252], ["lungs", "ANATOMY", 51, 56], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["respiratory disease", "OBSERVATION", 117, 136], ["excessive", "OBSERVATION_MODIFIER", 162, 171], ["inflammatory activation", "OBSERVATION", 172, 195], ["destruction", "OBSERVATION", 200, 211], ["bronchial", "ANATOMY", 219, 228], ["alveolar", "ANATOMY_MODIFIER", 233, 241], ["epithelium", "ANATOMY_MODIFIER", 242, 252]]], ["Indeed, in the latter pandemic, lung alveolar epithelial cells were identified as the most likely site of virus replication, and it was suggested that alveolar macrophages may be responsible for the dissemination of viruses within the lungs (3).", [["lung alveolar epithelial cells", "ANATOMY", 32, 62], ["alveolar macrophages", "ANATOMY", 151, 171], ["lungs", "ANATOMY", 235, 240], ["lung alveolar epithelial cells", "CELL", 32, 62], ["alveolar macrophages", "CELL", 151, 171], ["lungs", "ORGAN", 235, 240], ["lung alveolar epithelial cells", "CELL_TYPE", 32, 62], ["alveolar macrophages", "CELL_TYPE", 151, 171], ["lung alveolar epithelial cells", "PROBLEM", 32, 62], ["virus replication", "PROBLEM", 106, 123], ["alveolar macrophages", "PROBLEM", 151, 171], ["the dissemination of viruses within the lungs", "PROBLEM", 195, 240], ["lung", "ANATOMY", 32, 36], ["alveolar", "ANATOMY_MODIFIER", 37, 45], ["epithelial cells", "OBSERVATION", 46, 62], ["most likely", "UNCERTAINTY", 86, 97], ["virus replication", "OBSERVATION", 106, 123], ["alveolar macrophages", "OBSERVATION", 151, 171], ["may be responsible for", "UNCERTAINTY", 172, 194], ["viruses", "OBSERVATION", 216, 223], ["lungs", "ANATOMY", 235, 240]]], ["In accordance, initial histological analyses of lung biopsies from patients positive for SARS-CoV-2 have shown exfoliation of the bronchial epithelium, which may induce altered mucociliary clearance and affect host immune responses (5).IntroductionIndeed, there is no doubt that the latter are involved in modulating disease onset and progression.", [["lung biopsies", "ANATOMY", 48, 61], ["bronchial epithelium", "ANATOMY", 130, 150], ["mucociliary", "ANATOMY", 177, 188], ["lung biopsies", "CANCER", 48, 61], ["patients", "ORGANISM", 67, 75], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["bronchial epithelium", "TISSUE", 130, 150], ["mucociliary", "ORGAN", 177, 188], ["patients", "SPECIES", 67, 75], ["SARS-CoV", "SPECIES", 89, 97], ["lung biopsies", "TEST", 48, 61], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["exfoliation of the bronchial epithelium", "PROBLEM", 111, 150], ["altered mucociliary clearance", "PROBLEM", 169, 198], ["modulating disease onset", "PROBLEM", 306, 330], ["lung", "ANATOMY", 48, 52], ["biopsies", "OBSERVATION", 53, 61], ["exfoliation", "OBSERVATION", 111, 122], ["bronchial epithelium", "ANATOMY", 130, 150], ["mucociliary clearance", "OBSERVATION", 177, 198], ["no doubt", "UNCERTAINTY", 265, 273], ["disease", "OBSERVATION", 317, 324], ["progression", "OBSERVATION_MODIFIER", 335, 346]]], ["For example, early studies report that, similarly with what was observed with SARS-CoV, lymphopenia [sometimes equivalent or more severe than that observed in human immunodeficiency virus (HIV) infection] is often observed in severely affected patients progressing to ARDS.", [["SARS-CoV", "DISEASE", 78, 86], ["lymphopenia", "DISEASE", 88, 99], ["human immunodeficiency virus (HIV) infection", "DISEASE", 159, 203], ["ARDS", "DISEASE", 268, 272], ["SARS-CoV", "ORGANISM", 78, 86], ["human immunodeficiency virus", "ORGANISM", 159, 187], ["HIV", "ORGANISM", 189, 192], ["patients", "ORGANISM", 244, 252], ["human immunodeficiency virus (HIV", "SPECIES", 159, 192], ["patients", "SPECIES", 244, 252], ["SARS-CoV", "SPECIES", 78, 86], ["human immunodeficiency virus", "SPECIES", 159, 187], ["HIV", "SPECIES", 189, 192], ["early studies", "TEST", 13, 26], ["SARS", "PROBLEM", 78, 82], ["CoV", "PROBLEM", 83, 86], ["lymphopenia", "PROBLEM", 88, 99], ["human immunodeficiency virus (HIV) infection", "PROBLEM", 159, 203], ["ARDS", "PROBLEM", 268, 272], ["lymphopenia", "OBSERVATION", 88, 99], ["more severe", "OBSERVATION_MODIFIER", 125, 136], ["ARDS", "OBSERVATION", 268, 272]]], ["Despite, or maybe correlated with this, aberrant non-effective innate immune host responses seem associated with severe lung disease during SARS (6\u201312).IntroductionThe following sections will give an overview of the molecular and cellular mechanisms underpinning SARS-CoV virus infections and how lung and systemic host innate immune responses affect survival either positively, through downregulating the initial viral load, or negatively, by triggering uncontrolled inflammation.", [["lung", "ANATOMY", 120, 124], ["cellular", "ANATOMY", 230, 238], ["lung", "ANATOMY", 297, 301], ["lung disease", "DISEASE", 120, 132], ["SARS", "DISEASE", 140, 144], ["SARS-CoV virus infections", "DISEASE", 263, 288], ["inflammation", "DISEASE", 468, 480], ["lung", "ORGAN", 120, 124], ["cellular", "CELL", 230, 238], ["SARS-CoV virus", "ORGANISM", 263, 277], ["lung", "ORGAN", 297, 301], ["SARS-CoV virus", "SPECIES", 263, 277], ["severe lung disease", "PROBLEM", 113, 132], ["SARS", "PROBLEM", 263, 267], ["CoV virus infections", "PROBLEM", 268, 288], ["the initial viral load", "TEST", 402, 424], ["uncontrolled inflammation", "PROBLEM", 455, 480], ["associated with", "UNCERTAINTY", 97, 112], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["lung", "ANATOMY", 120, 124], ["disease", "OBSERVATION", 125, 132], ["lung", "ANATOMY", 297, 301], ["viral load", "OBSERVATION", 414, 424], ["uncontrolled", "OBSERVATION_MODIFIER", 455, 467], ["inflammation", "OBSERVATION", 468, 480]]], ["A particular emphasis will be put on the description of the host cellular signaling pathways and proteases involved with a view on tackling these therapeutically.Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)CoVs are enveloped viruses with a positive-polarity, single-stranded RNA genome encoding four structural proteins: the transmembrane trimeric spike glycoprotein (S, composed of two subunits S1 and S2), envelop (E), matrix (M), and nucleocapsid (N) (13).Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)The entry of CoV viruses into host epithelial cells is mediated by the interaction between the viral envelope S protein homotrimers and the cell surface receptors.", [["cellular", "ANATOMY", 65, 73], ["Epithelial Cells", "ANATOMY", 211, 227], ["transmembrane", "ANATOMY", 393, 406], ["Epithelial Cells", "ANATOMY", 576, 592], ["epithelial cells", "ANATOMY", 674, 690], ["cell surface", "ANATOMY", 779, 791], ["cellular", "CELL", 65, 73], ["Target Epithelial Cells", "CELL", 204, 227], ["1A#!sep#F1#!sep#fig#!end#)CoVs", "GENE_OR_GENE_PRODUCT", 248, 278], ["transmembrane", "CELLULAR_COMPONENT", 393, 406], ["S2", "GENE_OR_GENE_PRODUCT", 471, 473], ["envelop (E)", "GENE_OR_GENE_PRODUCT", 476, 487], ["matrix", "CELLULAR_COMPONENT", 489, 495], ["Target Epithelial Cells", "CELL", 569, 592], ["CoV viruses", "ORGANISM", 652, 663], ["host epithelial cells", "CELL", 669, 690], ["cell surface", "CELLULAR_COMPONENT", 779, 791], ["proteases", "PROTEIN", 97, 106], ["Target Epithelial Cells", "CELL_TYPE", 204, 227], ["1A#!sep#F1#!sep#fig#!end#)CoVs", "DNA", 248, 278], ["single-stranded RNA genome", "DNA", 327, 353], ["structural proteins", "PROTEIN", 368, 387], ["transmembrane trimeric spike glycoprotein", "PROTEIN", 393, 434], ["S", "PROTEIN", 436, 437], ["S1", "PROTEIN", 464, 466], ["S2", "PROTEIN", 471, 473], ["envelop", "PROTEIN", 476, 483], ["E", "PROTEIN", 485, 486], ["matrix (M)", "PROTEIN", 489, 499], ["nucleocapsid (N) (13)", "PROTEIN", 505, 526], ["Target Epithelial Cells", "CELL_TYPE", 569, 592], ["host epithelial cells", "CELL_TYPE", 669, 690], ["viral envelope S protein", "PROTEIN", 734, 758], ["homotrimers", "PROTEIN", 759, 770], ["cell surface receptors", "PROTEIN", 779, 801], ["CoV viruses", "SPECIES", 652, 663], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 176, 227], ["enveloped viruses", "PROBLEM", 283, 300], ["single-stranded RNA genome", "PROBLEM", 327, 353], ["the transmembrane trimeric spike glycoprotein", "PROBLEM", 389, 434], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 541, 592], ["CoV viruses into host epithelial cells", "PROBLEM", 652, 690], ["the viral envelope S protein homotrimers", "TREATMENT", 730, 770], ["the cell surface receptors", "TREATMENT", 775, 801], ["Epithelial Cells", "OBSERVATION", 211, 227], ["viruses", "OBSERVATION", 293, 300], ["RNA genome", "OBSERVATION", 343, 353], ["S2", "ANATOMY", 471, 473], ["Epithelial Cells", "OBSERVATION", 576, 592], ["CoV viruses", "OBSERVATION", 652, 663], ["host epithelial cells", "OBSERVATION", 669, 690], ["viral", "OBSERVATION", 734, 739], ["cell surface", "OBSERVATION", 779, 791]]], ["Following proteolytic cleavage of the CoV S protein (\u201cpriming\u201d), the S1 ecto-domain recognizes a membrane receptor [angiotensin-converting enzyme 2 (ACE2) for SARS-Cov and SARS-Cov-2 as well as Dipeptidyl peptidase 4 (DPP4) for MERS-Cov], whereas the S2 C-terminal domain is involved in cell fusion and viral entry (14\u201316).", [["membrane", "ANATOMY", 97, 105], ["cell", "ANATOMY", 287, 291], ["angiotensin", "CHEMICAL", 116, 127], ["C", "CHEMICAL", 254, 255], ["CoV S", "GENE_OR_GENE_PRODUCT", 38, 43], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 116, 147], ["ACE2", "GENE_OR_GENE_PRODUCT", 149, 153], ["SARS-Cov", "GENE_OR_GENE_PRODUCT", 159, 167], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 172, 182], ["Dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 194, 216], ["DPP4", "GENE_OR_GENE_PRODUCT", 218, 222], ["MERS-Cov", "GENE_OR_GENE_PRODUCT", 228, 236], ["cell", "CELL", 287, 291], ["CoV S protein", "PROTEIN", 38, 51], ["S1 ecto-domain", "PROTEIN", 69, 83], ["membrane receptor", "PROTEIN", 97, 114], ["angiotensin-converting enzyme 2", "PROTEIN", 116, 147], ["ACE2", "PROTEIN", 149, 153], ["Cov", "PROTEIN", 164, 167], ["SARS-Cov-2", "PROTEIN", 172, 182], ["Dipeptidyl peptidase 4", "PROTEIN", 194, 216], ["DPP4", "PROTEIN", 218, 222], ["MERS", "PROTEIN", 228, 232], ["Cov", "PROTEIN", 233, 236], ["S2 C-terminal domain", "PROTEIN", 251, 271], ["proteolytic cleavage", "TREATMENT", 10, 30], ["the CoV S protein", "TREATMENT", 34, 51], ["a membrane receptor", "TREATMENT", 95, 114], ["angiotensin", "TEST", 116, 127], ["converting enzyme", "TEST", 128, 145], ["ACE2", "TEST", 149, 153], ["SARS", "PROBLEM", 159, 163], ["Cov", "TEST", 164, 167], ["SARS", "TEST", 172, 176], ["Cov", "TEST", 177, 180], ["Dipeptidyl peptidase", "TREATMENT", 194, 214], ["MERS", "PROBLEM", 228, 232], ["terminal domain", "PROBLEM", 256, 271], ["cell fusion", "TREATMENT", 287, 298], ["viral entry", "TEST", 303, 314], ["S1", "ANATOMY", 69, 71], ["cell fusion", "OBSERVATION", 287, 298]]], ["This mechanism of action is very similar to that used by Influenza, except that the latter use sialic acids as the cognate receptor for its hemagglutinin (HA) ligand.", [["Influenza", "DISEASE", 57, 66], ["sialic acids", "CHEMICAL", 95, 107], ["sialic acids", "CHEMICAL", 95, 107], ["sialic acids", "SIMPLE_CHEMICAL", 95, 107], ["hemagglutinin (HA) ligand", "GENE_OR_GENE_PRODUCT", 140, 165], ["hemagglutinin (HA) ligand", "PROTEIN", 140, 165], ["Influenza", "PROBLEM", 57, 66], ["sialic acids", "TREATMENT", 95, 107], ["the cognate receptor", "TREATMENT", 111, 131], ["its hemagglutinin (HA) ligand", "TREATMENT", 136, 165]]], ["Importantly, many viruses (Influenza, MERS, CoV, and Paramyxoviruses such as Hendra and Nipah viruses) use similar host proteolytic enzymes for cleaving their ligands (HA and S), namely, mostly lysosomal (Cathepsins B, L), furin, or trypsin-like proteases (17, 18).", [["Influenza", "DISEASE", 27, 36], ["Hendra and Nipah viruses", "DISEASE", 77, 101], ["Influenza", "ORGANISM", 27, 36], ["MERS", "GENE_OR_GENE_PRODUCT", 38, 42], ["CoV", "ORGANISM", 44, 47], ["Hendra", "ORGANISM", 77, 83], ["Nipah viruses", "ORGANISM", 88, 101], ["lysosomal", "CELLULAR_COMPONENT", 194, 203], ["Cathepsins B, L)", "GENE_OR_GENE_PRODUCT", 205, 221], ["furin", "GENE_OR_GENE_PRODUCT", 223, 228], ["trypsin", "GENE_OR_GENE_PRODUCT", 233, 240], ["proteolytic enzymes", "PROTEIN", 120, 139], ["HA and S", "PROTEIN", 168, 176], ["lysosomal (Cathepsins B, L)", "PROTEIN", 194, 221], ["furin", "PROTEIN", 223, 228], ["trypsin-like proteases", "PROTEIN", 233, 255], ["17, 18", "PROTEIN", 257, 263], ["Nipah", "SPECIES", 88, 93], ["Nipah viruses", "SPECIES", 88, 101], ["many viruses", "PROBLEM", 13, 25], ["Influenza", "PROBLEM", 27, 36], ["MERS", "PROBLEM", 38, 42], ["CoV", "PROBLEM", 44, 47], ["Paramyxoviruses", "PROBLEM", 53, 68], ["Hendra and Nipah viruses", "TREATMENT", 77, 101], ["host proteolytic enzymes", "TEST", 115, 139], ["furin", "PROBLEM", 223, 228], ["trypsin-like proteases", "PROBLEM", 233, 255], ["many", "OBSERVATION_MODIFIER", 13, 17], ["viruses", "OBSERVATION", 18, 25]]], ["Indeed, it is believed that it is the cellular source of these proteases that may determine the infectivity spectrum of these viruses, with the lung and the gastro-intestinal tract being high producers (19, 20).Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Although a variety of these proteases have been studied and shown to be involved to varying degrees in virus activation, including neutrophil elastase (21), proteases of the type II transmembrane serine proteases (TTSP) family [HAT, Transmembrane protease, serine (TMPRSS)2, and TMPRSS4] have recently been demonstrated to be particularly important, albeit probably at different stages of the virus cell cycle (19, 20, 22, 23).", [["cellular", "ANATOMY", 38, 46], ["lung", "ANATOMY", 144, 148], ["gastro-intestinal tract", "ANATOMY", 157, 180], ["Epithelial Cells", "ANATOMY", 260, 276], ["cell", "ANATOMY", 722, 726], ["serine", "CHEMICAL", 519, 525], ["serine", "CHEMICAL", 580, 586], ["cellular", "CELL", 38, 46], ["lung", "ORGAN", 144, 148], ["gastro-", "ORGANISM", 157, 164], ["intestinal tract", "ORGAN", 164, 180], ["Target Epithelial Cells", "CELL", 253, 276], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 454, 473], ["type II transmembrane serine proteases", "GENE_OR_GENE_PRODUCT", 497, 535], ["TTSP", "GENE_OR_GENE_PRODUCT", 537, 541], ["Transmembrane protease, serine (TMPRSS)2", "GENE_OR_GENE_PRODUCT", 556, 596], ["TMPRSS4", "GENE_OR_GENE_PRODUCT", 602, 609], ["cell", "CELL", 722, 726], ["proteases", "PROTEIN", 63, 72], ["Target Epithelial Cells", "CELL_TYPE", 253, 276], ["proteases", "PROTEIN", 351, 360], ["neutrophil elastase", "PROTEIN", 454, 473], ["proteases", "PROTEIN", 480, 489], ["type II transmembrane serine proteases (TTSP) family", "PROTEIN", 497, 549], ["HAT", "PROTEIN", 551, 554], ["Transmembrane protease", "PROTEIN", 556, 578], ["serine (TMPRSS)2", "PROTEIN", 580, 596], ["TMPRSS4", "PROTEIN", 602, 609], ["these proteases", "PROBLEM", 57, 72], ["these viruses", "PROBLEM", 120, 133], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 225, 276], ["these proteases", "TREATMENT", 345, 360], ["virus activation", "PROBLEM", 426, 442], ["neutrophil elastase", "TEST", 454, 473], ["the type II transmembrane serine proteases", "TREATMENT", 493, 535], ["Transmembrane protease", "TREATMENT", 556, 578], ["serine (TMPRSS)", "TREATMENT", 580, 595], ["viruses", "OBSERVATION", 126, 133], ["lung", "ANATOMY", 144, 148], ["gastro", "ANATOMY", 157, 163], ["intestinal tract", "ANATOMY", 164, 180], ["high", "OBSERVATION_MODIFIER", 187, 191], ["Epithelial Cells", "OBSERVATION", 260, 276], ["virus cell", "OBSERVATION", 716, 726]]], ["In particular, recent research on SARS-Cov-2 has focused on TMPRSS2 and has shown it to be important (although mostly using cell lines infected with pseudotyped virus particles bearing SARS-Cov-2 S protein) for virus entry (24, 25).", [["cell lines", "ANATOMY", 124, 134], ["SARS", "DISEASE", 34, 38], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 60, 67], ["cell lines", "CELL", 124, 134], ["pseudotyped virus particles", "ORGANISM", 149, 176], ["SARS-Cov-2 S protein", "GENE_OR_GENE_PRODUCT", 185, 205], ["TMPRSS2", "DNA", 60, 67], ["SARS-Cov-2 S protein", "PROTEIN", 185, 205], ["SARS", "PROBLEM", 34, 38], ["Cov", "TEST", 39, 42], ["TMPRSS2", "TEST", 60, 67], ["cell lines", "TREATMENT", 124, 134], ["pseudotyped virus particles", "TREATMENT", 149, 176], ["SARS", "TEST", 185, 189], ["Cov", "TEST", 190, 193], ["virus entry", "TEST", 211, 222]]], ["In that context, it has also been demonstrated that the serine protease inhibitor camostat (see also below section on Therapeutic targets and Conclusion) was protective (24, 25).", [["camostat", "CHEMICAL", 82, 90], ["serine", "CHEMICAL", 56, 62], ["camostat", "CHEMICAL", 82, 90], ["camostat", "SIMPLE_CHEMICAL", 82, 90], ["the serine protease inhibitor camostat", "TREATMENT", 52, 90]]], ["In contrast, DPP4 which is necessary for the entry of MERS-CoV (26, 27) is not involved in SARS-Cov-2 entry (24).", [["DPP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 54, 62], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 91, 101], ["DPP4", "PROTEIN", 13, 17], ["MERS", "PROTEIN", 54, 58], ["MERS-CoV", "SPECIES", 54, 62], ["DPP4", "TEST", 13, 17], ["CoV", "TEST", 59, 62]]], ["Unlike other SARS-CoVs, the S protein of SARS-CoV-2 has a furin cleavage site at the boundary between the S1 and S2 subunits, which is processed during biogenesis and which may explain CoV-2 high infectivity (28).", [["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 13, 22], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["furin", "GENE_OR_GENE_PRODUCT", 58, 63], ["S1", "GENE_OR_GENE_PRODUCT", 106, 108], ["S2", "GENE_OR_GENE_PRODUCT", 113, 115], ["CoV-2", "GENE_OR_GENE_PRODUCT", 185, 190], ["SARS-CoVs", "PROTEIN", 13, 22], ["S protein", "PROTEIN", 28, 37], ["furin cleavage site", "PROTEIN", 58, 77], ["S1 and S2 subunits", "PROTEIN", 106, 124], ["SARS-CoV", "SPECIES", 41, 49], ["other SARS", "PROBLEM", 7, 17], ["the S protein", "TEST", 24, 37], ["SARS", "PROBLEM", 41, 45], ["CoV", "TEST", 46, 49], ["a furin cleavage site", "PROBLEM", 56, 77], ["CoV", "TEST", 185, 188], ["high infectivity", "PROBLEM", 191, 207], ["SARS", "OBSERVATION", 13, 17], ["CoVs", "OBSERVATION", 18, 22], ["S1", "ANATOMY", 106, 108], ["S2", "ANATOMY", 113, 115]]], ["Although mechanistic studies are obviously still in their infancy, it is very likely that SARS-CoV and SARS-CoV-2 target mainly respiratory epithelial cells with similar mechanisms.", [["respiratory epithelial cells", "ANATOMY", 128, 156], ["SARS", "DISEASE", 90, 94], ["SARS-CoV", "ORGANISM", 90, 98], ["SARS-CoV-2", "ORGANISM", 103, 113], ["respiratory epithelial cells", "CELL", 128, 156], ["respiratory epithelial cells", "CELL_TYPE", 128, 156], ["SARS-CoV", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 103, 111], ["mechanistic studies", "TEST", 9, 28], ["SARS", "PROBLEM", 90, 94], ["CoV", "TEST", 95, 98], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["respiratory epithelial cells", "PROBLEM", 128, 156], ["very likely", "UNCERTAINTY", 73, 84], ["respiratory epithelial cells", "OBSERVATION", 128, 156]]], ["Indeed, as indicated above, initial work has shown that ACE2 is the S receptor for both SARS-CoV (29) and SARS-CoV-2 viruses (24, 28, 30), and structural studies using cryo-electron microscopy suggest a binding of two S protein trimer to an ACE2 dimer (28, 30).Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Whether this is strictly dependent on ACE2/protease expression is debatable since ACE2 is present in other tissues in humans [such as the intestine, kidney, and testis (31)].", [["Epithelial Cells", "ANATOMY", 310, 326], ["tissues", "ANATOMY", 480, 487], ["intestine", "ANATOMY", 511, 520], ["kidney", "ANATOMY", 522, 528], ["testis", "ANATOMY", 534, 540], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["SARS-CoV", "ORGANISM", 88, 96], ["SARS-CoV-2 viruses", "ORGANISM", 106, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 241, 245], ["Target Epithelial Cells", "CELL", 303, 326], ["ACE2", "GENE_OR_GENE_PRODUCT", 411, 415], ["ACE2", "GENE_OR_GENE_PRODUCT", 455, 459], ["tissues", "TISSUE", 480, 487], ["humans", "ORGANISM", 491, 497], ["intestine", "ORGAN", 511, 520], ["kidney", "ORGAN", 522, 528], ["testis", "ORGAN", 534, 540], ["ACE2", "PROTEIN", 56, 60], ["S receptor", "PROTEIN", 68, 78], ["S protein trimer", "PROTEIN", 218, 234], ["ACE2 dimer", "PROTEIN", 241, 251], ["Target Epithelial Cells", "CELL_TYPE", 303, 326], ["ACE2", "PROTEIN", 411, 415], ["protease", "PROTEIN", 416, 424], ["ACE2", "PROTEIN", 455, 459], ["humans", "SPECIES", 491, 497], ["SARS-CoV", "SPECIES", 88, 96], ["humans", "SPECIES", 491, 497], ["ACE2", "TEST", 56, 60], ["the S receptor", "TEST", 64, 78], ["both SARS", "TEST", 83, 92], ["CoV", "TEST", 93, 96], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["structural studies", "TEST", 143, 161], ["cryo-electron microscopy", "TEST", 168, 192], ["an ACE2 dimer", "TEST", 238, 251], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 275, 326], ["ACE2/protease expression", "TREATMENT", 411, 435], ["ACE2", "PROBLEM", 455, 459], ["Epithelial Cells", "OBSERVATION", 310, 326], ["strictly dependent", "OBSERVATION_MODIFIER", 389, 407], ["intestine", "ANATOMY", 511, 520], ["kidney", "ANATOMY", 522, 528], ["testis", "ANATOMY", 534, 540]]], ["Indeed, \u201cseasonal\u201d low pathogenic CoVs (e.g., CoV-229E, CoV-OC43) infect mostly upper airways, whereas pathogenic CoVs (SARS-CoV/SARS-CoV-2 and MERS) have a tropism for the distal lung and can cause severe pneumonia and ARDS (32), as currently demonstrated again in the present pandemic.", [["upper airways", "ANATOMY", 80, 93], ["distal lung", "ANATOMY", 173, 184], ["pneumonia", "DISEASE", 206, 215], ["ARDS", "DISEASE", 220, 224], ["CoVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["CoV-229E", "ORGANISM", 46, 54], ["CoV-OC43", "ORGANISM", 56, 64], ["upper airways", "ORGAN", 80, 93], ["CoVs", "GENE_OR_GENE_PRODUCT", 114, 118], ["SARS-CoV", "ORGANISM", 120, 128], ["SARS-CoV-2", "ORGANISM", 129, 139], ["MERS", "GENE_OR_GENE_PRODUCT", 144, 148], ["lung", "ORGAN", 180, 184], ["CoV-229E", "SPECIES", 46, 54], ["SARS-CoV/SARS-CoV", "SPECIES", 120, 137], ["seasonal\u201d low pathogenic CoVs", "PROBLEM", 9, 38], ["CoV", "TEST", 46, 49], ["CoV", "TEST", 56, 59], ["pathogenic CoVs", "PROBLEM", 103, 118], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["SARS", "PROBLEM", 129, 133], ["CoV", "TEST", 134, 137], ["MERS", "PROBLEM", 144, 148], ["severe pneumonia", "PROBLEM", 199, 215], ["ARDS", "PROBLEM", 220, 224], ["pathogenic CoVs", "OBSERVATION", 23, 38], ["upper", "ANATOMY_MODIFIER", 80, 85], ["airways", "ANATOMY", 86, 93], ["distal", "ANATOMY_MODIFIER", 173, 179], ["lung", "ANATOMY", 180, 184], ["severe", "OBSERVATION_MODIFIER", 199, 205], ["pneumonia", "OBSERVATION", 206, 215], ["ARDS", "OBSERVATION", 220, 224], ["pandemic", "OBSERVATION", 278, 286]]], ["Indeed, potentially explaining this is the fact that seasonal coronaviruses do not use ACE2 as a receptor.", [["coronaviruses", "ORGANISM", 62, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["ACE2", "PROTEIN", 87, 91], ["seasonal coronaviruses", "PROBLEM", 53, 75]]], ["In vitro, primary nasal and tracheobronchial epithelial cells as well as the Calu-3 bronchial cell line were shown to express ACE2 (the latter not colocalizing with cilia), and their infection with SARS-CoV was shown to be highly cytotoxic (33, 34).", [["nasal", "ANATOMY", 18, 23], ["tracheobronchial epithelial cells", "ANATOMY", 28, 61], ["Calu-3 bronchial cell line", "ANATOMY", 77, 103], ["cilia", "ANATOMY", 165, 170], ["infection", "DISEASE", 183, 192], ["SARS", "DISEASE", 198, 202], ["nasal", "ORGAN", 18, 23], ["tracheobronchial epithelial cells", "CELL", 28, 61], ["Calu-3 bronchial cell line", "CELL", 77, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 126, 130], ["cilia", "CELLULAR_COMPONENT", 165, 170], ["SARS-CoV", "ORGANISM", 198, 206], ["primary nasal and tracheobronchial epithelial cells", "CELL_TYPE", 10, 61], ["Calu-3 bronchial cell line", "CELL_LINE", 77, 103], ["ACE2", "PROTEIN", 126, 130], ["SARS-CoV", "SPECIES", 198, 206], ["primary nasal and tracheobronchial epithelial cells", "PROBLEM", 10, 61], ["the Calu", "TEST", 73, 81], ["ACE2", "TEST", 126, 130], ["their infection", "PROBLEM", 177, 192], ["SARS", "PROBLEM", 198, 202], ["CoV", "PROBLEM", 203, 206], ["primary", "OBSERVATION_MODIFIER", 10, 17], ["nasal", "ANATOMY", 18, 23], ["tracheobronchial", "ANATOMY", 28, 44], ["epithelial cells", "OBSERVATION", 45, 61], ["bronchial", "ANATOMY", 84, 93], ["cell line", "OBSERVATION", 94, 103], ["infection", "OBSERVATION", 183, 192], ["cytotoxic", "OBSERVATION_MODIFIER", 230, 239]]], ["In the distal lung, as hinted above, primary alveolar type II epithelial (ATII) cells are also permissive to SARS-CoV infection (35, 36).", [["distal lung", "ANATOMY", 7, 18], ["primary alveolar type II epithelial (ATII) cells", "ANATOMY", 37, 85], ["SARS-CoV infection", "DISEASE", 109, 127], ["lung", "ORGAN", 14, 18], ["alveolar type II epithelial (ATII) cells", "CELL", 45, 85], ["SARS-CoV", "ORGANISM", 109, 117], ["primary alveolar type II epithelial (ATII) cells", "CELL_TYPE", 37, 85], ["SARS-CoV", "SPECIES", 109, 117], ["primary alveolar type II epithelial (ATII) cells", "PROBLEM", 37, 85], ["SARS", "PROBLEM", 109, 113], ["CoV infection", "PROBLEM", 114, 127], ["distal", "ANATOMY_MODIFIER", 7, 13], ["lung", "ANATOMY", 14, 18], ["primary", "OBSERVATION_MODIFIER", 37, 44], ["alveolar", "ANATOMY_MODIFIER", 45, 53], ["epithelial", "ANATOMY_MODIFIER", 62, 72], ["ATII) cells", "OBSERVATION", 74, 85], ["SARS", "OBSERVATION_MODIFIER", 109, 113], ["CoV", "OBSERVATION_MODIFIER", 114, 117], ["infection", "OBSERVATION", 118, 127]]], ["SARS-CoV-2 has also been shown to infect various respiratory epithelial cell lines including A549 (alveolar origin), BEAS2-B (bronchial origin), Calu-3 cells, as well as primary human bronchial epithelial cells (24).", [["respiratory epithelial cell lines", "ANATOMY", 49, 82], ["A549", "ANATOMY", 93, 97], ["alveolar", "ANATOMY", 99, 107], ["BEAS2-B", "ANATOMY", 117, 124], ["bronchial", "ANATOMY", 126, 135], ["Calu-3 cells", "ANATOMY", 145, 157], ["bronchial epithelial cells", "ANATOMY", 184, 210], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["respiratory epithelial cell lines", "CELL", 49, 82], ["A549", "CELL", 93, 97], ["BEAS2-B", "CELL", 117, 124], ["Calu-3 cells", "CELL", 145, 157], ["human", "ORGANISM", 178, 183], ["bronchial epithelial cells", "CELL", 184, 210], ["respiratory epithelial cell lines", "CELL_LINE", 49, 82], ["A549", "CELL_LINE", 93, 97], ["BEAS2-B", "CELL_LINE", 117, 124], ["Calu-3 cells", "CELL_LINE", 145, 157], ["primary human bronchial epithelial cells", "CELL_TYPE", 170, 210], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["various respiratory epithelial cell lines", "PROBLEM", 41, 82], ["BEAS2", "TEST", 117, 122], ["Calu", "TEST", 145, 149], ["primary human bronchial epithelial cells", "PROBLEM", 170, 210], ["respiratory epithelial cell lines", "OBSERVATION", 49, 82], ["A549", "OBSERVATION_MODIFIER", 93, 97], ["alveolar", "ANATOMY_MODIFIER", 99, 107], ["origin", "ANATOMY_MODIFIER", 108, 114], ["bronchial", "ANATOMY", 126, 135], ["origin", "ANATOMY_MODIFIER", 136, 142], ["3 cells", "OBSERVATION", 150, 157], ["bronchial", "ANATOMY", 184, 193], ["epithelial cells", "OBSERVATION", 194, 210]]], ["Besides the lung, ACE2 is also highly expressed in the intestine (37), and gastrointestinal symptoms have been recorded with COVID-19 (38).", [["lung", "ANATOMY", 12, 16], ["intestine", "ANATOMY", 55, 64], ["gastrointestinal", "ANATOMY", 75, 91], ["gastrointestinal symptoms", "DISEASE", 75, 100], ["COVID-19", "CHEMICAL", 125, 133], ["lung", "ORGAN", 12, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["intestine", "ORGAN", 55, 64], ["gastrointestinal", "ORGAN", 75, 91], ["ACE2", "PROTEIN", 18, 22], ["gastrointestinal symptoms", "PROBLEM", 75, 100], ["COVID", "TEST", 125, 130], ["lung", "ANATOMY", 12, 16], ["ACE2", "OBSERVATION", 18, 22], ["intestine", "ANATOMY", 55, 64], ["gastrointestinal", "ANATOMY", 75, 91]]], ["It was shown that SARS-COV2 is able to infect enterocytes as well as intestinal organoids and induces a viral response characterized by the expression of mediators related to type I and III IFN (39).Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Even if SARS-CoV2 is thought to originate from bats, the intermediate host between bats and humans is still unknown.", [["enterocytes", "ANATOMY", 46, 57], ["intestinal organoids", "ANATOMY", 69, 89], ["Epithelial Cells", "ANATOMY", 248, 264], ["SARS", "DISEASE", 319, 323], ["SARS-COV2", "GENE_OR_GENE_PRODUCT", 18, 27], ["enterocytes", "CELL", 46, 57], ["intestinal organoids", "CELL", 69, 89], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 175, 193], ["Target Epithelial Cells", "CELL", 241, 264], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 319, 328], ["bats", "ORGANISM", 394, 398], ["humans", "ORGANISM", 403, 409], ["COV2", "PROTEIN", 23, 27], ["intestinal organoids", "CELL_TYPE", 69, 89], ["Target Epithelial Cells", "CELL_TYPE", 241, 264], ["CoV2", "DNA", 324, 328], ["humans", "SPECIES", 403, 409], ["humans", "SPECIES", 403, 409], ["SARS-COV2", "PROBLEM", 18, 27], ["intestinal organoids", "PROBLEM", 69, 89], ["a viral response", "PROBLEM", 102, 118], ["type I and III IFN", "PROBLEM", 175, 193], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 213, 264], ["SARS", "PROBLEM", 319, 323], ["intestinal", "ANATOMY", 69, 79], ["organoids", "OBSERVATION", 80, 89], ["Epithelial Cells", "OBSERVATION", 248, 264]]], ["SARS-CoV was previously shown to infect various wild and domestic animals, including cats, ferrets and pigs (40\u201342).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["cats", "ORGANISM", 85, 89], ["ferrets", "ORGANISM", 91, 98], ["pigs", "ORGANISM", 103, 107], ["cats", "SPECIES", 85, 89], ["ferrets", "SPECIES", 91, 98], ["pigs", "SPECIES", 103, 107], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4]]], ["Similarly, recent work reveals that domestic animals, including ferrets and cats, are permissive to SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 100, 120], ["ferrets", "ORGANISM", 64, 71], ["cats", "ORGANISM", 76, 80], ["SARS-CoV-2", "ORGANISM", 100, 110], ["ferrets", "SPECIES", 64, 71], ["cats", "SPECIES", 76, 80], ["ferrets", "SPECIES", 64, 71], ["SARS-CoV-2", "SPECIES", 100, 110], ["SARS", "PROBLEM", 100, 104], ["CoV-2 infection", "PROBLEM", 105, 120], ["infection", "OBSERVATION", 111, 120]]], ["In contrast, the virus replicates poorly in pigs, ducks, chickens, and dogs (43).Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Given the described importance of host proteases in mediating infectivity of a number of viruses, it is no surprise that, upon virus infection, murine knock-out (KO) for some of these molecules has shown some protection.", [["Epithelial Cells", "ANATOMY", 130, 146], ["infection", "DISEASE", 326, 335], ["pigs", "ORGANISM", 44, 48], ["ducks", "ORGANISM", 50, 55], ["chickens", "ORGANISM", 57, 65], ["Target Epithelial Cells", "CELL", 123, 146], ["murine", "ORGANISM", 337, 343], ["Target Epithelial Cells", "CELL_TYPE", 123, 146], ["host proteases", "PROTEIN", 227, 241], ["pigs", "SPECIES", 44, 48], ["ducks", "SPECIES", 50, 55], ["chickens", "SPECIES", 57, 65], ["dogs", "SPECIES", 71, 75], ["murine", "SPECIES", 337, 343], ["pigs", "SPECIES", 44, 48], ["chickens", "SPECIES", 57, 65], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 95, 146], ["host proteases", "TREATMENT", 227, 241], ["viruses", "PROBLEM", 282, 289], ["virus infection", "PROBLEM", 320, 335], ["murine knock", "TEST", 337, 349], ["some of these molecules", "PROBLEM", 363, 386], ["virus", "OBSERVATION", 17, 22], ["Epithelial Cells", "OBSERVATION", 130, 146], ["viruses", "OBSERVATION", 282, 289], ["no surprise", "UNCERTAINTY", 297, 308]]], ["For example, TMPRSS2-KO mice were protected from pulmonary disease and death following H1N1 and H7N9 Influenza infection, but not from that of the influenza H3N2 subtype, demonstrating some specificity and showing also that other TTSP proteases [such as DESC1 (TMPRSS11E) and MSPL (TMPRSS13)] or other factors may be important (44\u201347).Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Similarly, TMPRSS2 KO mice showed reduced body weight and viral loads compared to WT mice in animals infected with SARS-CoV (48).Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Also, it was demonstrated that over-expression of the human DPP4 in mice promoted MERS-CoV infection, causing lethal disease (49), and that TMPRSS2 was instrumental in that context (48).Epithelial Cells ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)The control of viral infection requires an optimal and innate coordinated host antiviral immunity.", [["pulmonary", "ANATOMY", 49, 58], ["Epithelial Cells", "ANATOMY", 384, 400], ["body", "ANATOMY", 489, 493], ["Epithelial Cells", "ANATOMY", 625, 641], ["Epithelial Cells", "ANATOMY", 874, 890], ["pulmonary disease", "DISEASE", 49, 66], ["death", "DISEASE", 71, 76], ["Influenza infection", "DISEASE", 101, 120], ["SARS-CoV", "DISEASE", 562, 570], ["MERS-CoV infection", "DISEASE", 770, 788], ["lethal disease", "DISEASE", 798, 812], ["viral infection", "DISEASE", 1005, 1020], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 13, 20], ["pulmonary", "ORGAN", 49, 58], ["H7N9 Influenza", "ORGANISM", 96, 110], ["influenza H3N2", "ORGANISM", 147, 161], ["TTSP proteases", "GENE_OR_GENE_PRODUCT", 230, 244], ["DESC1", "GENE_OR_GENE_PRODUCT", 254, 259], ["MSPL", "GENE_OR_GENE_PRODUCT", 276, 280], ["Target Epithelial Cells", "CELL", 377, 400], ["TMPRSS2 KO mice", "ORGANISM", 458, 473], ["body", "ORGANISM_SUBDIVISION", 489, 493], ["WT mice", "ORGANISM", 529, 536], ["animals", "ORGANISM", 540, 547], ["SARS-CoV", "ORGANISM", 562, 570], ["Target Epithelial Cells", "CELL", 618, 641], ["human", "ORGANISM", 742, 747], ["DPP4", "GENE_OR_GENE_PRODUCT", 748, 752], ["mice", "ORGANISM", 756, 760], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 770, 778], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 828, 835], ["Epithelial Cells", "CELL", 874, 890], ["TMPRSS2", "PROTEIN", 13, 20], ["TTSP proteases", "PROTEIN", 230, 244], ["DESC1", "PROTEIN", 254, 259], ["TMPRSS11E", "PROTEIN", 261, 270], ["MSPL", "PROTEIN", 276, 280], ["TMPRSS13", "PROTEIN", 282, 290], ["Target Epithelial Cells", "CELL_TYPE", 377, 400], ["Target Epithelial Cells", "CELL_TYPE", 618, 641], ["human DPP4", "PROTEIN", 742, 752], ["TMPRSS2", "DNA", 828, 835], ["mice", "SPECIES", 24, 28], ["influenza H3N2", "SPECIES", 147, 161], ["mice", "SPECIES", 469, 473], ["mice", "SPECIES", 532, 536], ["human", "SPECIES", 742, 747], ["mice", "SPECIES", 756, 760], ["mice", "SPECIES", 24, 28], ["H7N9", "SPECIES", 96, 100], ["mice", "SPECIES", 469, 473], ["mice", "SPECIES", 532, 536], ["SARS-CoV", "SPECIES", 562, 570], ["human", "SPECIES", 742, 747], ["mice", "SPECIES", 756, 760], ["MERS-CoV", "SPECIES", 770, 778], ["TMPRSS2", "TEST", 13, 20], ["pulmonary disease", "PROBLEM", 49, 66], ["death", "PROBLEM", 71, 76], ["H1N1", "PROBLEM", 87, 91], ["H7N9 Influenza infection", "PROBLEM", 96, 120], ["the influenza H3N2 subtype", "PROBLEM", 143, 169], ["other TTSP proteases", "PROBLEM", 224, 244], ["MSPL", "PROBLEM", 276, 280], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 349, 400], ["TMPRSS2 KO mice", "TEST", 458, 473], ["reduced body weight", "PROBLEM", 481, 500], ["viral loads", "PROBLEM", 505, 516], ["Entry of Coronaviruses into Target Epithelial Cells", "PROBLEM", 590, 641], ["the human DPP4", "TREATMENT", 738, 752], ["CoV infection", "PROBLEM", 775, 788], ["lethal disease", "PROBLEM", 798, 812], ["TMPRSS2", "TEST", 828, 835], ["Epithelial Cells", "PROBLEM", 874, 890], ["viral infection", "PROBLEM", 1005, 1020], ["an optimal and innate coordinated host antiviral immunity", "TREATMENT", 1030, 1087], ["pulmonary", "ANATOMY", 49, 58], ["disease", "OBSERVATION", 59, 66], ["Epithelial Cells", "OBSERVATION", 384, 400], ["reduced", "OBSERVATION_MODIFIER", 481, 488], ["viral loads", "OBSERVATION", 505, 516], ["Epithelial Cells", "OBSERVATION", 625, 641], ["CoV infection", "OBSERVATION", 775, 788], ["viral", "OBSERVATION_MODIFIER", 1005, 1010], ["infection", "OBSERVATION", 1011, 1020], ["antiviral immunity", "OBSERVATION", 1069, 1087]]], ["This response is activated by various sensors, including pattern recognition receptors (PRR), which recognize pathogen-associated molecular patterns (PAMPs).", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 57, 86], ["PRR", "GENE_OR_GENE_PRODUCT", 88, 91], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 110, 148], ["PAMPs", "GENE_OR_GENE_PRODUCT", 150, 155], ["pattern recognition receptors", "PROTEIN", 57, 86], ["PRR", "PROTEIN", 88, 91], ["pathogen-associated molecular patterns", "PROTEIN", 110, 148], ["PAMPs", "PROTEIN", 150, 155]]], ["Although for many viruses, viral RNA is a PAMP classically detected by different sensors, including Toll-Like Receptors (TLR)3 (which senses double stranded (ds)RNA), TLR7 and TLR8 [which sense single stranded (ss)RNA], RIG-I (which senses short dsRNA and ssRNA specific motifs), and MDA-5 (which senses long dsRNA) (50), the sensors potentially recognizing SARS-CoV genomic material are still elusive.", [["PAMP", "GENE_OR_GENE_PRODUCT", 42, 46], ["Toll-Like Receptors (TLR)3", "GENE_OR_GENE_PRODUCT", 100, 126], ["TLR7", "GENE_OR_GENE_PRODUCT", 167, 171], ["TLR8", "GENE_OR_GENE_PRODUCT", 176, 180], ["single stranded (ss)", "GENE_OR_GENE_PRODUCT", 194, 214], ["RIG-I", "GENE_OR_GENE_PRODUCT", 220, 225], ["MDA-5", "GENE_OR_GENE_PRODUCT", 284, 289], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 358, 366], ["viral RNA", "RNA", 27, 36], ["PAMP", "PROTEIN", 42, 46], ["Toll-Like Receptors (TLR)3", "PROTEIN", 100, 126], ["double stranded (ds)RNA", "RNA", 141, 164], ["TLR7", "PROTEIN", 167, 171], ["TLR8", "PROTEIN", 176, 180], ["RIG-I", "DNA", 220, 225], ["ssRNA specific motifs", "DNA", 256, 277], ["MDA-5", "DNA", 284, 289], ["SARS-CoV", "SPECIES", 358, 366], ["many viruses", "PROBLEM", 13, 25], ["viral RNA", "PROBLEM", 27, 36], ["a PAMP", "PROBLEM", 40, 46], ["Toll-Like Receptors (TLR)", "TREATMENT", 100, 125], ["double stranded (ds)RNA", "TREATMENT", 141, 164], ["TLR7 and TLR8", "TREATMENT", 167, 180], ["short dsRNA", "TREATMENT", 240, 251], ["ssRNA specific motifs", "TEST", 256, 277], ["MDA", "TEST", 284, 287], ["the sensors", "TEST", 322, 333], ["SARS", "PROBLEM", 358, 362], ["CoV genomic material", "PROBLEM", 363, 383], ["viruses", "OBSERVATION", 18, 25], ["viral RNA", "OBSERVATION", 27, 36], ["TLR7", "ANATOMY", 167, 171]]], ["In addition, although, as mentioned above, distal peripheral lung alveolar epithelial cells seem to harbor SARS-CoV infection in vivo, and although respiratory epithelial cells are known to express TLR3, TLR7, and TLR8 (51, 52) and initiate innate immunity in the lung (53), the study of these cells in anti-CoV responses has been hampered by their general poor permissibility to the virus in vitro (except for intestinal Caco-2 and HEK293 kidney epithelial cells) (54).", [["peripheral lung alveolar epithelial cells", "ANATOMY", 50, 91], ["respiratory epithelial cells", "ANATOMY", 148, 176], ["lung", "ANATOMY", 264, 268], ["cells", "ANATOMY", 294, 299], ["anti-CoV", "ANATOMY", 303, 311], ["intestinal Caco-2", "ANATOMY", 411, 428], ["HEK293 kidney epithelial cells", "ANATOMY", 433, 463], ["SARS-CoV infection", "DISEASE", 107, 125], ["peripheral lung alveolar epithelial cells", "CELL", 50, 91], ["SARS-CoV", "ORGANISM", 107, 115], ["respiratory epithelial cells", "CELL", 148, 176], ["TLR3", "GENE_OR_GENE_PRODUCT", 198, 202], ["TLR7", "GENE_OR_GENE_PRODUCT", 204, 208], ["TLR8", "GENE_OR_GENE_PRODUCT", 214, 218], ["lung", "ORGAN", 264, 268], ["cells", "CELL", 294, 299], ["anti-CoV", "CELL", 303, 311], ["intestinal Caco-2", "CELL", 411, 428], ["HEK293 kidney epithelial cells", "CELL", 433, 463], ["distal peripheral lung alveolar epithelial cells", "CELL_TYPE", 43, 91], ["respiratory epithelial cells", "CELL_TYPE", 148, 176], ["TLR3", "PROTEIN", 198, 202], ["TLR7", "PROTEIN", 204, 208], ["TLR8", "PROTEIN", 214, 218], ["HEK293 kidney epithelial cells", "CELL_LINE", 433, 463], ["SARS-CoV", "SPECIES", 107, 115], ["distal peripheral lung alveolar epithelial cells", "PROBLEM", 43, 91], ["harbor SARS", "PROBLEM", 100, 111], ["CoV infection in vivo", "PROBLEM", 112, 133], ["respiratory epithelial cells", "PROBLEM", 148, 176], ["TLR3", "TEST", 198, 202], ["TLR7", "TEST", 204, 208], ["TLR8", "TEST", 214, 218], ["the study", "TEST", 275, 284], ["the virus", "PROBLEM", 380, 389], ["intestinal Caco", "TEST", 411, 426], ["distal", "ANATOMY_MODIFIER", 43, 49], ["peripheral", "ANATOMY_MODIFIER", 50, 60], ["lung", "ANATOMY", 61, 65], ["alveolar", "ANATOMY_MODIFIER", 66, 74], ["epithelial cells", "OBSERVATION", 75, 91], ["CoV", "OBSERVATION_MODIFIER", 112, 115], ["infection", "OBSERVATION", 116, 125], ["respiratory epithelial cells", "OBSERVATION", 148, 176], ["lung", "ANATOMY", 264, 268], ["intestinal", "ANATOMY", 411, 421], ["kidney", "ANATOMY", 440, 446], ["epithelial cells", "OBSERVATION", 447, 463]]], ["In that respect, although the specific PRR involved was not identified, the M protein of SARS-CoV was indeed shown to induce interferon (IFN)-\u03b2 in a TLR-related-TRAF3-independent mechanism in HEK293 cells (55).", [["HEK293 cells", "ANATOMY", 192, 204], ["SARS", "DISEASE", 89, 93], ["PRR", "GENE_OR_GENE_PRODUCT", 39, 42], ["SARS-CoV", "ORGANISM", 89, 97], ["interferon (IFN)-\u03b2", "GENE_OR_GENE_PRODUCT", 125, 143], ["TLR", "GENE_OR_GENE_PRODUCT", 149, 152], ["TRAF3", "GENE_OR_GENE_PRODUCT", 161, 166], ["HEK293 cells", "CELL", 192, 204], ["PRR", "PROTEIN", 39, 42], ["M protein", "PROTEIN", 76, 85], ["interferon (IFN)-\u03b2", "PROTEIN", 125, 143], ["TLR", "PROTEIN", 149, 152], ["TRAF3", "PROTEIN", 161, 166], ["HEK293 cells", "CELL_LINE", 192, 204], ["SARS-CoV", "SPECIES", 89, 97], ["the M protein", "TEST", 72, 85], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["interferon (IFN", "TREATMENT", 125, 140], ["a TLR", "TEST", 147, 152]]], ["Regarding the lung, the differentiated Calu-3 cell line [when cultured at the air-liquid interface (ALI)] is the model of choice: in that set-up, SARS-CoV infection triggered an inflammatory response characterized by increased production of interleukin (IL)-6, IL-8, gamma interferon (IFN-\u03b3), inducible protein 10 (IP-10), and activation of the transcription factor NF-\u03baB (56).", [["lung", "ANATOMY", 14, 18], ["Calu-3 cell line", "ANATOMY", 39, 55], ["SARS", "DISEASE", 146, 150], ["infection", "DISEASE", 155, 164], ["lung", "ORGAN", 14, 18], ["Calu-3 cell line", "CELL", 39, 55], ["SARS-CoV", "ORGANISM", 146, 154], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 241, 259], ["IL-8", "GENE_OR_GENE_PRODUCT", 261, 265], ["gamma interferon", "GENE_OR_GENE_PRODUCT", 267, 283], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 285, 290], ["inducible protein 10", "GENE_OR_GENE_PRODUCT", 293, 313], ["IP-10", "GENE_OR_GENE_PRODUCT", 315, 320], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 366, 371], ["Calu-3 cell line", "CELL_LINE", 39, 55], ["interleukin (IL)-6", "PROTEIN", 241, 259], ["IL-8", "PROTEIN", 261, 265], ["gamma interferon", "PROTEIN", 267, 283], ["IFN", "PROTEIN", 285, 288], ["\u03b3", "PROTEIN", 289, 290], ["inducible protein 10", "PROTEIN", 293, 313], ["IP-10", "PROTEIN", 315, 320], ["transcription factor", "PROTEIN", 345, 365], ["NF-\u03baB", "PROTEIN", 366, 371], ["SARS-CoV", "SPECIES", 146, 154], ["the differentiated Calu-3 cell line", "TREATMENT", 20, 55], ["SARS", "PROBLEM", 146, 150], ["CoV infection", "PROBLEM", 151, 164], ["an inflammatory response", "PROBLEM", 175, 199], ["interleukin (IL)", "TEST", 241, 257], ["IL", "TEST", 261, 263], ["gamma interferon", "TREATMENT", 267, 283], ["IFN", "TEST", 285, 288], ["inducible protein", "PROBLEM", 293, 310], ["IP", "TEST", 315, 317], ["lung", "ANATOMY", 14, 18], ["cell line", "OBSERVATION", 46, 55], ["inflammatory", "OBSERVATION_MODIFIER", 178, 190], ["increased", "OBSERVATION_MODIFIER", 217, 226]]], ["However, the kinetics of this response was extremely slow, and importantly, type I IFN, an important mediator of anti-viral responses, was undetected.Epithelial Cells ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Also, another study involving A549 cells demonstrated that the trimeric spike S glyprotein and virus-like particles were able to modestly upregulate CCL2, an important monocytic chemokine (57).Epithelial Cells ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)In addition to lung epithelial cells cultured at ALI, precision-cut lung slices could also be an interesting tool to study SARS-CoV2-cells interactions (58), as demonstrated in Influenza infections with human (59) or animal-derived material (60).Epithelial Cells ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)As mentioned above, TTSPs can activate virus-ligands (HA and S protein), but they are also able to modulate cell signaling pathways.", [["Epithelial Cells", "ANATOMY", 150, 166], ["A549 cells", "ANATOMY", 296, 306], ["monocytic", "ANATOMY", 434, 443], ["Epithelial Cells", "ANATOMY", 459, 475], ["lung epithelial cells", "ANATOMY", 590, 611], ["lung slices", "ANATOMY", 643, 654], ["SARS-CoV2-cells", "ANATOMY", 698, 713], ["Epithelial Cells", "ANATOMY", 821, 837], ["cell", "ANATOMY", 1045, 1049], ["SARS", "DISEASE", 698, 702], ["Influenza infections", "DISEASE", 752, 772], ["type I IFN", "GENE_OR_GENE_PRODUCT", 76, 86], ["Epithelial Cells", "CELL", 150, 166], ["A549 cells", "CELL", 296, 306], ["spike S glyprotein", "GENE_OR_GENE_PRODUCT", 338, 356], ["CCL2", "GENE_OR_GENE_PRODUCT", 415, 419], ["Epithelial Cells", "CELL", 459, 475], ["lung epithelial cells", "CELL", 590, 611], ["lung slices", "MULTI-TISSUE_STRUCTURE", 643, 654], ["SARS-CoV2-cells", "CELL", 698, 713], ["Influenza", "ORGANISM", 752, 761], ["human", "ORGANISM", 778, 783], ["Epithelial Cells", "CELL", 821, 837], ["TTSPs", "GENE_OR_GENE_PRODUCT", 957, 962], ["HA and S protein", "GENE_OR_GENE_PRODUCT", 991, 1007], ["cell", "CELL", 1045, 1049], ["type I IFN", "PROTEIN", 76, 86], ["A549 cells", "CELL_LINE", 296, 306], ["trimeric spike S glyprotein", "PROTEIN", 329, 356], ["CCL2", "PROTEIN", 415, 419], ["monocytic chemokine", "PROTEIN", 434, 453], ["lung epithelial cells", "CELL_TYPE", 590, 611], ["TTSPs", "PROTEIN", 957, 962], ["HA and S protein", "PROTEIN", 991, 1007], ["human", "SPECIES", 778, 783], ["human", "SPECIES", 778, 783], ["Epithelial Cells", "PROBLEM", 150, 166], ["another study", "TEST", 272, 285], ["A549 cells", "TEST", 296, 306], ["the trimeric spike S glyprotein", "TEST", 325, 356], ["virus-like particles", "PROBLEM", 361, 381], ["CCL2", "TEST", 415, 419], ["Epithelial Cells", "PROBLEM", 459, 475], ["lung epithelial cells", "TEST", 590, 611], ["study SARS", "TEST", 692, 702], ["Influenza infections", "PROBLEM", 752, 772], ["Epithelial Cells", "PROBLEM", 821, 837], ["HA and S protein", "TEST", 991, 1007], ["lung", "ANATOMY", 590, 594], ["epithelial cells", "OBSERVATION", 595, 611], ["lung", "ANATOMY", 643, 647], ["Influenza infections", "OBSERVATION", 752, 772]]], ["For example, recombinant HAT is able to activate mucin gene expression in NCI-H292 lung epithelial cells (61).", [["NCI-H292 lung epithelial cells", "ANATOMY", 74, 104], ["HAT", "GENE_OR_GENE_PRODUCT", 25, 28], ["mucin", "GENE_OR_GENE_PRODUCT", 49, 54], ["NCI-H292 lung epithelial cells", "CELL", 74, 104], ["recombinant HAT", "PROTEIN", 13, 28], ["mucin gene", "DNA", 49, 59], ["NCI-H292 lung epithelial cells", "CELL_LINE", 74, 104], ["NCI", "TEST", 74, 77], ["lung epithelial cells", "TEST", 83, 104], ["lung", "ANATOMY", 83, 87], ["epithelial cells", "OBSERVATION", 88, 104]]], ["Relatedly, we have shown both in vitro in epithelial cells and in a murine model that Influenza H3N2 is able to upregulate mucin expression and that this is dependent on human (or mouse) HAT upregulation and TACE activity (62).", [["epithelial cells", "ANATOMY", 42, 58], ["H3N2", "DISEASE", 96, 100], ["epithelial cells", "CELL", 42, 58], ["murine", "ORGANISM", 68, 74], ["Influenza H3N2", "ORGANISM", 86, 100], ["mucin", "GENE_OR_GENE_PRODUCT", 123, 128], ["human", "ORGANISM", 170, 175], ["mouse", "ORGANISM", 180, 185], ["HAT", "GENE_OR_GENE_PRODUCT", 187, 190], ["TACE", "GENE_OR_GENE_PRODUCT", 208, 212], ["epithelial cells", "CELL_TYPE", 42, 58], ["mucin", "PROTEIN", 123, 128], ["TACE", "PROTEIN", 208, 212], ["murine", "SPECIES", 68, 74], ["human", "SPECIES", 170, 175], ["mouse", "SPECIES", 180, 185], ["Influenza H3N2", "SPECIES", 86, 100], ["human", "SPECIES", 170, 175], ["mouse", "SPECIES", 180, 185], ["Influenza H3N2", "PROBLEM", 86, 100], ["human (or mouse) HAT upregulation", "TREATMENT", 170, 203], ["TACE activity", "TEST", 208, 221], ["epithelial cells", "OBSERVATION", 42, 58]]], ["Interestingly, Haga et al. have shown that inhibiting TACE prevents SARS-CoV cellular entry (63).", [["cellular", "ANATOMY", 77, 85], ["TACE", "GENE_OR_GENE_PRODUCT", 54, 58], ["cellular", "CELL", 77, 85], ["TACE", "PROTEIN", 54, 58], ["SARS-CoV", "SPECIES", 68, 76], ["SARS", "PROBLEM", 68, 72]]], ["Strengthening the signaling potential of the receptors, Iwata-Yoshikawa et al. demonstrated in vivo that poly IC (TLR3 ligand) induces the expression of a variety of pro-inflammatory mediators (CCL2, KC, and IL-1) through the expression of TMPRSS2 (48).Epithelial Cells ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)In addition, although unclear as whether it is beneficial or detrimental to the host cell, SARS-CoV have been shown to activate host stress response, apoptosis, and autophagy (13).", [["Epithelial Cells", "ANATOMY", 253, 269], ["cell", "ANATOMY", 454, 458], ["poly IC", "GENE_OR_GENE_PRODUCT", 105, 112], ["TLR3 ligand", "GENE_OR_GENE_PRODUCT", 114, 125], ["CCL2", "GENE_OR_GENE_PRODUCT", 194, 198], ["KC", "GENE_OR_GENE_PRODUCT", 200, 202], ["IL-1", "GENE_OR_GENE_PRODUCT", 208, 212], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 240, 247], ["Epithelial Cells", "CELL", 253, 269], ["host cell", "CELL", 449, 458], ["SARS-CoV", "ORGANISM", 460, 468], ["TLR3 ligand", "PROTEIN", 114, 125], ["pro-inflammatory mediators", "PROTEIN", 166, 192], ["CCL2", "PROTEIN", 194, 198], ["KC", "PROTEIN", 200, 202], ["IL-1", "PROTEIN", 208, 212], ["TMPRSS2", "PROTEIN", 240, 247], ["SARS-CoV", "SPECIES", 460, 468], ["the receptors", "TEST", 41, 54], ["poly IC (TLR3 ligand)", "TREATMENT", 105, 126], ["TMPRSS2", "TEST", 240, 247], ["Epithelial Cells", "PROBLEM", 253, 269], ["SARS", "PROBLEM", 460, 464], ["apoptosis", "PROBLEM", 519, 528], ["autophagy", "TEST", 534, 543]]], ["These are also various pathways that may also need to be evaluated therapeutically in the context of the current pandemic.", [["pandemic", "OBSERVATION", 113, 121]]], ["Relatedly, we have shown that chloroquine, which also inhibits the autophagic cellular flux by decreasing autophagosome-lysosome fusion, can inhibit Influenza-mediated CCL5 production (64).Epithelial Cells ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Importantly, after having established a foothold in the epithelial compartment, SARS-CoV can disrupt the epithelial polarity, thereby getting access to the parenchyma tissue: for example, it has been shown that the virus membrane protein E binds to PALS1 (Protein Associated With Lin Seven 1), a junction protein involved in epithelial polarity, and modifies its cellular distribution at the surface of HEK-293 cells (65).Myeloid Cells and Myeloid-Epithelial Cells Interaction ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Myeloid cells, e.g., alveolar and interstitial macrophages or dendritic cells (DCs), elicit different immune responses toward influenza viruses, according to their subtypes (66).", [["cellular", "ANATOMY", 78, 86], ["autophagosome", "ANATOMY", 106, 119], ["lysosome", "ANATOMY", 120, 128], ["Epithelial Cells", "ANATOMY", 189, 205], ["epithelial compartment", "ANATOMY", 361, 383], ["epithelial", "ANATOMY", 410, 420], ["parenchyma tissue", "ANATOMY", 461, 478], ["epithelial", "ANATOMY", 630, 640], ["cellular", "ANATOMY", 668, 676], ["surface", "ANATOMY", 697, 704], ["HEK-293 cells", "ANATOMY", 708, 721], ["Myeloid Cells", "ANATOMY", 727, 740], ["Myeloid-Epithelial Cells", "ANATOMY", 745, 769], ["Myeloid cells", "ANATOMY", 881, 894], ["alveolar", "ANATOMY", 902, 910], ["interstitial macrophages", "ANATOMY", 915, 939], ["dendritic cells", "ANATOMY", 943, 958], ["DCs", "ANATOMY", 960, 963], ["chloroquine", "CHEMICAL", 30, 41], ["influenza viruses", "DISEASE", 1007, 1024], ["chloroquine", "CHEMICAL", 30, 41], ["chloroquine", "SIMPLE_CHEMICAL", 30, 41], ["cellular", "CELL", 78, 86], ["autophagosome", "CELLULAR_COMPONENT", 106, 119], ["lysosome", "CELLULAR_COMPONENT", 120, 128], ["CCL5", "GENE_OR_GENE_PRODUCT", 168, 172], ["Epithelial Cells", "CELL", 189, 205], ["epithelial compartment", "TISSUE", 361, 383], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 385, 393], ["epithelial", "TISSUE", 410, 420], ["parenchyma tissue", "TISSUE", 461, 478], ["E", "GENE_OR_GENE_PRODUCT", 543, 544], ["PALS1", "GENE_OR_GENE_PRODUCT", 554, 559], ["Lin Seven 1", "GENE_OR_GENE_PRODUCT", 585, 596], ["epithelial", "TISSUE", 630, 640], ["cellular", "CELL", 668, 676], ["surface", "CELLULAR_COMPONENT", 697, 704], ["HEK-293 cells", "CELL", 708, 721], ["Myeloid Cells", "CELL", 727, 740], ["Myeloid-Epithelial Cells", "CELL", 745, 769], ["Myeloid cells", "CELL", 881, 894], ["alveolar", "CELL", 902, 910], ["interstitial macrophages", "CELL", 915, 939], ["dendritic cells", "CELL", 943, 958], ["DCs", "CELL", 960, 963], ["influenza viruses", "ORGANISM", 1007, 1024], ["CCL5", "PROTEIN", 168, 172], ["virus membrane protein E", "PROTEIN", 520, 544], ["PALS1", "PROTEIN", 554, 559], ["Protein Associated With Lin Seven 1", "PROTEIN", 561, 596], ["junction protein", "PROTEIN", 601, 617], ["HEK-293 cells", "CELL_LINE", 708, 721], ["Myeloid Cells", "CELL_TYPE", 727, 740], ["Myeloid cells", "CELL_TYPE", 881, 894], ["alveolar and interstitial macrophages", "CELL_TYPE", 902, 939], ["dendritic cells", "CELL_TYPE", 943, 958], ["DCs", "CELL_TYPE", 960, 963], ["SARS-CoV", "SPECIES", 385, 393], ["chloroquine", "TREATMENT", 30, 41], ["the autophagic cellular flux", "PROBLEM", 63, 91], ["decreasing autophagosome-lysosome fusion", "TREATMENT", 95, 135], ["Influenza", "PROBLEM", 149, 158], ["Epithelial Cells", "PROBLEM", 189, 205], ["a foothold in the epithelial compartment", "PROBLEM", 343, 383], ["SARS", "PROBLEM", 385, 389], ["the virus membrane protein E binds", "PROBLEM", 516, 550], ["PALS1", "TEST", 554, 559], ["a junction protein", "TEST", 599, 617], ["epithelial polarity", "TEST", 630, 649], ["Myeloid Cells", "TEST", 727, 740], ["Myeloid cells", "PROBLEM", 881, 894], ["alveolar and interstitial macrophages", "PROBLEM", 902, 939], ["dendritic cells", "PROBLEM", 943, 958], ["influenza viruses", "PROBLEM", 1007, 1024], ["autophagic cellular flux", "OBSERVATION", 67, 91], ["lysosome fusion", "OBSERVATION", 120, 135], ["epithelial compartment", "ANATOMY", 361, 383], ["epithelial polarity", "OBSERVATION", 410, 429], ["parenchyma", "ANATOMY", 461, 471], ["epithelial polarity", "OBSERVATION", 630, 649], ["cellular distribution", "OBSERVATION", 668, 689], ["Myeloid", "ANATOMY", 745, 752], ["Epithelial Cells", "OBSERVATION", 753, 769], ["alveolar", "ANATOMY_MODIFIER", 902, 910], ["interstitial", "ANATOMY_MODIFIER", 915, 927], ["macrophages", "OBSERVATION", 928, 939], ["dendritic cells", "OBSERVATION", 943, 958], ["influenza viruses", "OBSERVATION", 1007, 1024]]], ["It is thus predictable that specificities may also exist with respect to SARS-COV-2 infections.", [["infections", "DISEASE", 84, 94], ["SARS", "PROBLEM", 73, 77], ["COV-2 infections", "PROBLEM", 78, 94], ["infections", "OBSERVATION", 84, 94]]], ["Indeed, although studies are scant, these cells have generally been shown to be poorly permissive to SARS-CoV replication (54, 67, 68).Myeloid Cells and Myeloid-Epithelial Cells Interaction ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)However, a few studies have shown that myeloid cells can respond to SARS-Cov infection.", [["cells", "ANATOMY", 42, 47], ["Myeloid Cells", "ANATOMY", 135, 148], ["Myeloid-Epithelial Cells", "ANATOMY", 153, 177], ["myeloid cells", "ANATOMY", 328, 341], ["SARS", "DISEASE", 101, 105], ["SARS-Cov infection", "DISEASE", 357, 375], ["cells", "CELL", 42, 47], ["SARS-CoV", "ORGANISM", 101, 109], ["Myeloid Cells", "CELL", 135, 148], ["Myeloid-Epithelial Cells", "CELL", 153, 177], ["myeloid cells", "CELL", 328, 341], ["Myeloid Cells", "CELL_TYPE", 135, 148], ["myeloid cells", "CELL_TYPE", 328, 341], ["SARS-CoV", "SPECIES", 101, 109], ["studies", "TEST", 17, 24], ["CoV replication", "TEST", 106, 121], ["Myeloid Cells", "TEST", 135, 148], ["a few studies", "TEST", 298, 311], ["myeloid cells", "PROBLEM", 328, 341], ["SARS", "PROBLEM", 357, 361], ["Cov infection", "PROBLEM", 362, 375], ["Myeloid", "ANATOMY", 153, 160], ["Epithelial Cells", "OBSERVATION", 161, 177], ["myeloid cells", "OBSERVATION", 328, 341], ["Cov", "OBSERVATION_MODIFIER", 362, 365], ["infection", "OBSERVATION", 366, 375]]], ["Indeed, Dosch et al. showed that the S protein could, through TLR2, trigger NF-\u03baB activation and inflammatory responses in peripheral blood mononuclear cells (PBMC) (69).", [["peripheral blood mononuclear cells", "ANATOMY", 123, 157], ["PBMC", "ANATOMY", 159, 163], ["TLR2", "GENE_OR_GENE_PRODUCT", 62, 66], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 76, 81], ["peripheral blood mononuclear cells", "CELL", 123, 157], ["PBMC", "CELL", 159, 163], ["S protein", "PROTEIN", 37, 46], ["TLR2", "PROTEIN", 62, 66], ["NF-\u03baB", "PROTEIN", 76, 81], ["peripheral blood mononuclear cells", "CELL_TYPE", 123, 157], ["PBMC", "CELL_TYPE", 159, 163], ["the S protein", "TEST", 33, 46], ["TLR2", "TEST", 62, 66], ["NF", "TEST", 76, 78], ["inflammatory responses", "PROBLEM", 97, 119], ["peripheral blood mononuclear cells", "TEST", 123, 157], ["PBMC", "TEST", 159, 163], ["inflammatory", "OBSERVATION_MODIFIER", 97, 109], ["peripheral", "ANATOMY_MODIFIER", 123, 133], ["blood", "ANATOMY", 134, 139], ["mononuclear cells", "OBSERVATION", 140, 157]]], ["Also, in common with epithelial cells, it was shown that PBMCs and DCs infected with SARS-CoV produced cytokines and chemokines such as and C-C Motif Chemokine Ligand (CCL)-2 and/or C-X-C Motif Chemokine Ligand (CXCL)-10/RANTES/Tumor Necrosis Factor (TNF)/IL-8/IL-6, but, importantly, not IFN-\u03b2 (67, 68).", [["epithelial cells", "ANATOMY", 21, 37], ["PBMCs", "ANATOMY", 57, 62], ["DCs", "ANATOMY", 67, 70], ["epithelial cells", "CELL", 21, 37], ["PBMCs", "CELL", 57, 62], ["DCs", "CELL", 67, 70], ["SARS-CoV", "ORGANISM", 85, 93], ["C-C Motif Chemokine Ligand (CCL)-2", "GENE_OR_GENE_PRODUCT", 140, 174], ["C-X-C Motif Chemokine Ligand", "GENE_OR_GENE_PRODUCT", 182, 210], ["CXCL)-10", "GENE_OR_GENE_PRODUCT", 212, 220], ["RANTES", "GENE_OR_GENE_PRODUCT", 221, 227], ["Tumor Necrosis Factor", "GENE_OR_GENE_PRODUCT", 228, 249], ["TNF", "GENE_OR_GENE_PRODUCT", 251, 254], ["IL-8", "GENE_OR_GENE_PRODUCT", 256, 260], ["IL-6", "GENE_OR_GENE_PRODUCT", 261, 265], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 289, 294], ["epithelial cells", "CELL_TYPE", 21, 37], ["PBMCs", "CELL_TYPE", 57, 62], ["DCs", "CELL_TYPE", 67, 70], ["cytokines", "PROTEIN", 103, 112], ["chemokines", "PROTEIN", 117, 127], ["RANTES", "PROTEIN", 221, 227], ["Tumor Necrosis Factor (TNF)/IL-8/IL-6", "PROTEIN", 228, 265], ["IFN", "PROTEIN", 289, 292], ["SARS-CoV", "SPECIES", 85, 93], ["epithelial cells", "PROBLEM", 21, 37], ["PBMCs", "PROBLEM", 57, 62], ["SARS", "PROBLEM", 85, 89], ["cytokines", "TREATMENT", 103, 112], ["chemokines", "TREATMENT", 117, 127], ["C", "TEST", 140, 141], ["-C Motif Chemokine Ligand", "TREATMENT", 141, 166], ["CCL", "TEST", 168, 171], ["C", "TEST", 182, 183], ["Motif Chemokine Ligand", "TEST", 188, 210], ["CXCL", "TEST", 212, 216], ["RANTES", "TEST", 221, 227], ["Tumor Necrosis Factor", "TEST", 228, 249], ["TNF", "TEST", 251, 254], ["IL", "TEST", 256, 258], ["IL", "TEST", 261, 263], ["IFN", "TEST", 289, 292], ["epithelial cells", "ANATOMY", 21, 37], ["Tumor Necrosis", "OBSERVATION", 228, 242]]], ["By contrast, a study performed mostly on THP-1 macrophages suggest that MERS S protein suppresses macrophages pro-inflammatory responses through DPP4-induction of IRAK-M and PPAR\u03b3 (70).Myeloid Cells and Myeloid-Epithelial Cells Interaction ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Furthermore, in an interesting \u201c2-way\u201d system involving differentiated SARS-permissive lung Calu-3 cells and monocyte-derived Macs and DCs, it was shown that mediators produced by Calu-3 cells activate cytokine production by macrophages (IL-1\u03b2, G-CSF, MIP-1, and TNF-\u03b1) and DCs (IL-12p40, MIP-1, IFN-\u03b3, IL-6, IL-8, and MCP-1) but that some of these Calu-3 derived mediators (in particular IL-6 and IL-8) compromised the ability of DCs and Macs to activate na\u00efve T cells and phagocytosis (4, 56).", [["THP-1 macrophages", "ANATOMY", 41, 58], ["macrophages", "ANATOMY", 98, 109], ["Myeloid Cells", "ANATOMY", 185, 198], ["Myeloid-Epithelial Cells", "ANATOMY", 203, 227], ["lung Calu-3 cells", "ANATOMY", 426, 443], ["monocyte", "ANATOMY", 448, 456], ["Macs", "ANATOMY", 465, 469], ["DCs", "ANATOMY", 474, 477], ["Calu-3 cells", "ANATOMY", 519, 531], ["macrophages", "ANATOMY", 564, 575], ["DCs", "ANATOMY", 613, 616], ["DCs", "ANATOMY", 770, 773], ["na\u00efve T cells", "ANATOMY", 795, 808], ["SARS", "DISEASE", 410, 414], ["THP-1 macrophages", "CELL", 41, 58], ["MERS S protein", "GENE_OR_GENE_PRODUCT", 72, 86], ["macrophages", "CELL", 98, 109], ["DPP4", "GENE_OR_GENE_PRODUCT", 145, 149], ["IRAK-M", "GENE_OR_GENE_PRODUCT", 163, 169], ["PPAR\u03b3 (70)", "GENE_OR_GENE_PRODUCT", 174, 184], ["Myeloid Cells", "CELL", 185, 198], ["Myeloid-Epithelial Cells", "CELL", 203, 227], ["lung Calu-3 cells", "CELL", 426, 443], ["monocyte", "CELL", 448, 456], ["Macs", "CELL", 465, 469], ["DCs", "CELL", 474, 477], ["Calu-3 cells", "CELL", 519, 531], ["macrophages", "CELL", 564, 575], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 577, 582], ["G-CSF", "GENE_OR_GENE_PRODUCT", 584, 589], ["MIP-1", "GENE_OR_GENE_PRODUCT", 591, 596], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 602, 607], ["DCs", "CELL", 613, 616], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 618, 626], ["MIP-1", "GENE_OR_GENE_PRODUCT", 628, 633], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 635, 640], ["IL-6", "GENE_OR_GENE_PRODUCT", 642, 646], ["IL-8", "GENE_OR_GENE_PRODUCT", 648, 652], ["MCP-1", "GENE_OR_GENE_PRODUCT", 658, 663], ["Calu-3", "GENE_OR_GENE_PRODUCT", 688, 694], ["IL-6", "GENE_OR_GENE_PRODUCT", 728, 732], ["IL-8", "GENE_OR_GENE_PRODUCT", 737, 741], ["DCs", "CELL", 770, 773], ["Macs", "GENE_OR_GENE_PRODUCT", 778, 782], ["na\u00efve T cells", "CELL", 795, 808], ["THP-1 macrophages", "CELL_LINE", 41, 58], ["MERS S protein", "PROTEIN", 72, 86], ["macrophages", "CELL_TYPE", 98, 109], ["DPP4", "PROTEIN", 145, 149], ["IRAK", "PROTEIN", 163, 167], ["PPAR\u03b3", "PROTEIN", 174, 179], ["Myeloid Cells", "CELL_TYPE", 185, 198], ["SARS-permissive lung Calu-3 cells", "CELL_LINE", 410, 443], ["Macs", "CELL_TYPE", 465, 469], ["DCs", "CELL_TYPE", 474, 477], ["Calu-3 cells", "CELL_LINE", 519, 531], ["cytokine", "PROTEIN", 541, 549], ["macrophages", "CELL_TYPE", 564, 575], ["CSF", "PROTEIN", 586, 589], ["MIP", "PROTEIN", 591, 594], ["TNF", "PROTEIN", 602, 605], ["DCs", "CELL_TYPE", 613, 616], ["IFN", "PROTEIN", 635, 638], ["MCP", "PROTEIN", 658, 661], ["Calu-3 derived mediators", "PROTEIN", 688, 712], ["IL-8", "PROTEIN", 737, 741], ["DCs", "CELL_TYPE", 770, 773], ["Macs", "CELL_TYPE", 778, 782], ["na\u00efve T cells", "CELL_TYPE", 795, 808], ["a study", "TEST", 13, 20], ["THP-1 macrophages", "TEST", 41, 58], ["MERS S protein suppresses macrophages", "PROBLEM", 72, 109], ["pro-inflammatory responses", "TEST", 110, 136], ["DPP4", "TEST", 145, 149], ["IRAK", "TEST", 163, 167], ["PPAR", "TEST", 174, 178], ["Myeloid Cells", "TEST", 185, 198], ["differentiated SARS", "PROBLEM", 395, 414], ["permissive lung Calu", "TEST", 415, 435], ["monocyte", "TEST", 448, 456], ["DCs", "TEST", 474, 477], ["Calu", "TEST", 519, 523], ["cytokine production", "TEST", 541, 560], ["macrophages", "TEST", 564, 575], ["IL", "TEST", 577, 579], ["G", "TEST", 584, 585], ["CSF", "TEST", 586, 589], ["MIP", "TEST", 591, 594], ["TNF", "TEST", 602, 605], ["DCs", "TEST", 613, 616], ["IL", "TEST", 618, 620], ["MIP", "TEST", 628, 631], ["IFN", "TEST", 635, 638], ["IL", "TEST", 642, 644], ["IL", "TEST", 648, 650], ["MCP", "TEST", 658, 661], ["these Calu", "TEST", 682, 692], ["IL", "TEST", 728, 730], ["phagocytosis", "TEST", 813, 825], ["Myeloid", "ANATOMY", 203, 210], ["Epithelial Cells", "OBSERVATION", 211, 227], ["lung", "ANATOMY", 426, 430]]], ["This echoes data obtained from patients suggesting that SARS may in fact be partly caused by a \u201cparalysis\u201d of the adaptive immune system, characterized by a diminished number of immune cell types including T lymphocytes, DCs and Macs (4).From Murine Models to Human Genetics ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Demonstrating that SARS-CoV can induce TLR-dependent host responses in vivo, Tlr4, Tlr3, and Tram KO mice were shown to be more susceptible to mouse-adapted SARS-CoV, albeit without exhibiting extra mortality (71).", [["immune system", "ANATOMY", 123, 136], ["immune cell", "ANATOMY", 178, 189], ["T lymphocytes", "ANATOMY", 206, 219], ["DCs", "ANATOMY", 221, 224], ["SARS", "DISEASE", 56, 60], ["paralysis", "DISEASE", 96, 105], ["SARS", "DISEASE", 531, 535], ["patients", "ORGANISM", 31, 39], ["immune system", "ANATOMICAL_SYSTEM", 123, 136], ["immune cell", "CELL", 178, 189], ["T lymphocytes", "CELL", 206, 219], ["DCs", "CELL", 221, 224], ["Murine", "ORGANISM", 243, 249], ["Human", "ORGANISM", 260, 265], ["SARS-CoV", "ORGANISM", 393, 401], ["TLR", "GENE_OR_GENE_PRODUCT", 413, 416], ["Tlr4", "GENE_OR_GENE_PRODUCT", 451, 455], ["Tlr3", "GENE_OR_GENE_PRODUCT", 457, 461], ["Tram KO mice", "ORGANISM", 467, 479], ["mouse", "ORGANISM", 517, 522], ["SARS-CoV", "ORGANISM", 531, 539], ["immune cell types", "CELL_TYPE", 178, 195], ["T lymphocytes", "CELL_TYPE", 206, 219], ["DCs", "CELL_TYPE", 221, 224], ["TLR", "PROTEIN", 413, 416], ["Tlr4", "PROTEIN", 451, 455], ["Tlr3", "PROTEIN", 457, 461], ["patients", "SPECIES", 31, 39], ["Human", "SPECIES", 260, 265], ["mice", "SPECIES", 475, 479], ["mouse", "SPECIES", 517, 522], ["SARS-CoV", "SPECIES", 393, 401], ["mice", "SPECIES", 475, 479], ["mouse", "SPECIES", 517, 522], ["SARS-CoV", "SPECIES", 531, 539], ["This echoes data", "TEST", 0, 16], ["SARS", "PROBLEM", 56, 60], ["a \u201cparalysis", "PROBLEM", 93, 105], ["the adaptive immune system", "PROBLEM", 110, 136], ["a diminished number of immune cell types", "PROBLEM", 155, 195], ["SARS", "PROBLEM", 393, 397], ["TLR", "TEST", 413, 416], ["paralysis", "OBSERVATION", 96, 105], ["diminished", "OBSERVATION_MODIFIER", 157, 167], ["immune cell types", "OBSERVATION", 178, 195]]], ["In comparison, mice deficient for the signaling molecule Trif were highly susceptible to CoV infections, exhibited diminished lung function, aberrant inflammatory responses, and importantly, higher mortality (71).From Murine Models to Human Genetics ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)In addition, a mouse genetic study revealed that the TLR adaptor protein Ticam2 was a susceptibility gene to SARS-CoV (72); mice KO for Ticam2 (72), but also MyD88 (73), another TLR adaptor protein, were highly susceptible to a mouse-adapted SARS-CoV lung infection.", [["lung", "ANATOMY", 126, 130], ["lung", "ANATOMY", 600, 604], ["CoV infections", "DISEASE", 89, 103], ["SARS-CoV lung infection", "DISEASE", 591, 614], ["mice", "ORGANISM", 15, 19], ["Trif", "GENE_OR_GENE_PRODUCT", 57, 61], ["CoV", "ORGANISM", 89, 92], ["lung", "ORGAN", 126, 130], ["Murine", "ORGANISM", 218, 224], ["Human", "ORGANISM", 235, 240], ["mouse", "ORGANISM", 364, 369], ["TLR", "GENE_OR_GENE_PRODUCT", 402, 405], ["Ticam2", "GENE_OR_GENE_PRODUCT", 422, 428], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 458, 466], ["mice KO", "ORGANISM", 473, 480], ["Ticam2", "GENE_OR_GENE_PRODUCT", 485, 491], ["MyD88", "GENE_OR_GENE_PRODUCT", 507, 512], ["TLR", "GENE_OR_GENE_PRODUCT", 527, 530], ["mouse", "ORGANISM", 577, 582], ["SARS-CoV", "ORGANISM", 591, 599], ["lung", "ORGAN", 600, 604], ["signaling molecule Trif", "PROTEIN", 38, 61], ["TLR adaptor protein", "PROTEIN", 402, 421], ["Ticam2", "PROTEIN", 422, 428], ["susceptibility gene", "DNA", 435, 454], ["MyD88", "PROTEIN", 507, 512], ["TLR adaptor protein", "PROTEIN", 527, 546], ["mice", "SPECIES", 15, 19], ["Human", "SPECIES", 235, 240], ["mouse", "SPECIES", 364, 369], ["mice", "SPECIES", 473, 477], ["mouse", "SPECIES", 577, 582], ["mice", "SPECIES", 15, 19], ["CoV", "SPECIES", 89, 92], ["mouse", "SPECIES", 364, 369], ["SARS-CoV", "SPECIES", 458, 466], ["mice", "SPECIES", 473, 477], ["mouse", "SPECIES", 577, 582], ["SARS-CoV", "SPECIES", 591, 599], ["the signaling molecule Trif", "PROBLEM", 34, 61], ["CoV infections", "PROBLEM", 89, 103], ["diminished lung function", "PROBLEM", 115, 139], ["aberrant inflammatory responses", "PROBLEM", 141, 172], ["a mouse genetic study", "TEST", 362, 383], ["the TLR adaptor protein Ticam2", "TEST", 398, 428], ["SARS", "TEST", 458, 462], ["CoV", "TEST", 463, 466], ["mice KO", "TEST", 473, 480], ["Ticam2", "TEST", 485, 491], ["MyD88", "TEST", 507, 512], ["another TLR adaptor protein", "TEST", 519, 546], ["CoV lung infection", "PROBLEM", 596, 614], ["infections", "OBSERVATION", 93, 103], ["diminished", "OBSERVATION_MODIFIER", 115, 125], ["lung", "ANATOMY", 126, 130], ["aberrant", "OBSERVATION_MODIFIER", 141, 149], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162], ["lung", "ANATOMY", 600, 604], ["infection", "OBSERVATION", 605, 614]]], ["Since polymorphisms of TLRs and MyD88 have been associated in humans with heightened sensitivity to a variety of pathogens (74), these studies, in addition to demonstrating the role of TLR pathways in the SARS-CoV infection, suggested a human genetic predisposition to SARS-CoV, and this could explain the variability of severity in patients with COVID-19 disease.", [["SARS-CoV infection", "DISEASE", 205, 223], ["SARS-CoV", "DISEASE", 269, 277], ["TLRs", "GENE_OR_GENE_PRODUCT", 23, 27], ["MyD88", "GENE_OR_GENE_PRODUCT", 32, 37], ["humans", "ORGANISM", 62, 68], ["TLR", "GENE_OR_GENE_PRODUCT", 185, 188], ["SARS-CoV", "ORGANISM", 205, 213], ["human", "ORGANISM", 237, 242], ["SARS-CoV", "ORGANISM", 269, 277], ["patients", "ORGANISM", 333, 341], ["TLRs", "PROTEIN", 23, 27], ["MyD88", "PROTEIN", 32, 37], ["TLR", "PROTEIN", 185, 188], ["humans", "SPECIES", 62, 68], ["human", "SPECIES", 237, 242], ["patients", "SPECIES", 333, 341], ["humans", "SPECIES", 62, 68], ["SARS-CoV", "SPECIES", 205, 213], ["human", "SPECIES", 237, 242], ["SARS-CoV", "SPECIES", 269, 277], ["polymorphisms of TLRs", "PROBLEM", 6, 27], ["MyD88", "TREATMENT", 32, 37], ["heightened sensitivity", "PROBLEM", 74, 96], ["pathogens", "PROBLEM", 113, 122], ["these studies", "TEST", 129, 142], ["the SARS", "PROBLEM", 201, 209], ["CoV infection", "PROBLEM", 210, 223], ["SARS", "PROBLEM", 269, 273], ["CoV", "PROBLEM", 274, 277], ["severity", "PROBLEM", 321, 329], ["COVID-19 disease", "PROBLEM", 347, 363], ["infection", "OBSERVATION", 214, 223]]], ["Forthcoming human genetic studies from international collaborative efforts (https://www.covid19hg.org) could reveal genetic variants associated with SARS-CoV2 susceptibility, as in the gene encoding ACE2 as recently suggested (75).", [["SARS-CoV2", "DISEASE", 149, 158], ["human", "ORGANISM", 12, 17], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 149, 158], ["ACE2", "GENE_OR_GENE_PRODUCT", 199, 203], ["CoV2", "DNA", 154, 158], ["ACE2", "PROTEIN", 199, 203], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["Forthcoming human genetic studies", "TEST", 0, 33], ["genetic variants", "PROBLEM", 116, 132], ["SARS", "PROBLEM", 149, 153], ["CoV2 susceptibility", "PROBLEM", 154, 173], ["genetic variants", "OBSERVATION", 116, 132]]], ["Indeed, ACE2 genetic variants may be associated with a modulated ACE2 protein expression, the SARS-Cov-2 receptor, which may explain in part patients' susceptibility to infection.", [["infection", "DISEASE", 169, 178], ["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["SARS-Cov-2 receptor", "GENE_OR_GENE_PRODUCT", 94, 113], ["patients", "ORGANISM", 141, 149], ["ACE2", "PROTEIN", 8, 12], ["ACE2", "PROTEIN", 65, 69], ["SARS-Cov-2 receptor", "PROTEIN", 94, 113], ["patients", "SPECIES", 141, 149], ["ACE2 genetic variants", "PROBLEM", 8, 29], ["a modulated ACE2 protein expression", "PROBLEM", 53, 88], ["the SARS", "TEST", 90, 98], ["infection", "PROBLEM", 169, 178], ["protein expression", "OBSERVATION", 70, 88], ["may explain", "UNCERTAINTY", 121, 132], ["infection", "OBSERVATION", 169, 178]]], ["Genes associated with TLR pathways also represent good candidates, as demonstrated in other respiratory viral infection (e.g., influenza) where TLR3 variants (76) were shown to modulate its virulence.Maladaptive Activation of Innate Immune Responses (see Figure 1BF1fig) ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)As already mentioned above, aberrant maladaptive innate immune host responses, including \u201ccytokine storm\u201d events, have been associated with severe lung disease and the development of ARDS during SARS and the COVID-19 current episode.", [["lung", "ANATOMY", 517, 521], ["respiratory viral infection", "DISEASE", 92, 119], ["influenza", "DISEASE", 127, 136], ["lung disease", "DISEASE", 517, 529], ["ARDS", "DISEASE", 553, 557], ["SARS", "DISEASE", 565, 569], ["TLR", "GENE_OR_GENE_PRODUCT", 22, 25], ["TLR3", "GENE_OR_GENE_PRODUCT", 144, 148], ["lung", "ORGAN", 517, 521], ["TLR", "PROTEIN", 22, 25], ["TLR3", "PROTEIN", 144, 148], ["cytokine", "PROTEIN", 460, 468], ["other respiratory viral infection", "PROBLEM", 86, 119], ["influenza", "PROBLEM", 127, 136], ["severe lung disease", "PROBLEM", 510, 529], ["ARDS", "PROBLEM", 553, 557], ["SARS", "PROBLEM", 565, 569], ["the COVID", "TEST", 574, 583], ["good candidates", "OBSERVATION", 50, 65], ["respiratory", "ANATOMY", 92, 103], ["viral infection", "OBSERVATION", 104, 119], ["associated with", "UNCERTAINTY", 494, 509], ["severe", "OBSERVATION_MODIFIER", 510, 516], ["lung", "ANATOMY", 517, 521], ["disease", "OBSERVATION", 522, 529], ["ARDS", "OBSERVATION", 553, 557]]], ["Mechanistically, these events usually occur at a late stage of the disease, and several mechanisms have been proposed.", [["the disease", "PROBLEM", 63, 74], ["disease", "OBSERVATION", 67, 74]]], ["In particular, a murine study has shown that a prolonged (albeit delayed, as demonstrated also in vitro, see above) type I IFN signaling was instrumental in triggering over-exuberant innate inflammatory monocytes\u2013macrophages immune responses and an impaired virus-specific T-cell response (77).Maladaptive Activation of Innate Immune Responses (see Figure 1BF1fig) ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)In complement to the mechanism proposed above, increased lung inflammatory protease (neutrophil elastase and metalloprotease) activity has been demonstrated in ARDS (78, 79), with a concomitant imbalance between protease and protease inhibitors activity (80).", [["T-cell", "ANATOMY", 273, 279], ["lung", "ANATOMY", 521, 525], ["ARDS", "DISEASE", 624, 628], ["murine", "ORGANISM", 17, 23], ["type I IFN", "GENE_OR_GENE_PRODUCT", 116, 126], ["monocytes\u2013macrophages", "GENE_OR_GENE_PRODUCT", 203, 224], ["T-cell", "CELL", 273, 279], ["lung", "ORGAN", 521, 525], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 549, 568], ["metalloprotease", "GENE_OR_GENE_PRODUCT", 573, 588], ["IFN", "PROTEIN", 123, 126], ["lung inflammatory protease", "PROTEIN", 521, 547], ["neutrophil elastase", "PROTEIN", 549, 568], ["metalloprotease", "PROTEIN", 573, 588], ["protease", "PROTEIN", 676, 684], ["murine", "SPECIES", 17, 23], ["a murine study", "TEST", 15, 29], ["a prolonged (albeit delayed", "PROBLEM", 45, 72], ["type I IFN signaling", "PROBLEM", 116, 136], ["an impaired virus", "PROBLEM", 246, 263], ["increased lung inflammatory protease", "PROBLEM", 511, 547], ["neutrophil elastase and metalloprotease) activity", "PROBLEM", 549, 598], ["ARDS", "PROBLEM", 624, 628], ["a concomitant imbalance", "PROBLEM", 644, 667], ["protease and protease inhibitors activity", "TREATMENT", 676, 717], ["exuberant", "OBSERVATION_MODIFIER", 173, 182], ["inflammatory monocytes\u2013macrophages", "OBSERVATION", 190, 224], ["increased", "OBSERVATION_MODIFIER", 511, 520], ["lung", "ANATOMY", 521, 525], ["inflammatory protease", "OBSERVATION", 526, 547], ["neutrophil elastase", "OBSERVATION", 549, 568], ["ARDS", "OBSERVATION", 624, 628]]], ["In addition, although not yet measured, to our knowledge, in SARS murine models, we and others have shown increased protease-mediated lung damage in mice infected with Influenza (81\u201383).", [["lung", "ANATOMY", 134, 138], ["SARS", "DISEASE", 61, 65], ["lung damage", "DISEASE", 134, 145], ["Influenza", "DISEASE", 168, 177], ["murine", "ORGANISM", 66, 72], ["lung", "ORGAN", 134, 138], ["mice", "ORGANISM", 149, 153], ["protease", "PROTEIN", 116, 124], ["murine", "SPECIES", 66, 72], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 149, 153], ["SARS murine models", "TEST", 61, 79], ["increased protease", "PROBLEM", 106, 124], ["lung damage", "PROBLEM", 134, 145], ["Influenza", "PROBLEM", 168, 177], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["lung", "ANATOMY", 134, 138], ["damage", "OBSERVATION", 139, 145]]], ["Additionally, in a MERS-CoV murine model, it was shown that excessive complement activation was partly responsible for exacerbated lung inflammation (84).Maladaptive Activation of Innate Immune Responses (see Figure 1BF1fig) ::: Activation/Modulation of Host Signaling Pathways (SEE #!start#FIGURE 1A#!sep#F1#!sep#fig#!end#)Lastly, \u201ccytokines storm\u201d may also results from SOCS (suppressors of cytokine signaling) inhibition (85).", [["lung", "ANATOMY", 131, 135], ["lung inflammation", "DISEASE", 131, 148], ["MERS-CoV murine", "ORGANISM", 19, 34], ["lung", "ORGAN", 131, 135], ["SOCS", "GENE_OR_GENE_PRODUCT", 372, 376], ["cytokines", "PROTEIN", 333, 342], ["SOCS", "PROTEIN", 372, 376], ["cytokine", "PROTEIN", 393, 401], ["murine", "SPECIES", 28, 34], ["MERS-CoV", "SPECIES", 19, 27], ["excessive complement activation", "PROBLEM", 60, 91], ["exacerbated lung inflammation", "PROBLEM", 119, 148], ["cytokine signaling) inhibition", "TREATMENT", 393, 423], ["partly responsible for", "UNCERTAINTY", 96, 118], ["exacerbated", "OBSERVATION_MODIFIER", 119, 130], ["lung", "ANATOMY", 131, 135], ["inflammation", "OBSERVATION", 136, 148]]], ["Indeed, upon Influenza infection, SOCS1 and SOCS3 were shown to reduce type I IFN antiviral responses in human bronchial epithelial cells (86).", [["bronchial epithelial cells", "ANATOMY", 111, 137], ["Influenza infection", "DISEASE", 13, 32], ["SOCS1", "GENE_OR_GENE_PRODUCT", 34, 39], ["SOCS3", "GENE_OR_GENE_PRODUCT", 44, 49], ["type I IFN", "GENE_OR_GENE_PRODUCT", 71, 81], ["human", "ORGANISM", 105, 110], ["bronchial epithelial cells", "CELL", 111, 137], ["SOCS1", "PROTEIN", 34, 39], ["SOCS3", "PROTEIN", 44, 49], ["IFN", "PROTEIN", 78, 81], ["human bronchial epithelial cells", "CELL_TYPE", 105, 137], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["Influenza infection", "PROBLEM", 13, 32], ["SOCS1", "PROBLEM", 34, 39], ["SOCS3", "PROBLEM", 44, 49], ["type I IFN antiviral responses in human bronchial epithelial cells", "PROBLEM", 71, 137], ["Influenza", "OBSERVATION_MODIFIER", 13, 22], ["infection", "OBSERVATION", 23, 32], ["bronchial epithelial", "ANATOMY", 111, 131]]], ["Also, SOCS4-deficient mice exhibited heightened sensitivity to Influenza infection (87).", [["Influenza infection", "DISEASE", 63, 82], ["SOCS4", "GENE_OR_GENE_PRODUCT", 6, 11], ["mice", "ORGANISM", 22, 26], ["SOCS4", "PROTEIN", 6, 11], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["SOCS4", "TEST", 6, 11], ["heightened sensitivity", "PROBLEM", 37, 59], ["Influenza infection", "PROBLEM", 63, 82]]], ["Studies about SOCS involvement during coronavirus infections are currently lacking and should therefore bring new interesting information.Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)On May 12, 2020, using the term \u201cCOVID,\u201d an unbiased search of already registered trials on https://clinicaltrials.gov/ retrieved 1,409 hits, and, when refined with \u201cdouble blind/placebo,\u201d 119 hits were found.", [["coronavirus infections", "DISEASE", 38, 60], ["SOCS", "GENE_OR_GENE_PRODUCT", 14, 18], ["coronavirus", "ORGANISM", 38, 49], ["SOCS", "PROTEIN", 14, 18], ["coronavirus infections", "PROBLEM", 38, 60], ["\u201cdouble blind/placebo", "TREATMENT", 393, 414]]], ["Although the number of trials that are ongoing or \u201cunder recruitment\u201d is expectedly very high, the range of molecules tested is relatively narrow and aimed at targeting mainly antivirals.", [["antivirals", "TREATMENT", 176, 186], ["narrow", "OBSERVATION_MODIFIER", 139, 145]]], ["These include remdesivir (21 hits), lopinavir/ritonavir (also used in AIDS), as well as interferons (46 hits).", [["remdesivir", "CHEMICAL", 14, 24], ["lopinavir/ritonavir", "CHEMICAL", 36, 55], ["AIDS", "DISEASE", 70, 74], ["remdesivir", "CHEMICAL", 14, 24], ["lopinavir", "CHEMICAL", 36, 45], ["ritonavir", "CHEMICAL", 46, 55], ["remdesivir", "SIMPLE_CHEMICAL", 14, 24], ["lopinavir", "SIMPLE_CHEMICAL", 36, 45], ["ritonavir", "SIMPLE_CHEMICAL", 46, 55], ["interferons", "PROTEIN", 88, 99], ["remdesivir", "TREATMENT", 14, 24], ["lopinavir", "TREATMENT", 36, 45], ["ritonavir", "TREATMENT", 46, 55], ["interferons", "TREATMENT", 88, 99]]], ["Also falling in that category are trials testing molecules aiming to block viral entry at the cellular surface by targeting ACE-inhibitors (32 hits) or the membrane proteases of the TTSP family (see above) using camostat mesilate (5 hits).", [["cellular surface", "ANATOMY", 94, 110], ["membrane", "ANATOMY", 156, 164], ["cellular surface", "CELLULAR_COMPONENT", 94, 110], ["ACE", "GENE_OR_GENE_PRODUCT", 124, 127], ["TTSP", "GENE_OR_GENE_PRODUCT", 182, 186], ["camostat mesilate", "SIMPLE_CHEMICAL", 212, 229], ["ACE", "PROTEIN", 124, 127], ["membrane proteases", "PROTEIN", 156, 174], ["TTSP family", "PROTEIN", 182, 193], ["trials testing molecules", "TREATMENT", 34, 58], ["block viral entry", "PROBLEM", 69, 86], ["targeting ACE-inhibitors", "TREATMENT", 114, 138], ["camostat mesilate", "TREATMENT", 212, 229]]], ["Repurposing of non-antiviral drugs may offer new promising options, such as with Ivermectin\u2014an FDA-approved anti-parasitic drug widely available and recently shown to inhibit SARS-CoV-2 in vitro (88).Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)Because the virus load is not necessarily correlated with symptoms deterioration in SARS (the latter being often caused by worsening of inflammation at day 7\u201310 post onset of clinical signs), it follows that anti-inflammatory drugs could/should be prescribed during that stage of the disease (8).Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)In that context, \u201cclassical\u201d anti-inflammatory drugs are indeed currently being tested against COVID-19 [e.g., methylprednisolone, budesonide, hydrocortisone, azithromycin, and non-stero\u00efdal anti-inflammatory drugs (NSAIDs)].", [["SARS", "DISEASE", 374, 378], ["inflammation", "DISEASE", 426, 438], ["COVID-19", "CHEMICAL", 771, 779], ["methylprednisolone", "CHEMICAL", 787, 805], ["budesonide", "CHEMICAL", 807, 817], ["hydrocortisone", "CHEMICAL", 819, 833], ["azithromycin", "CHEMICAL", 835, 847], ["NSAIDs", "CHEMICAL", 892, 898], ["COVID-19", "CHEMICAL", 771, 779], ["methylprednisolone", "CHEMICAL", 787, 805], ["budesonide", "CHEMICAL", 807, 817], ["hydrocortisone", "CHEMICAL", 819, 833], ["azithromycin", "CHEMICAL", 835, 847], ["SARS-CoV-2", "ORGANISM", 175, 185], ["COVID-19", "SIMPLE_CHEMICAL", 771, 779], ["methylprednisolone", "SIMPLE_CHEMICAL", 787, 805], ["budesonide", "SIMPLE_CHEMICAL", 807, 817], ["hydrocortisone", "SIMPLE_CHEMICAL", 819, 833], ["azithromycin", "SIMPLE_CHEMICAL", 835, 847], ["non-stero\u00efdal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 853, 890], ["NSAIDs", "SIMPLE_CHEMICAL", 892, 898], ["non-antiviral drugs", "TREATMENT", 15, 34], ["Ivermectin\u2014an FDA", "TREATMENT", 81, 98], ["anti-parasitic drug", "TREATMENT", 108, 127], ["CoV", "TEST", 180, 183], ["the virus load", "TEST", 298, 312], ["symptoms deterioration", "PROBLEM", 348, 370], ["SARS", "PROBLEM", 374, 378], ["inflammation", "PROBLEM", 426, 438], ["clinical signs", "PROBLEM", 465, 479], ["anti-inflammatory drugs", "TREATMENT", 498, 521], ["the disease", "PROBLEM", 570, 581], ["classical\u201d anti-inflammatory drugs", "TREATMENT", 694, 728], ["COVID", "TREATMENT", 771, 776], ["methylprednisolone", "TREATMENT", 787, 805], ["budesonide", "TREATMENT", 807, 817], ["hydrocortisone", "TREATMENT", 819, 833], ["azithromycin", "TREATMENT", 835, 847], ["non-stero\u00efdal anti-inflammatory drugs", "TREATMENT", 853, 890], ["NSAIDs", "TREATMENT", 892, 898], ["virus", "OBSERVATION", 302, 307], ["not necessarily", "UNCERTAINTY", 316, 331], ["worsening", "OBSERVATION_MODIFIER", 413, 422], ["inflammation", "OBSERVATION", 426, 438], ["anti-inflammatory drugs", "OBSERVATION", 705, 728]]], ["In addition, more specific agents are also being investigated, targeting either IL-\u03b2 (anakinra, 13 hits), IL-6 signaling (Siltuximab/3 hits, Tocilizumab/42 hits, Sarilumab/13 hits), or CD24 (CD24Fc) with the main objective to modulate the \u201ccytokine storm.\u201dPotential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)However, chloroquine/hydroxychloroquine has, so far, undoubtedly taken the lion's share (178 hits), and it has attracted a lot of media attention.", [["chloroquine", "CHEMICAL", 355, 366], ["hydroxychloroquine", "CHEMICAL", 367, 385], ["chloroquine", "CHEMICAL", 355, 366], ["hydroxychloroquine", "CHEMICAL", 367, 385], ["IL-\u03b2", "GENE_OR_GENE_PRODUCT", 80, 84], ["anakinra", "SIMPLE_CHEMICAL", 86, 94], ["IL-6", "GENE_OR_GENE_PRODUCT", 106, 110], ["CD24", "GENE_OR_GENE_PRODUCT", 185, 189], ["CD24Fc", "GENE_OR_GENE_PRODUCT", 191, 197], ["chloroquine", "SIMPLE_CHEMICAL", 355, 366], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 367, 385], ["IL", "PROTEIN", 80, 82], ["CD24", "PROTEIN", 185, 189], ["CD24Fc", "PROTEIN", 191, 197], ["cytokine", "PROTEIN", 240, 248], ["IL", "TEST", 80, 82], ["anakinra", "TEST", 86, 94], ["IL", "TEST", 106, 108], ["Siltuximab", "TEST", 122, 132], ["Tocilizumab", "TREATMENT", 141, 152], ["Sarilumab", "TEST", 162, 171], ["chloroquine", "TREATMENT", 355, 366], ["hydroxychloroquine", "TREATMENT", 367, 385], ["cytokine storm", "OBSERVATION", 240, 254]]], ["In that respect, the results from an initial pan-European endeavor (\u201cDiscovery\u201d), now conducted largely in France because of enrollment difficulties, are eagerly awaited.", [["enrollment difficulties", "PROBLEM", 125, 148]]], ["Indeed, it acts as an anti-viral (presumably through inhibition of lysosomal enzymes requiring an acidic pH and of activation of endolysosomes, see above section \u201cMechanisms of entry\u201d) and as an anti-inflammatory molecule, and it has notably been used in inflammatory rheumatic diseases (89).", [["lysosomal", "ANATOMY", 67, 76], ["inflammatory rheumatic diseases", "DISEASE", 255, 286], ["lysosomal enzymes", "GENE_OR_GENE_PRODUCT", 67, 84], ["lysosomal enzymes", "PROTEIN", 67, 84], ["lysosomal enzymes", "TEST", 67, 84], ["an acidic pH", "TREATMENT", 95, 107], ["activation of endolysosomes", "PROBLEM", 115, 142], ["an anti-inflammatory molecule", "PROBLEM", 192, 221], ["inflammatory rheumatic diseases", "PROBLEM", 255, 286], ["anti-inflammatory molecule", "OBSERVATION", 195, 221], ["inflammatory", "OBSERVATION_MODIFIER", 255, 267]]], ["Despite a relative safe profile, having been administered to millions of people over the years, worries have nevertheless arisen about cardiac issues in many individuals with severe Covid-19, and this will have to be properly assessed (90).Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)Regardless, the ultimate prize in the fight against COVID-19 (or further SARS-CoV infections) undoubtedly lies with the future generation of effective vaccines and the development of neutralizing antibodies (91, 92).Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)Unfortunately, coronavirus vaccines in general have attracted less attention compared to the effort dedicated to vaccines against other potential pandemic viruses such as Influenza.", [["cardiac", "ANATOMY", 135, 142], ["COVID-19", "CHEMICAL", 382, 390], ["SARS-CoV infections", "DISEASE", 403, 422], ["Influenza", "DISEASE", 807, 816], ["people", "ORGANISM", 73, 79], ["cardiac", "ORGAN", 135, 142], ["COVID-19", "ORGANISM", 382, 390], ["SARS-CoV", "ORGANISM", 403, 411], ["coronavirus", "ORGANISM", 651, 662], ["Influenza", "ORGANISM", 807, 816], ["neutralizing antibodies", "PROTEIN", 513, 536], ["people", "SPECIES", 73, 79], ["Influenza", "SPECIES", 807, 816], ["SARS-CoV", "SPECIES", 403, 411], ["cardiac issues", "PROBLEM", 135, 149], ["COVID", "TEST", 382, 387], ["further SARS-CoV infections", "PROBLEM", 395, 422], ["effective vaccines", "TREATMENT", 471, 489], ["neutralizing antibodies", "TEST", 513, 536], ["coronavirus vaccines", "TREATMENT", 651, 671], ["vaccines", "TREATMENT", 749, 757], ["other potential pandemic viruses", "PROBLEM", 766, 798], ["Influenza", "PROBLEM", 807, 816], ["neutralizing antibodies", "OBSERVATION", 513, 536]]], ["For example, from 2012 onwards, few SARS-CoV vaccines reached phase 1 clinical trials for lack of interest from the pharmaceutical industry when it became evident that the virus was not making a \u201ccomeback\u201d after its initial appearance.", [["SARS", "DISEASE", 36, 40], ["SARS-CoV", "ORGANISM", 36, 44], ["SARS-CoV", "SPECIES", 36, 44], ["few SARS", "PROBLEM", 32, 40], ["CoV vaccines", "TREATMENT", 41, 53], ["the virus", "PROBLEM", 168, 177]]], ["However, although probably too late for affecting the current \u201cfirst wave\u201d of SARS-CoV-2 pandemic, many pharmaceutical companies and research laboratories are now working on a plethora of vaccine formulations [for a review, see (91) and https://clinicaltrials.gov, the latter reporting so far 83 clinical trials on vaccines].Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)Indeed, in pre-clinical studies, the determination of cryo-EM structures of the SARS-CoV-2 S ectodomain trimer is providing a blueprint for the design of vaccines and inhibitors of viral entry (28).", [["SARS-CoV-2 pandemic", "DISEASE", 78, 97], ["SARS-CoV-2", "ORGANISM", 78, 88], ["SARS-CoV-2 S ectodomain trimer", "PROTEIN", 495, 525], ["SARS-CoV", "SPECIES", 78, 86], ["SARS", "PROBLEM", 78, 82], ["pandemic", "PROBLEM", 89, 97], ["research laboratories", "TEST", 133, 154], ["vaccine formulations", "TREATMENT", 188, 208], ["vaccines", "TREATMENT", 315, 323], ["pre-clinical studies", "TEST", 426, 446], ["the SARS", "PROBLEM", 491, 499], ["CoV-2 S ectodomain trimer", "TREATMENT", 500, 525], ["the design of vaccines", "TREATMENT", 555, 577], ["inhibitors", "TREATMENT", 582, 592], ["viral entry", "TEST", 596, 607]]], ["In this context, promising results show that murine polyclonal antibodies against S protein of SARS-CoV are able to elicit polyclonal antibody responses, preventing SARS-CoV-2 entry into cells, and thus indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination (28).Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)In addition to testing the best SARS-CoV-2 specific epitopes from the most suitable proteins (S, N, etc.) and way of administration (best vectors, etc.), it is important to select the best animal models.", [["cells", "ANATOMY", 187, 192], ["murine", "ORGANISM", 45, 51], ["polyclonal antibodies against S protein", "GENE_OR_GENE_PRODUCT", 52, 91], ["SARS-CoV", "ORGANISM", 95, 103], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 165, 175], ["cells", "CELL", 187, 192], ["murine polyclonal antibodies", "PROTEIN", 45, 73], ["S protein", "PROTEIN", 82, 91], ["cross-neutralizing antibodies", "PROTEIN", 219, 248], ["S epitopes", "PROTEIN", 269, 279], ["SARS-CoV-2 specific epitopes", "PROTEIN", 440, 468], ["murine", "SPECIES", 45, 51], ["SARS-CoV", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 165, 173], ["murine polyclonal antibodies", "TEST", 45, 73], ["S protein", "TEST", 82, 91], ["SARS", "PROBLEM", 95, 99], ["CoV", "PROBLEM", 100, 103], ["polyclonal antibody responses", "TEST", 123, 152], ["SARS", "TEST", 165, 169], ["CoV", "TEST", 170, 173], ["cross-neutralizing antibodies", "PROBLEM", 219, 248], ["testing", "TEST", 423, 430], ["CoV", "TEST", 445, 448], ["2 specific epitopes", "PROBLEM", 449, 468]]], ["Although convincing murine studies are still pending, as indicated above in the section \u201cMechanisms of entry\u2026\u201d, studies in other animals investigated the virus susceptibility of chickens, ducks, dogs, pigs, cats, and ferrets, with the latter two being the most permissive (43).", [["murine", "ORGANISM", 20, 26], ["chickens", "ORGANISM", 178, 186], ["ducks", "ORGANISM", 188, 193], ["dogs", "ORGANISM", 195, 199], ["pigs", "ORGANISM", 201, 205], ["cats", "ORGANISM", 207, 211], ["ferrets", "ORGANISM", 217, 224], ["murine", "SPECIES", 20, 26], ["chickens", "SPECIES", 178, 186], ["ducks", "SPECIES", 188, 193], ["dogs", "SPECIES", 195, 199], ["pigs", "SPECIES", 201, 205], ["cats", "SPECIES", 207, 211], ["ferrets", "SPECIES", 217, 224], ["chickens", "SPECIES", 178, 186], ["pigs", "SPECIES", 201, 205], ["murine studies", "TEST", 20, 34]]], ["Further up in the phylogenetic scale, a recent study reported that an inactivated vaccine candidate for SARS-CoV-2 was protective in macaques (93).Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)Finally, large epidemiological studies have demonstrated that Bacille Calmette-Guerin (BCG) can heterologously protect against virus infections [e.g., yellow fever virus (94), probably by tapping on trained immunity mechanisms (95, 96)].", [["SARS", "DISEASE", 104, 108], ["Bacille Calmette-Guerin", "CHEMICAL", 299, 322], ["infections", "DISEASE", 370, 380], ["yellow fever", "DISEASE", 388, 400], ["SARS-CoV-2", "ORGANISM", 104, 114], ["macaques", "ORGANISM", 133, 141], ["Bacille Calmette-Guerin", "ORGANISM", 299, 322], ["BCG", "ORGANISM", 324, 327], ["yellow fever virus", "ORGANISM", 388, 406], ["macaques", "SPECIES", 133, 141], ["yellow fever virus", "SPECIES", 388, 406], ["SARS-CoV", "SPECIES", 104, 112], ["yellow fever virus", "SPECIES", 388, 406], ["a recent study", "TEST", 38, 52], ["an inactivated vaccine", "TREATMENT", 67, 89], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["large epidemiological studies", "TEST", 246, 275], ["Bacille Calmette", "TREATMENT", 299, 315], ["Guerin (BCG", "TREATMENT", 316, 327], ["virus infections", "PROBLEM", 364, 380], ["yellow fever virus", "PROBLEM", 388, 406], ["large", "OBSERVATION_MODIFIER", 246, 251]]], ["Using such adjuvant-mediated strategies against SARS-CoV viruses may therefore be an exciting avenue worthwhile pursuing (97\u201399).Author ContributionsAll authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["SARS-CoV viruses", "DISEASE", 48, 64], ["SARS-CoV viruses", "ORGANISM", 48, 64], ["SARS-CoV viruses", "SPECIES", 48, 64], ["such adjuvant-mediated strategies", "TREATMENT", 6, 39], ["SARS", "PROBLEM", 48, 52], ["CoV viruses", "PROBLEM", 53, 64]]]], "PMC7491718": [["According to World Health Organization (WHO) estimates, the global under-5 mortality rate decreased by 59% between 1990 and 2018, from 93 to 39 deaths per 1,000 live births [1].", [["deaths", "DISEASE", 144, 150], ["mortality rate", "TEST", 75, 89]]], ["This remarkable reduction was achieved largely by increasing the coverage of vaccination against measles and other childhood infections, rolling out new vaccines against Streptococcus pneumoniae and Haemophilus influenzae type b, and introducing artemisinin combination treatment and long-lasting, insecticide-treated bed nets for the treatment and prevention of malaria.", [["measles", "DISEASE", 97, 104], ["infections", "DISEASE", 125, 135], ["Streptococcus pneumoniae", "DISEASE", 170, 194], ["Haemophilus influenzae type b", "DISEASE", 199, 228], ["artemisinin", "CHEMICAL", 246, 257], ["malaria", "DISEASE", 363, 370], ["artemisinin", "CHEMICAL", 246, 257], ["Streptococcus pneumoniae", "ORGANISM", 170, 194], ["Haemophilus influenzae type b", "ORGANISM", 199, 228], ["artemisinin", "SIMPLE_CHEMICAL", 246, 257], ["Streptococcus pneumoniae", "SPECIES", 170, 194], ["Haemophilus influenzae", "SPECIES", 199, 221], ["measles", "SPECIES", 97, 104], ["Streptococcus pneumoniae", "SPECIES", 170, 194], ["Haemophilus influenzae", "SPECIES", 199, 221], ["vaccination", "TREATMENT", 77, 88], ["measles", "PROBLEM", 97, 104], ["other childhood infections", "PROBLEM", 109, 135], ["new vaccines", "TREATMENT", 149, 161], ["Streptococcus pneumoniae", "PROBLEM", 170, 194], ["Haemophilus influenzae type b", "PROBLEM", 199, 228], ["artemisinin combination treatment", "TREATMENT", 246, 279], ["the treatment", "TREATMENT", 331, 344], ["malaria", "PROBLEM", 363, 370], ["reduction", "OBSERVATION_MODIFIER", 16, 25], ["infections", "OBSERVATION", 125, 135], ["malaria", "OBSERVATION", 363, 370]]]], "PMC7383121": [["IntroductionSince December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia has spread rapidly in China and soon after around the world.", [["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["pneumonia", "DISEASE", 94, 103], ["SARS-CoV-2", "ORGANISM", 82, 92], ["CoV-2", "SPECIES", 87, 92], ["severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV-2", "SPECIES", 82, 92], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 33, 78], ["SARS", "PROBLEM", 82, 86], ["pneumonia", "PROBLEM", 94, 103], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66], ["pneumonia", "OBSERVATION", 94, 103], ["spread", "OBSERVATION_MODIFIER", 108, 114], ["rapidly", "OBSERVATION_MODIFIER", 115, 122]]], ["It has been declared by WHO as a global public health emergency and named as Coronavirus disease 2019 (COVID-19) on January 13, 2020 (Huang et al.2020; Zhou et al. 2020b; Zhu et al.2020).", [["Coronavirus disease", "DISEASE", 77, 96], ["Coronavirus disease", "PROBLEM", 77, 96], ["COVID", "TEST", 103, 108]]], ["As of July 08, 2020, there have been about 11,669,259 confirmed cases, and 539,906 deaths caused by the COVID-19 (WHO 2020a).IntroductionThe clinical spectrum of patients with COVID-19 varies from asymptomatic infection, mild discomfort to severe viral pneumonia with respiratory failure and even death (Chen et al.2020; Wang et al.2020).", [["respiratory", "ANATOMY", 268, 279], ["deaths", "DISEASE", 83, 89], ["infection", "DISEASE", 210, 219], ["viral pneumonia", "DISEASE", 247, 262], ["respiratory failure", "DISEASE", 268, 287], ["death", "DISEASE", 297, 302], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["COVID", "TEST", 176, 181], ["asymptomatic infection", "PROBLEM", 197, 219], ["mild discomfort", "PROBLEM", 221, 236], ["severe viral pneumonia", "PROBLEM", 240, 262], ["respiratory failure", "PROBLEM", 268, 287], ["even death", "PROBLEM", 292, 302], ["asymptomatic", "OBSERVATION_MODIFIER", 197, 209], ["infection", "OBSERVATION", 210, 219], ["mild", "OBSERVATION_MODIFIER", 221, 225], ["discomfort", "OBSERVATION", 226, 236], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["viral", "OBSERVATION_MODIFIER", 247, 252], ["pneumonia", "OBSERVATION", 253, 262], ["respiratory failure", "OBSERVATION", 268, 287]]], ["The symptoms and clinical features of patients with COVID-19 include lower respiratory tract illness with fever, dry cough and dyspnea.", [["lower respiratory tract", "ANATOMY", 69, 92], ["COVID-19", "CHEMICAL", 52, 60], ["respiratory tract illness", "DISEASE", 75, 100], ["fever", "DISEASE", 106, 111], ["dry cough", "DISEASE", 113, 122], ["dyspnea", "DISEASE", 127, 134], ["patients", "ORGANISM", 38, 46], ["lower", "ORGANISM_SUBDIVISION", 69, 74], ["respiratory tract", "ORGANISM_SUBDIVISION", 75, 92], ["patients", "SPECIES", 38, 46], ["The symptoms", "PROBLEM", 0, 12], ["COVID", "TEST", 52, 57], ["lower respiratory tract illness", "PROBLEM", 69, 100], ["fever", "PROBLEM", 106, 111], ["dry cough", "PROBLEM", 113, 122], ["dyspnea", "PROBLEM", 127, 134], ["lower", "ANATOMY_MODIFIER", 69, 74], ["respiratory tract", "ANATOMY", 75, 92], ["fever", "OBSERVATION", 106, 111], ["dry", "OBSERVATION_MODIFIER", 113, 116], ["cough", "OBSERVATION", 117, 122]]], ["These symptoms are similar to those of two other diseases caused by coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (Tsang et al. 2003; Assiri et al. 2013).IntroductionPrompt and accurate diagnosis is the first and vital step to effectively control the ongoing outbreak of emerging COVID-19 epidemics (Sridhar et al.2015; Yang et al.2020).", [["coronaviruses", "DISEASE", 68, 81], ["acute respiratory syndrome", "DISEASE", 90, 116], ["SARS", "DISEASE", 118, 122], ["Middle East respiratory syndrome", "DISEASE", 128, 160], ["MERS", "DISEASE", 162, 166], ["Middle East respiratory syndrome (MERS)", "SPECIES", 128, 167], ["These symptoms", "PROBLEM", 0, 14], ["two other diseases", "PROBLEM", 39, 57], ["coronaviruses", "PROBLEM", 68, 81], ["severe acute respiratory syndrome", "PROBLEM", 83, 116], ["SARS)", "PROBLEM", 118, 123], ["Middle East respiratory syndrome", "PROBLEM", 128, 160], ["emerging COVID", "TREATMENT", 325, 339], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116], ["Middle", "ANATOMY_MODIFIER", 128, 134], ["respiratory syndrome", "OBSERVATION", 140, 160]]], ["The radiological characteristics of patients with COVID-19 pneumonia are diverse, from nondistinctive features, diffuse changes, to destruction of the pulmonary parenchyma (Shi et al.2020).", [["pulmonary parenchyma", "ANATOMY", 151, 171], ["pneumonia", "DISEASE", 59, 68], ["patients", "ORGANISM", 36, 44], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 151, 171], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 50, 55], ["pneumonia", "PROBLEM", 59, 68], ["nondistinctive features", "PROBLEM", 87, 110], ["diffuse changes", "PROBLEM", 112, 127], ["destruction of the pulmonary parenchyma", "PROBLEM", 132, 171], ["pneumonia", "OBSERVATION", 59, 68], ["diverse", "OBSERVATION_MODIFIER", 73, 80], ["diffuse", "OBSERVATION_MODIFIER", 112, 119], ["destruction", "OBSERVATION", 132, 143], ["pulmonary", "ANATOMY", 151, 160], ["parenchyma", "ANATOMY_MODIFIER", 161, 171]]], ["However, the evidences based on radiological characteristics alone are not sufficient to confirm the virus.", [["the virus", "PROBLEM", 97, 106]]], ["One commonly accepted clinical method in confirming infected cases of COVID-19 is based on detection of unique sequences of virus RNA via quantitative reverse transcriptase polymerase-chain-reaction (qRT-PCR), which has the advantages of high-accuracy and high specificity.IntroductionHowever, there is still a possibility that false-negative results might occur due to the low viral loads of the samples (To et al.2020; Zou et al.2020).", [["samples", "ANATOMY", 397, 404], ["COVID-19", "DNA", 70, 78], ["virus RNA", "RNA", 124, 133], ["reverse transcriptase", "PROTEIN", 151, 172], ["COVID", "TEST", 70, 75], ["virus RNA", "PROBLEM", 124, 133], ["quantitative reverse transcriptase polymerase", "TEST", 138, 183], ["chain-reaction", "PROBLEM", 184, 198], ["the low viral loads of the samples", "PROBLEM", 370, 404]]], ["Measurement of anti-SARS-CoV-2 antibodies theoretically could remedy the detection of nucleic acid and be used for retrospective diagnosis and contact tracing.", [["nucleic acid", "CHEMICAL", 86, 98], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 30], ["nucleic acid", "SIMPLE_CHEMICAL", 86, 98], ["anti-SARS-CoV-2 antibodies", "PROTEIN", 15, 41], ["anti-SARS", "TEST", 15, 24], ["CoV", "TEST", 25, 28], ["nucleic acid", "TREATMENT", 86, 98], ["contact tracing", "TEST", 143, 158]]], ["Therefore, in the present study, we retrospectively analyzed the sensitivities and dynamics of IgG and IgM antibodies detected by ELISA in COVID-19 patients at early stage of outbreak in Wuhan, as to provide early diagnosis information in this field.Study Design and Participants ::: Materials and MethodsThis single-center, retrospective study was conducted at Jin-Yin-Tan Hospital (Wuhan, China), which is a designated hospital to treat COVID-19 patients.", [["COVID", "DISEASE", 439, 444], ["IgG", "GENE_OR_GENE_PRODUCT", 95, 98], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 103, 117], ["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 448, 456], ["IgG", "PROTEIN", 95, 98], ["IgM antibodies", "PROTEIN", 103, 117], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 448, 456], ["the present study", "TEST", 14, 31], ["the sensitivities", "TEST", 61, 78], ["IgG", "TEST", 95, 98], ["IgM antibodies", "TEST", 103, 117], ["ELISA", "TEST", 130, 135], ["retrospective study", "TEST", 325, 344]]], ["We recruited 131 patients who had been diagnosed with COVID-19 before 15 January 2020.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["COVID", "TEST", 54, 59]]], ["According to WHO interim guidance, at least one-time antibody detection was done during their hospitalization (WHO 2020b).Serological Tests for Anti-SARS-CoV-2 Antibodies ::: Materials and MethodsAnti-SARS-CoV-2 IgG and IgM antibodies in serum samples of COVID-19 patients were detected with the serological methods as reported previously, which showed no cross-reactivity with other commonly circulating human coronaviruses (e.g. HCoV-OC43) (Kissler et al.2020).", [["serum samples", "ANATOMY", 238, 251], ["Anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 144, 159], ["MethodsAnti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 189, 215], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 220, 234], ["serum samples", "ORGANISM_SUBSTANCE", 238, 251], ["patients", "ORGANISM", 264, 272], ["human", "ORGANISM", 405, 410], ["Anti-SARS-CoV", "PROTEIN", 144, 157], ["MethodsAnti-SARS-CoV-2 IgG", "PROTEIN", 189, 215], ["IgM antibodies", "PROTEIN", 220, 234], ["patients", "SPECIES", 264, 272], ["human", "SPECIES", 405, 410], ["human coronaviruses", "SPECIES", 405, 424], ["antibody detection", "TEST", 53, 71], ["Serological Tests", "TEST", 122, 139], ["Anti-SARS-CoV", "TEST", 144, 157], ["Materials", "TEST", 175, 184], ["MethodsAnti-SARS", "TEST", 189, 205], ["CoV", "TEST", 206, 209], ["IgG", "TEST", 212, 215], ["IgM antibodies", "TEST", 220, 234], ["serum samples", "TEST", 238, 251], ["COVID", "TEST", 255, 260], ["the serological methods", "TEST", 292, 315], ["cross-reactivity", "PROBLEM", 356, 372], ["other commonly circulating human coronaviruses", "PROBLEM", 378, 424], ["HCoV", "TEST", 431, 435]]], ["In-house anti-SARS-CoV-2 IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 nucleocapsid protein (NP) as antigen, which is > 90% amino acid identity compared to reported SARSr-CoVs (Wang et al.2018; Zhou et al. 2020a).", [["amino acid", "CHEMICAL", 136, 146], ["amino acid", "CHEMICAL", 136, 146], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 9, 28], ["IgM", "ORGANISM", 33, 36], ["SARSr-CoV Rp3 nucleocapsid protein (NP)", "GENE_OR_GENE_PRODUCT", 69, 108], ["amino acid", "AMINO_ACID", 136, 146], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 177, 187], ["In-house anti-SARS-CoV-2 IgG", "PROTEIN", 0, 28], ["IgM", "PROTEIN", 33, 36], ["SARSr-CoV Rp3 nucleocapsid protein", "PROTEIN", 69, 103], ["NP", "PROTEIN", 105, 107], ["SARSr", "PROTEIN", 177, 182], ["CoVs", "PROTEIN", 183, 187], ["SARSr-CoV", "SPECIES", 69, 78], ["anti-SARS", "TEST", 9, 18], ["CoV", "TEST", 19, 22], ["IgG", "TEST", 25, 28], ["IgM ELISA kits", "TEST", 33, 47], ["SARSr", "TEST", 69, 74], ["CoV Rp3 nucleocapsid protein", "TEST", 75, 103], ["amino acid identity", "TEST", 136, 155]]], ["For IgG test, MaxiSorp Nunc-immuno 96 well ELISA plates were coated with 100 ng/well of recombinant NP overnight, then incubated with human sera in duplicates at a dilution of 1:20 for an hour at 37 \u00b0C, and followed by detection with anti-Human IgG-HRP conjugated monoclonal antibody (Kyab Biotech Co., Ltd, Wuhan, China) at a dilution of 1:40,000.", [["sera", "ANATOMY", 140, 144], ["IgG", "GENE_OR_GENE_PRODUCT", 4, 7], ["human", "ORGANISM", 134, 139], ["sera", "ORGANISM_SUBSTANCE", 140, 144], ["HRP", "GENE_OR_GENE_PRODUCT", 249, 252], ["IgG", "PROTEIN", 4, 7], ["anti-Human IgG", "PROTEIN", 234, 248], ["HRP conjugated monoclonal antibody", "PROTEIN", 249, 283], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["IgG test", "TEST", 4, 12], ["MaxiSorp Nunc-immuno", "TREATMENT", 14, 34], ["ELISA plates", "TREATMENT", 43, 55], ["recombinant NP", "TREATMENT", 88, 102], ["anti-Human IgG", "TEST", 234, 248], ["monoclonal antibody", "TEST", 264, 283]]], ["For IgM test, MaxiSorp Nunc-immuno 96 well ELISA plates were coated with 500 ng/well anti-human IgM (\u00b5 chain) overnight, then incubated with human sera in duplicates at 1:100 dilution for 40 min at 37 \u00b0C, and followed by detection with anti-Rp3 NP-HRP conjugated antibody (Kyab Biotech Co., Ltd, Wuhan, China) at a dilution of 1:4000.", [["sera", "ANATOMY", 147, 151], ["IgM", "GENE_OR_GENE_PRODUCT", 4, 7], ["anti-human", "ORGANISM", 85, 95], ["IgM", "GENE_OR_GENE_PRODUCT", 96, 99], ["human", "ORGANISM", 141, 146], ["sera", "ORGANISM_SUBSTANCE", 147, 151], ["HRP", "GENE_OR_GENE_PRODUCT", 248, 251], ["IgM", "PROTEIN", 4, 7], ["anti-human IgM", "PROTEIN", 85, 99], ["\u00b5 chain", "PROTEIN", 101, 108], ["HRP conjugated antibody", "PROTEIN", 248, 271], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146], ["IgM test", "TEST", 4, 12], ["MaxiSorp Nunc-immuno", "TREATMENT", 14, 34], ["ELISA plates", "TREATMENT", 43, 55], ["human sera", "TREATMENT", 141, 151], ["anti", "TEST", 236, 240], ["HRP conjugated antibody", "TEST", 248, 271]]], ["The OD values of 450\u2013630 nm were calculated.", [["The OD values", "TEST", 0, 13]]], ["240 random negative control samples and two SARS-CoV-2 positive control samples were used to set the cutoff values of IgG and IgM.", [["samples", "ANATOMY", 28, 35], ["samples", "ANATOMY", 72, 79], ["samples", "CANCER", 28, 35], ["samples", "CANCER", 72, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 118, 121], ["IgG", "PROTEIN", 118, 121], ["SARS-CoV", "SPECIES", 44, 52], ["two SARS", "TEST", 40, 48], ["CoV", "TEST", 49, 52], ["the cutoff values", "TEST", 97, 114], ["IgG", "TEST", 118, 121]]], ["According to the Kit instruction, we used the mean OD value of the negative control samples plus three standard deviations to set the cutoff values of IgG and IgM at 0.143 and 0.142, respectively.", [["samples", "ANATOMY", 84, 91], ["IgG", "GENE_OR_GENE_PRODUCT", 151, 154], ["IgM", "GENE_OR_GENE_PRODUCT", 159, 162], ["IgG", "PROTEIN", 151, 154], ["IgM", "PROTEIN", 159, 162], ["the mean OD value", "TEST", 42, 59], ["IgG", "TEST", 151, 154], ["IgM", "TEST", 159, 162]]], ["The specificity of these positive samples was confirmed by Western blot with recombinant Rp3 NP.Collection of Clinical Data and Evaluation of Chest CT ::: Materials and MethodsAll the clinical data on epidemiology, including exposure history, symptoms, underlying comorbidities and laboratory results were retrospectively extracted from electronic medical records.", [["samples", "ANATOMY", 34, 41], ["Rp3", "GENE_OR_GENE_PRODUCT", 89, 92], ["recombinant Rp3 NP", "PROTEIN", 77, 95], ["these positive samples", "PROBLEM", 19, 41], ["recombinant Rp3 NP", "TREATMENT", 77, 95], ["Clinical Data", "TEST", 110, 123], ["Evaluation of Chest CT", "TEST", 128, 150], ["symptoms", "PROBLEM", 243, 251], ["underlying comorbidities", "PROBLEM", 253, 277], ["Chest", "ANATOMY", 142, 147]]], ["The date of disease onset was defined as the day when the symptom was noticed.", [["the symptom", "PROBLEM", 54, 65], ["disease", "OBSERVATION", 12, 19]]], ["All CT images were reviewed by two experienced radiologists, and decisions were reached by consensus agreement.Statistical Methods ::: Materials and MethodsAll statistical analyses were performed with SPSS software (version 20.0, IBM, Armonk, NY).", [["All CT images", "TEST", 0, 13], ["All statistical analyses", "TEST", 156, 180], ["SPSS software", "TEST", 201, 214]]]], "9ef6fcc15caf2f8efac313693e45f74bfcaf7863": [["IntroductionThe novel viral infection of COVID-19, recently declared a pandemic by the WHO, represents one of the most serious global emergencies of the twenty-first century.", [["viral infection", "DISEASE", 22, 37], ["COVID-19", "CHEMICAL", 41, 49], ["The novel viral infection of COVID", "PROBLEM", 12, 46], ["viral", "OBSERVATION_MODIFIER", 22, 27], ["infection", "OBSERVATION", 28, 37]]], ["Since the first appearance of this new Coronavirus (SARS-CoV-2), the COVID-19 infection has been viewed in a range of ways; these vary from a perception of it as a disease no more serious than a seasonal flu to that of a highly severe and troubling threat [1] .", [["infection", "DISEASE", 78, 87], ["flu", "DISEASE", 204, 207], ["Coronavirus", "CANCER", 39, 50], ["SARS-CoV-2", "ORGANISM", 52, 62], ["COVID-19", "ORGANISM", 69, 77], ["COVID-19", "SPECIES", 69, 77], ["this new Coronavirus (SARS", "PROBLEM", 30, 56], ["CoV", "TEST", 57, 60], ["the COVID", "TEST", 65, 74], ["infection", "PROBLEM", 78, 87], ["a disease", "PROBLEM", 162, 171], ["a seasonal flu", "PROBLEM", 193, 207], ["a highly severe and troubling threat", "PROBLEM", 219, 255], ["new", "OBSERVATION_MODIFIER", 35, 38], ["Coronavirus", "OBSERVATION", 39, 50], ["infection", "OBSERVATION", 78, 87], ["severe", "OBSERVATION_MODIFIER", 228, 234]]], ["The epidemic was first detected in the city of Wuhan, China at the regions in Italy through their industries, agriculture, and international commerce.", [["The epidemic", "PROBLEM", 0, 12]]], ["The Lombardia and the Po Valley, the hardest hit by the epidemic, are also the most polluted areas not only in Italy but also in the whole of Europe by the fine air particulate matter (PM10, PM2.5) and ozone [6, 7] .IntroductionThe onset and the evolution of COVID-19 infection in Italy, and more specifically in Lombardia Region, was anomalous and unusually lethal with respect to all other countries, including China where the infection began.", [["PM10", "CHEMICAL", 185, 189], ["PM2.5", "CHEMICAL", 191, 196], ["ozone", "CHEMICAL", 202, 207], ["COVID-19", "CHEMICAL", 259, 267], ["infection", "DISEASE", 268, 277], ["infection", "DISEASE", 429, 438], ["PM2.5", "CHEMICAL", 191, 196], ["ozone", "CHEMICAL", 202, 207], ["PM10", "SIMPLE_CHEMICAL", 185, 189], ["ozone", "SIMPLE_CHEMICAL", 202, 207], ["COVID-19", "ORGANISM", 259, 267], ["COVID-19 infection", "PROBLEM", 259, 277], ["the infection", "PROBLEM", 425, 438], ["infection", "OBSERVATION", 268, 277], ["anomalous", "OBSERVATION", 335, 344], ["infection", "OBSERVATION", 429, 438]]], ["Although the media (and also many specialists interviewed by media) highlight the velocity of infection in Italy as \"exponential\", the number of infected people has never followed an exponential distribution burring in the early days of the epidemic.", [["infection", "DISEASE", 94, 103], ["people", "ORGANISM", 154, 160], ["people", "SPECIES", 154, 160], ["infection", "PROBLEM", 94, 103], ["velocity", "OBSERVATION_MODIFIER", 82, 90], ["infection", "OBSERVATION", 94, 103], ["number", "OBSERVATION_MODIFIER", 135, 141], ["infected", "OBSERVATION", 145, 153], ["exponential", "OBSERVATION_MODIFIER", 183, 194], ["distribution", "OBSERVATION_MODIFIER", 195, 207]]], ["Figure 1a shows the number of recorded infections as a function of time (in days since 24 February 2020) in a semi-logarithmic scale.IntroductionIt is evident that the distribution is markedly different from a straight line, typical of an exponential distribution in such a scale, and it is fairly well fitted by a cubic polynomial, which is much slower than an exponential growth rate.", [["infections", "DISEASE", 39, 49], ["recorded infections", "PROBLEM", 30, 49], ["a semi-logarithmic scale", "TREATMENT", 108, 132], ["a straight line", "TREATMENT", 208, 223], ["an exponential distribution", "PROBLEM", 236, 263], ["a cubic polynomial", "TEST", 313, 331], ["infections", "OBSERVATION", 39, 49], ["distribution", "OBSERVATION_MODIFIER", 168, 180], ["markedly", "OBSERVATION_MODIFIER", 184, 192], ["different", "OBSERVATION_MODIFIER", 193, 202], ["straight line", "OBSERVATION_MODIFIER", 210, 223], ["exponential", "OBSERVATION_MODIFIER", 239, 250], ["distribution", "OBSERVATION_MODIFIER", 251, 263], ["cubic polynomial", "OBSERVATION", 315, 331], ["much", "OBSERVATION_MODIFIER", 342, 346], ["slower", "OBSERVATION_MODIFIER", 347, 353], ["exponential", "OBSERVATION_MODIFIER", 362, 373], ["growth", "OBSERVATION_MODIFIER", 374, 380]]], ["The cubic polynomial fit and the exponential one present in the figure both use data referred to 18 days starting on the date of acknowledgement of the first cases (from 24 February to 12 March 2020); starting from that date, the cubic fit, according to AIC test, scores better than the exponential one.", [["The cubic polynomial fit", "PROBLEM", 0, 24], ["AIC test", "TEST", 254, 262], ["cubic", "OBSERVATION_MODIFIER", 4, 9], ["polynomial fit", "OBSERVATION", 10, 24], ["exponential", "OBSERVATION_MODIFIER", 33, 44]]], ["In the figure, we also show the fit obtained from a logistic function for comparison; logistic fit scores become better than the exponential one from 12 March 2020 and better than the cubic one after 25 March 2020.", [["logistic fit scores", "PROBLEM", 86, 105]]], ["Figure 1b shows the same quantity in a linear scale, together with the three mentioned fitting functions.IntroductionAlthough the number of people infected is the main parameter taken into account by the authorities and the number highlighted by media, its real value is largely uncertain and likely underestimated.", [["people", "ORGANISM", 140, 146], ["people", "SPECIES", 140, 146], ["a linear scale", "TREATMENT", 37, 51], ["main", "OBSERVATION_MODIFIER", 163, 167]]], ["Critically, that infection tally relies on the number of laboratory tests available, which is limited and miniscule compared to the percentage of the population likely to have had contact with infected individuals.", [["infection", "DISEASE", 17, 26], ["infection", "PROBLEM", 17, 26], ["laboratory tests", "TEST", 57, 73], ["infected individuals", "PROBLEM", 193, 213], ["infection", "OBSERVATION", 17, 26], ["infected", "OBSERVATION", 193, 201]]], ["Furthermore, the procedures to test people are highly variable within the different regions of Italy and have changed in the weeks following the onset of the infections; because of this inconsistency, this number is statistically very unreliable and unfit as a foundation to interpret the actual evolution of the infection.IntroductionThe number of tests performed in Italy fluctuates widely but in general increased in time from about 2427 (27 February 2020) to 26,336 (21 March 2020) and decreased again to 25,180 (22 March 2020 ) and 17,066 (23 March 2020).", [["infections", "DISEASE", 158, 168], ["infection", "DISEASE", 313, 322], ["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["the infections", "PROBLEM", 154, 168], ["the infection", "PROBLEM", 309, 322], ["tests", "TEST", 349, 354], ["infections", "OBSERVATION", 158, 168], ["infection", "OBSERVATION", 313, 322]]], ["It reached a peak value of 36,615 on 26 March, but then it decreased in subsequent days [8] .", [["a peak value", "TEST", 11, 23], ["decreased", "OBSERVATION_MODIFIER", 59, 68]]], ["A very important quantity, the CFR (defined as the ratio of the number of people deceased divided by the number of total recorded infections), is extremely high in Italy at about 11%.", [["infections", "DISEASE", 130, 140], ["people", "SPECIES", 74, 80], ["the CFR", "TEST", 27, 34], ["total recorded infections", "PROBLEM", 115, 140], ["very", "OBSERVATION_MODIFIER", 2, 6], ["important quantity", "OBSERVATION_MODIFIER", 7, 25], ["infections", "OBSERVATION", 130, 140], ["extremely", "OBSERVATION_MODIFIER", 146, 155], ["high", "OBSERVATION_MODIFIER", 156, 160]]], ["This high value is skewed by the lethality in Lombardia, where about 50% of all the Italian infections have been recorded, with a CFR of about 16%.", [["infections", "DISEASE", 92, 102], ["the lethality", "PROBLEM", 29, 42], ["a CFR", "TEST", 128, 133], ["skewed", "OBSERVATION_MODIFIER", 19, 25], ["lethality", "OBSERVATION", 33, 42], ["infections", "OBSERVATION", 92, 102]]], ["CFR is a generally overestimated value of the true lethality (IFR) given the likely underestimation of the real number of infection cases (i.e., including asymptomatic and pauci-symptomatic cases, which are easily overlooked by the small number of tests).", [["infection", "DISEASE", 122, 131], ["the true lethality", "PROBLEM", 42, 60], ["infection cases", "PROBLEM", 122, 137], ["asymptomatic and pauci-symptomatic cases", "PROBLEM", 155, 195], ["tests", "TEST", 248, 253], ["infection", "OBSERVATION", 122, 131]]], ["IFR is the parameter that measures the percentage of deceases over the total population infected (including the generally unknown number of non recorded cases).", [["infected", "OBSERVATION", 88, 96]]], ["Table 1 [2] reports the number of infections, deaths, and CFR observed in several countries in the world as of 30 March 2020.", [["infections", "DISEASE", 34, 44], ["deaths", "DISEASE", 46, 52], ["infections", "PROBLEM", 34, 44], ["infections", "OBSERVATION", 34, 44]]], ["The lethality rate for different countries is highly variable, ranging from a minimum of 0.4% (i.e., Australia and Israel) to a maximum of 11.3% in Italy.IntroductionRegion, was anomalous and unusually lethal with respect to all other countries, including China where the infection began.", [["infection", "DISEASE", 272, 281], ["The lethality rate", "TEST", 0, 18], ["the infection", "PROBLEM", 268, 281], ["lethality", "OBSERVATION", 4, 13], ["highly", "OBSERVATION_MODIFIER", 46, 52], ["variable", "OBSERVATION_MODIFIER", 53, 61], ["anomalous", "OBSERVATION", 178, 187], ["infection", "OBSERVATION", 272, 281]]], ["Although the media (and also many specialists interviewed by media) highlight the velocity of infection in Italy as \"exponential\", the number of infected people has never followed an exponential distribution burring in the early days of the epidemic.", [["infection", "DISEASE", 94, 103], ["people", "ORGANISM", 154, 160], ["people", "SPECIES", 154, 160], ["infection", "PROBLEM", 94, 103], ["velocity", "OBSERVATION_MODIFIER", 82, 90], ["infection", "OBSERVATION", 94, 103], ["number", "OBSERVATION_MODIFIER", 135, 141], ["infected", "OBSERVATION", 145, 153], ["exponential", "OBSERVATION_MODIFIER", 183, 194], ["distribution", "OBSERVATION_MODIFIER", 195, 207]]], ["Figure 1a shows the number of recorded infections as a function of time (in days since 24 February 2020) in a semilogarithmic scale.", [["infections", "DISEASE", 39, 49], ["recorded infections", "PROBLEM", 30, 49], ["a semilogarithmic scale", "TREATMENT", 108, 131], ["infections", "OBSERVATION", 39, 49]]], ["30 March 2020 according to Protezione Civile (black dots) with logistic (blue solid line), exponential (red solid line), and cubic (green solid line) infection rates.", [["infection", "DISEASE", 150, 159], ["Protezione Civile (black dots", "TREATMENT", 27, 56], ["logistic (blue solid line", "TREATMENT", 63, 88], ["exponential (red solid line", "TREATMENT", 91, 118], ["cubic (green solid line) infection rates", "PROBLEM", 125, 165], ["solid line", "OBSERVATION", 108, 118], ["green", "OBSERVATION_MODIFIER", 132, 137], ["solid line", "OBSERVATION", 138, 148], ["infection", "OBSERVATION", 150, 159]]], ["Dotted black vertical lines mark the dates of Italian school lockdown and the nationwide total lockdown; the asterisk indicates that the exponential and the cubic fits are based on data until 12 March: score from Akaike Information Criterion (AIC) test (not reported) on logistic, cubic, and exponential fits shows higher reliability of the first two after this 30 March 2020 according to Protezione Civile (black dots) with logistic (blue solid line), exponential (red solid line), and cubic (green solid line) infection rates.", [["infection", "DISEASE", 512, 521], ["black vertical lines", "CELL", 7, 27], ["black vertical lines", "CELL_LINE", 7, 27], ["the exponential and the cubic fits", "PROBLEM", 133, 167], ["Protezione Civile (black dots", "TREATMENT", 389, 418], ["logistic (blue solid line", "TREATMENT", 425, 450], ["exponential (red solid line", "TREATMENT", 453, 480], ["cubic (green solid line) infection rates", "PROBLEM", 487, 527], ["black", "OBSERVATION_MODIFIER", 7, 12], ["vertical lines", "OBSERVATION", 13, 27], ["solid line", "OBSERVATION", 440, 450], ["solid line", "OBSERVATION", 470, 480], ["green", "OBSERVATION_MODIFIER", 494, 499], ["solid line", "OBSERVATION", 500, 510], ["infection", "OBSERVATION", 512, 521]]], ["Dotted black vertical lines mark the dates of Italian school lockdown and the nationwide total lockdown; the asterisk indicates that the exponential and the cubic fits are based on data until 12 March: score from Akaike Information Criterion (AIC) test (not reported) on logistic, cubic, and exponential fits shows higher reliability of the first two after this date and for the logistic against the cubic after 25 March 2020. (a) Fits obtained from the data in semi-logarithmic scale; (b) same data and fits shown in linear scale.", [["black vertical lines", "CELL", 7, 27], ["black vertical lines", "CELL_LINE", 7, 27], ["the exponential and the cubic fits", "PROBLEM", 133, 167], ["the data in semi-logarithmic scale", "TEST", 450, 484], ["black", "OBSERVATION_MODIFIER", 7, 12], ["vertical lines", "OBSERVATION", 13, 27]]], ["Fit parameters: Logistic (y = K 1+me xr 1+ne xr ; K = (135 \u00b1 2)\u00b710 3 , m = \u22121.4 \u00b1 0.2, n = 170 \u00b1 9, r = 0.174 \u00b1 0.003); Exponential (y = Ae Bx ; A = 410 \u00b1 30, B = 0.2 \u00b1 0.01; Cubic = a + bx + cx 2 + dx 3 ; a = \u221240 \u00b1 20, b = 36 \u00b1 8, c = \u22126.7 \u00b1 0.9, d = 0.44 \u00b1 0.03).", [["bx", "PROTEIN", 187, 189], ["Fit parameters", "TEST", 0, 14], ["Logistic", "TEST", 16, 24], ["K", "TEST", 30, 31], ["xr", "TEST", 37, 39], ["xr", "TEST", 45, 47], ["K", "TEST", 50, 51], ["m", "TEST", 71, 72], ["\u2212", "TEST", 75, 76], ["n", "TEST", 87, 88], ["\u00b1", "TEST", 95, 96], ["r", "TEST", 100, 101], ["Exponential", "TEST", 120, 131], ["Ae Bx", "TEST", 137, 142], ["A", "TEST", 145, 146], ["B", "TEST", 159, 160], ["Cubic", "TEST", 175, 180], ["bx", "TEST", 187, 189], ["cx", "TEST", 192, 194], ["dx", "TEST", 199, 201], ["a", "TEST", 206, 207], ["b", "TEST", 220, 221], ["c", "TEST", 232, 233], ["\u2212", "TEST", 236, 237], ["d", "TEST", 248, 249]]], ["Several countries as of 30 March, however, had lethality rates around 1-2% (Germany, USA, Austria, Portugal, Ireland, etc.).", [["lethality rates", "TEST", 47, 62]]], ["While the reported data refer to different stages of the spread of the epidemic, it is important to note that countries at a later epidemic stage than Italy are characterized by a CFR of less than 5% (for instance China, South Korea), indicating that the high value of the CFR observed in Italy is not a general characteristic of the epidemic.", [["a CFR", "TEST", 178, 183], ["the CFR", "TEST", 269, 276], ["epidemic", "OBSERVATION", 334, 342]]], ["It appears evident, therefore, that the CFR of Italy, and even more of Lombardia Region, is unusually high when compared to other countries.", [["the CFR", "TEST", 36, 43], ["Italy", "OBSERVATION_MODIFIER", 47, 52], ["unusually", "OBSERVATION_MODIFIER", 92, 101], ["high", "OBSERVATION_MODIFIER", 102, 106]]], ["This CFR is more than double thatof the CFR obtained in China, where the epidemic first appeared.", [["This CFR", "TEST", 0, 8]]], ["We propose that, in addition to the CFR, it is important to obtain a reasonable estimation of the IFR during the epidemic spread to understand the real hazard of the disease and/or to determine the true number of infected people.The IFR for COVID-19 and the Lethality in ItalyThe problem of unbiased estimation of the IFR for COVID-19 is complicated by the complex laboratory procedures that are necessary to identify the infected cases, ultimately limiting the total number of tested individuals.", [["Lethality", "DISEASE", 258, 267], ["people", "ORGANISM", 222, 228], ["people", "SPECIES", 222, 228], ["the disease", "PROBLEM", 162, 173], ["The IFR", "TEST", 229, 236], ["COVID", "TEST", 241, 246], ["COVID", "TEST", 326, 331], ["infected", "OBSERVATION", 213, 221], ["infected", "OBSERVATION", 422, 430]]], ["Since the IFR is the ratio between the number of deaths due to the disease and the total number of infected, the CFR, which is computed on the number of \"known\" infected is an upper limit of IFR.", [["deaths", "DISEASE", 49, 55], ["the IFR", "TEST", 6, 13], ["the disease", "PROBLEM", 63, 74], ["the CFR", "TEST", 109, 116], ["disease", "OBSERVATION", 67, 74], ["total", "OBSERVATION_MODIFIER", 83, 88], ["number", "OBSERVATION_MODIFIER", 89, 95], ["infected", "OBSERVATION", 99, 107], ["infected", "OBSERVATION", 161, 169], ["upper limit", "OBSERVATION_MODIFIER", 176, 187]]], ["Normally, CFR (and hence IFR) should be determined at the end of an epidemic, because death occurs at the end of the epidemic cycle.", [["death", "DISEASE", 86, 91], ["death", "PROBLEM", 86, 91]]], ["Usually, at the very beginning of an epidemic, the CFR can be underestimated because the individual outcome of the disease (recovery or death) has not yet occured.", [["death", "DISEASE", 136, 141], ["the CFR", "TREATMENT", 47, 54], ["the disease", "PROBLEM", 111, 122], ["death", "PROBLEM", 136, 141], ["disease", "OBSERVATION", 115, 122]]], ["For COVID-19, however, it was noted in China and in South Korea that CFR was generally higher in the first phase of the infection spread.", [["infection", "DISEASE", 120, 129], ["COVID", "TEST", 4, 9], ["CFR", "TEST", 69, 72], ["the infection spread", "PROBLEM", 116, 136], ["higher", "OBSERVATION_MODIFIER", 87, 93], ["first phase", "OBSERVATION_MODIFIER", 101, 112], ["infection", "OBSERVATION", 120, 129]]], ["A further problem is that the number of underestimated infected cases is generally variable and could become progressively more critical as the real number of infected rapidly rises with time while the number of tests remains stationary.", [["infected", "DISEASE", 55, 63], ["A further problem", "PROBLEM", 0, 17], ["underestimated infected cases", "PROBLEM", 40, 69], ["underestimated", "OBSERVATION_MODIFIER", 40, 54], ["infected", "OBSERVATION", 55, 63], ["infected", "OBSERVATION_MODIFIER", 159, 167], ["rapidly", "OBSERVATION_MODIFIER", 168, 175], ["rises", "OBSERVATION_MODIFIER", 176, 181]]], ["Mass testing in the village of Vo' Euganeo suggested that the number of asymptomatic persons infected by the SARS-CoV-2 is at least 50% [9] .", [["SARS", "DISEASE", 109, 113], ["persons", "ORGANISM", 85, 92], ["SARS-CoV-2", "ORGANISM", 109, 119], ["persons", "SPECIES", 85, 92], ["SARS-CoV", "SPECIES", 109, 117], ["Mass testing", "TEST", 0, 12], ["the SARS", "TEST", 105, 113], ["CoV", "TEST", 114, 117]]], ["From Table 1 , we observe that each country has a very variable CFR associated with the COVID-19 infection.", [["infection", "DISEASE", 97, 106], ["COVID-19", "SPECIES", 88, 96], ["a very variable CFR", "PROBLEM", 48, 67], ["the COVID-19 infection", "PROBLEM", 84, 106], ["infection", "OBSERVATION", 97, 106]]], ["Since the IFR is intrinsically overestimated by the CFR, presuming the virus strain is the same in every country, we can assume the minimum value of the observed CFR as the minimum upper limit for IFR.", [["IFR", "PROTEIN", 10, 13], ["the IFR", "TEST", 6, 13], ["the CFR", "TEST", 48, 55], ["the virus strain", "PROBLEM", 67, 83], ["virus", "OBSERVATION", 71, 76]]], ["Following this procedure, the University of Oxford used one of the minimum CFR values (around 0.4%) taken from Israel, Australia, and Iceland; then, to properly account for the undetected asymptomatics, they halved it to obtain an IFR of 0.2% [2, 10] .The IFR for COVID-19 and the Lethality in ItalyFor the COVID-19 epidemics, there is an independent way to obtain a rather unbiased estimate of IFR using the only \"laboratory-like\" case study: the Diamond Princess cruise ship anchored in the port of Yokohama from 4 February to 2 March.", [["this procedure", "TREATMENT", 10, 24], ["the minimum CFR values", "TEST", 63, 85], ["an IFR", "TEST", 228, 234], ["The IFR", "TEST", 252, 259], ["COVID", "TEST", 264, 269], ["the COVID", "TEST", 303, 312], ["port", "ANATOMY", 493, 497]]], ["All 3711 passengers and crew were tested, and 712 (19.2%) persons had positive test results.", [["persons", "ORGANISM", 58, 65], ["persons", "SPECIES", 58, 65], ["positive test results", "PROBLEM", 70, 91]]], ["Of these, 331 (46.5%) were asymptomatic at the time of testing, a similar value to the one obtained in Vo' Euganeo.", [["testing", "TEST", 55, 62]]], ["Among 381 symptomatic patients, 37 (9.7%) required intensive care, and 9 died [10, 11] .", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["Because the Diamond Princess is a perfectly isolated case in which the entire population was tested, the precise number of infected individuals is known, and we can crudely assume that IFR = CFR.", [["infected", "OBSERVATION", 123, 131]]], ["The crude IFR computed from the Diamond Princess is then 1.3%.", [["The crude IFR", "TEST", 0, 13]]], ["Moreover, CFR values even smaller than 1% in some countries (i.e., Australia, Norway, Israel) have been computed.", [["CFR values", "TEST", 10, 20], ["smaller", "OBSERVATION_MODIFIER", 26, 33]]], ["In the light of such derived lethality range, the observed CFR (11.3%) in Italy appears very abnormal and in particular the CFR in the Lombardia Region (16.1%) is anomalous.The IFR for COVID-19 and the Lethality in ItalyIn the discussion that follows, we try to point out the possible explanations for such an anomalous outcome.", [["Lethality", "DISEASE", 202, 211], ["the observed CFR", "TEST", 46, 62], ["very abnormal", "PROBLEM", 88, 101], ["anomalous", "PROBLEM", 163, 172], ["The IFR", "TEST", 173, 180], ["COVID", "TEST", 185, 190], ["an anomalous outcome", "PROBLEM", 307, 327], ["very", "OBSERVATION_MODIFIER", 88, 92], ["abnormal", "OBSERVATION", 93, 101], ["Lombardia", "ANATOMY", 135, 144], ["Region", "ANATOMY_MODIFIER", 145, 151], ["anomalous", "OBSERVATION", 163, 172]]], ["We assume that the virus strain is effectively the same in every country despite possible genome variations.", [["the virus strain", "PROBLEM", 15, 31], ["genome variations", "PROBLEM", 90, 107], ["virus", "OBSERVATION", 19, 24], ["possible", "UNCERTAINTY", 81, 89], ["genome variations", "OBSERVATION", 90, 107]]], ["The first, most obvious way to explain such a high lethality is to hypothesize that the number of infected cases was substantially underestimated.", [["infected", "DISEASE", 98, 106], ["a high lethality", "PROBLEM", 44, 60], ["infected", "OBSERVATION", 98, 106], ["substantially", "OBSERVATION_MODIFIER", 117, 130], ["underestimated", "OBSERVATION_MODIFIER", 131, 145]]], ["A clear sign of this is the fact that lethality increased from roughly 2% at the beginning (20 February 2020) to 11% on 30 March 2020.", [["lethality", "PROBLEM", 38, 47], ["clear", "OBSERVATION", 2, 7], ["lethality", "OBSERVATION_MODIFIER", 38, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57]]], ["During this period, the number of detected cases rose from few cases to around 100,000, whereas the daily number of laboratory tests changed from few hundreds to about 30,000.The IFR for COVID-19 and the Lethality in ItalyIn addition to the CFR, which is only linked to the recorded infection cases, it is important to understand the \"local\" IFR estimate for Italy in order to derive the real number of infected people.", [["Lethality", "DISEASE", 204, 213], ["infection", "DISEASE", 283, 292], ["people", "ORGANISM", 412, 418], ["people", "SPECIES", 412, 418], ["laboratory tests", "TEST", 116, 132], ["The IFR", "TEST", 175, 182], ["COVID", "TEST", 187, 192], ["the CFR", "TEST", 237, 244], ["few", "OBSERVATION_MODIFIER", 59, 62], ["infection", "OBSERVATION", 283, 292], ["infected", "OBSERVATION", 403, 411]]], ["Lacking evidence for the existence of a different virus strain that is somehow more aggressive and lethal in Italy, we assume that the IFR is the same as in other places and a consistent trait of the overall pandemic.", [["a different virus strain", "PROBLEM", 38, 62], ["the IFR", "TEST", 131, 138], ["overall", "OBSERVATION_MODIFIER", 200, 207], ["pandemic", "OBSERVATION", 208, 216]]], ["We could then choose between the University of Oxford estimate of IFR = 0.2% or the Diamond Princess laboratory-like estimation of IFR = 1.3%.", [["IFR", "TEST", 66, 69], ["IFR", "TEST", 131, 134]]], ["If the extreme lethality observed is only due to the underestimation of the number of infected people, assuming a \"true\" IFR ranging between 0.2% and 1.3%, to correct for the Italian 11.3% CFR, we should either multiply by 56.5 or by 8.7, the official number of infected cases (101,739 on 30 March 2020); the resulting number would then range between about 885,000 and 5.7 million infected people, respectively, with the higher extimate in agreement with one provided by the Imperial College [12] .", [["people", "ORGANISM", 95, 101], ["people", "ORGANISM", 390, 396], ["people", "SPECIES", 95, 101], ["people", "SPECIES", 390, 396], ["the extreme lethality", "PROBLEM", 3, 24], ["a \"true\" IFR", "TEST", 112, 124], ["extreme", "OBSERVATION_MODIFIER", 7, 14], ["lethality", "OBSERVATION", 15, 24], ["infected", "OBSERVATION", 86, 94], ["infected", "OBSERVATION_MODIFIER", 262, 270]]], ["We also note that the CFR of whole Italy is very similar to the 11% rate observed in hospital case reports [13] .", [["the CFR", "TEST", 18, 25]]], ["This can be explained by the tendency to only test hospitalized and severe cases excluding therefore mild and asymptomatic patients from the officially reported cases.The IFR for COVID-19 and the Lethality in ItalyWe cannot exclude, however, the possibility that the true IFR in Italy could be significantly higher than in other countries because of several concurrent reasons.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["severe cases", "PROBLEM", 68, 80], ["mild and asymptomatic patients", "PROBLEM", 101, 131], ["The IFR", "TEST", 167, 174], ["COVID", "TEST", 179, 184], ["the Lethality", "PROBLEM", 192, 205], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["significantly", "OBSERVATION_MODIFIER", 294, 307], ["higher", "OBSERVATION_MODIFIER", 308, 314]]], ["For instance, the higher average age of the Italian people has often been indicated as a possible explanation for the high COVID-19 CFR.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58], ["higher", "OBSERVATION_MODIFIER", 18, 24]]], ["Globally, Italy is ranked second highest in its population's average age; however, the top position (oldest population) is held by Japan, which showed a very low number of infections and CFR (see Table 1 ), thus this possibility alone appears unlikely.The IFR for COVID-19 and the Lethality in ItalyAnother possible cause of comorbidity could be related to the high level of pollution in the Lombardia region, as it is considered the most polluted region in Europe by fine particulate (PM10, PM2.5) and ozone.", [["infections", "DISEASE", 172, 182], ["Lethality", "DISEASE", 281, 290], ["PM10", "CHEMICAL", 486, 490], ["PM2.5", "CHEMICAL", 492, 497], ["ozone", "CHEMICAL", 503, 508], ["PM2.5", "CHEMICAL", 492, 497], ["ozone", "CHEMICAL", 503, 508], ["PM10", "SIMPLE_CHEMICAL", 486, 490], ["PM2.5", "SIMPLE_CHEMICAL", 492, 497], ["ozone", "SIMPLE_CHEMICAL", 503, 508], ["a very low number of infections", "PROBLEM", 151, 182], ["The IFR", "TEST", 252, 259], ["COVID", "TEST", 264, 269], ["the Lethality", "PROBLEM", 277, 290], ["comorbidity", "PROBLEM", 325, 336], ["Italy", "OBSERVATION_MODIFIER", 10, 15], ["ranked", "OBSERVATION_MODIFIER", 19, 25], ["second", "OBSERVATION_MODIFIER", 26, 32], ["highest", "OBSERVATION_MODIFIER", 33, 40], ["top", "OBSERVATION_MODIFIER", 87, 90], ["position", "OBSERVATION_MODIFIER", 91, 99], ["very", "OBSERVATION_MODIFIER", 153, 157], ["low number", "OBSERVATION_MODIFIER", 158, 168], ["infections", "OBSERVATION", 172, 182], ["appears unlikely", "UNCERTAINTY", 235, 251], ["comorbidity", "OBSERVATION", 325, 336], ["pollution", "OBSERVATION", 375, 384]]], ["As shown in several papers (e.g., [14, 15] ), there is a correlation between the diffusion of viruses and the pollution by fine particulate.", [["viruses", "OBSERVATION", 94, 101]]], ["Exposure to fine powders contributes to a higher severity in respiratory viral infections [16, 17] .", [["respiratory viral infections", "DISEASE", 61, 89], ["fine powders", "TREATMENT", 12, 24], ["a higher severity in respiratory viral infections", "PROBLEM", 40, 89], ["higher severity", "OBSERVATION_MODIFIER", 42, 57], ["respiratory", "ANATOMY", 61, 72], ["viral infections", "OBSERVATION", 73, 89]]], ["The incidence of fine particulate pollution could hence, in principle, be one of the reasons for the high lethality rate observed in Lombardia (and partially in Emilia-Romagna around the Po Valley).", [["Lombardia", "CHEMICAL", 133, 142], ["fine particulate pollution", "PROBLEM", 17, 43], ["the high lethality rate", "PROBLEM", 97, 120], ["fine", "OBSERVATION_MODIFIER", 17, 21], ["particulate", "OBSERVATION_MODIFIER", 22, 33], ["pollution", "OBSERVATION", 34, 43]]], ["Although the ability of this kind of pollution to amplify the lethality observed for a severe pulmonary disease seems reasonable, it is very difficult to quantify.", [["pulmonary", "ANATOMY", 94, 103], ["pulmonary disease", "DISEASE", 94, 111], ["pulmonary", "ORGAN", 94, 103], ["the lethality", "PROBLEM", 58, 71], ["a severe pulmonary disease", "PROBLEM", 85, 111], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["pulmonary", "ANATOMY", 94, 103], ["disease", "OBSERVATION", 104, 111]]], ["It is also very difficult to suggest that it can be significantly stronger than in other highly industrialized areas of Europe (Germany, France, Netherlands, etc.).", [["highly", "OBSERVATION_MODIFIER", 89, 95], ["industrialized", "OBSERVATION_MODIFIER", 96, 110]]], ["The Italian National Institute of Health (ISS), in a recent position statement [18] , specifies the association between air pollution and Covid-19 is still uncertain and not scientifically proven yet.The IFR for COVID-19 and the Lethality in ItalyOther tentative explanations for the extreme lethality could be the high number of smokers in Italy and the antibiotic-resistance of Italian people.", [["people", "ORGANISM", 388, 394], ["people", "SPECIES", 388, 394], ["air pollution", "TEST", 120, 133], ["Covid", "TEST", 138, 143], ["The IFR", "TEST", 200, 207], ["COVID", "TEST", 212, 217], ["the Lethality", "PROBLEM", 225, 238], ["the extreme lethality", "PROBLEM", 280, 301], ["the antibiotic", "TREATMENT", 351, 365]]], ["Regarding the percentage of smokers, however, Italy's 23% smoking rate is lower than the European average of 29% [19] .", [["smoking rate", "TEST", 58, 70]]], ["The antibiotic-resistance, moreover, is also claimed to be a critical factor.", [["The antibiotic", "TREATMENT", 0, 14], ["resistance", "OBSERVATION_MODIFIER", 15, 25]]], ["Of the roughly 33,000 annual deaths in the EU from antibiotic-resistant bacteria, a disproportionately high number of approximately 10,000 occur in Italy (ISSa, 2019).", [["deaths", "DISEASE", 29, 35], ["antibiotic", "TREATMENT", 51, 61], ["resistant bacteria", "PROBLEM", 62, 80], ["resistant", "OBSERVATION_MODIFIER", 62, 71], ["bacteria", "OBSERVATION", 72, 80], ["disproportionately", "OBSERVATION_MODIFIER", 84, 102], ["high", "OBSERVATION_MODIFIER", 103, 107], ["number", "OBSERVATION_MODIFIER", 108, 114]]], ["As therapies to combat the SARS-CoV-2 infection involve one or more antibiotics, this issue could result in higher lethality in Italy.", [["SARS-CoV-2 infection", "DISEASE", 27, 47], ["SARS-CoV-2", "ORGANISM", 27, 37], ["SARS-CoV-2", "SPECIES", 27, 37], ["therapies", "TREATMENT", 3, 12], ["the SARS", "PROBLEM", 23, 31], ["CoV", "PROBLEM", 32, 35], ["2 infection", "PROBLEM", 36, 47], ["antibiotics", "TREATMENT", 68, 79], ["higher lethality", "PROBLEM", 108, 124], ["higher lethality", "OBSERVATION", 108, 124]]], ["It is not easy to quantify this effect, however, which appears marginal in the normal seasonal flu outbreaks, during which the CFR for Italy is little different from that of other European countries [20] .", [["flu", "DISEASE", 95, 98], ["marginal", "OBSERVATION_MODIFIER", 63, 71], ["normal", "OBSERVATION_MODIFIER", 79, 85], ["seasonal", "OBSERVATION_MODIFIER", 86, 94], ["flu outbreaks", "OBSERVATION", 95, 108], ["little different", "OBSERVATION_MODIFIER", 144, 160]]], ["Moreover, the use of antibiotics in COVID-19 cases is intended to avoid bacterial superinfection rather than prevent death; hence, even if there was a more pronounced antibiotic resistance, this would account for only a marginal number of deaths [21] .", [["superinfection", "DISEASE", 82, 96], ["death", "DISEASE", 117, 122], ["deaths", "DISEASE", 239, 245], ["antibiotics in COVID", "TREATMENT", 21, 41], ["bacterial superinfection", "PROBLEM", 72, 96], ["death", "PROBLEM", 117, 122], ["a more pronounced antibiotic resistance", "PROBLEM", 149, 188], ["superinfection", "OBSERVATION", 82, 96], ["marginal", "OBSERVATION_MODIFIER", 220, 228]]], ["We can compare, for instance, the number of deaths directly or indirectly associated with seasonal flu (the number of indirect deaths is much more significant in this case, because it is mostly linked to bacteria super-infections) in Italy and in Germany (where COVID-19 CFR is about 1%).", [["deaths", "DISEASE", 44, 50], ["flu", "DISEASE", 99, 102], ["deaths", "DISEASE", 127, 133], ["infections", "DISEASE", 219, 229], ["seasonal flu", "PROBLEM", 90, 102], ["indirect deaths", "PROBLEM", 118, 133], ["COVID", "TEST", 262, 267], ["CFR", "TEST", 271, 274], ["flu", "OBSERVATION", 99, 102], ["more significant", "OBSERVATION_MODIFIER", 142, 158], ["infections", "OBSERVATION", 219, 229]]], ["The average yearly number of such deaths in Italy is around 8000 [22] ; in Germany, the deaths associated with the 2017-2018 flu, although very severe that year, totalled 25,000 [23] .The IFR for COVID-19 and the Lethality in ItalyAnother possibility is that the healthcare system was unprepared for such an emergency.", [["deaths", "DISEASE", 34, 40], ["deaths", "DISEASE", 88, 94], ["flu", "DISEASE", 125, 128], ["Lethality", "DISEASE", 213, 222], ["The IFR", "TEST", 184, 191], ["COVID", "TEST", 196, 201]]], ["Prior to the COVID-19 epidemic, Italy (60 million people) had approximately 5090 beds in intensive care units (ICU); by comparison, Germany (82 million people) had 28,000 beds.", [["people", "ORGANISM", 50, 56], ["people", "ORGANISM", 152, 158], ["people", "SPECIES", 50, 56], ["people", "SPECIES", 152, 158], ["the COVID", "TEST", 9, 18]]], ["We indeed observe high pressure on the ICU system by severe and critical cases, particularly in Lombardia, where the number of ICU beds before the crisis was 900; this number increased to over 1000, but, as of 30 March 2020, over 1300 patients were hosted in ICU facilities.", [["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 235, 243], ["high pressure", "OBSERVATION", 18, 31], ["severe", "OBSERVATION_MODIFIER", 53, 59]]], ["On 14 March, the government of Lombardia declared that almost all available ICU beds were filled and no remaining facilities existed.", [["ICU beds", "TREATMENT", 76, 84]]], ["Another indication that something went wrong during the first phase of management of the infection is the very high number (6414) of infected medical staff in the Lombardia hospitals [24] .", [["infection", "DISEASE", 89, 98], ["management", "TREATMENT", 71, 81], ["the infection", "PROBLEM", 85, 98], ["infection", "OBSERVATION", 89, 98]]], ["The hospitals themselves may have been the most effective transmitters of the virus in the first phase of rapidly increasing infections in Lombardia, as observed also in Wuhan [25] .Possible Forecast of Future Behaviour of InfectionIn order to forecast the evolution and the end of the COVID-19 epidemic in Italy, we could, in principle, use three kinds of data.", [["infections", "DISEASE", 125, 135], ["the virus", "PROBLEM", 74, 83], ["rapidly increasing infections in Lombardia", "PROBLEM", 106, 148], ["the COVID", "TEST", 282, 291], ["rapidly", "OBSERVATION_MODIFIER", 106, 113], ["increasing", "OBSERVATION_MODIFIER", 114, 124], ["infections", "OBSERVATION", 125, 135]]], ["The most obvious would be the daily infection rate data.", [["infection", "DISEASE", 36, 45], ["the daily infection rate data", "PROBLEM", 26, 55], ["infection", "OBSERVATION", 36, 45]]], ["They are generally very variable and inconsistent both within and between regions as well as over time.", [["very", "OBSERVATION_MODIFIER", 19, 23], ["variable", "OBSERVATION_MODIFIER", 24, 32]]], ["Since, as we noted, the real number of infections is likely much higher (by orders of magnitude) than the sampled number, the inhomogeneous sampling can strongly condition the number of infections and make them not useful for a statistical study.", [["infections", "DISEASE", 39, 49], ["infections", "DISEASE", 186, 196], ["infections", "PROBLEM", 39, 49], ["the inhomogeneous sampling", "PROBLEM", 122, 148], ["infections", "PROBLEM", 186, 196], ["a statistical study", "TEST", 226, 245], ["infections", "OBSERVATION", 39, 49], ["is likely", "UNCERTAINTY", 50, 59], ["much higher", "OBSERVATION_MODIFIER", 60, 71], ["inhomogeneous", "OBSERVATION_MODIFIER", 126, 139], ["infections", "OBSERVATION", 186, 196]]], ["Another possible indicator of the epidemic evolution could be the number of people in an ICU.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["possible indicator of", "UNCERTAINTY", 8, 29], ["epidemic", "OBSERVATION", 34, 42]]], ["Contrary to the number of people infected, the number of people in an ICU should be objective because only those with serious respiratory problems will be hospitalized with that level of care.", [["respiratory problems", "DISEASE", 126, 146], ["people", "ORGANISM", 26, 32], ["people", "ORGANISM", 57, 63], ["people", "SPECIES", 26, 32], ["people", "SPECIES", 57, 63], ["serious respiratory problems", "PROBLEM", 118, 146]]], ["However, in this phase of the epidemic crisis, this number has two major problems; the first is that the ICU capacity was overwhelmed, particularly in the hard hit area of Lombardia, hence not everyone in need of ICU hospitalization had access to it.", [["the epidemic crisis", "PROBLEM", 26, 45], ["the ICU capacity", "PROBLEM", 101, 117], ["ICU hospitalization", "TREATMENT", 213, 232], ["epidemic crisis", "OBSERVATION", 30, 45], ["major", "OBSERVATION_MODIFIER", 67, 72], ["problems", "OBSERVATION", 73, 81]]], ["The second problem is that the daily numbers given by Italian Civil Protection only mention the total number of people hospitalized in ICUs in that day and not the daily incremental number.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118]]], ["It is not possible, therefore, to know the real cumulative number of people hosted in ICUs, because we do not know how many people each day left them due to recovery or by death.Possible Forecast of Future Behaviour of InfectionThe only number that has rigorous statistical meaning, then, is the daily cumulative number of deaths.", [["death", "DISEASE", 172, 177], ["Infection", "DISEASE", 219, 228], ["deaths", "DISEASE", 323, 329], ["people", "ORGANISM", 69, 75], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 69, 75], ["people", "SPECIES", 124, 130], ["Infection", "PROBLEM", 219, 228], ["not possible", "UNCERTAINTY", 6, 18], ["Infection", "OBSERVATION", 219, 228]]], ["We choose to use this number in order to statistically analyse the evolution of the epidemic and to predict its end.", [["the epidemic", "PROBLEM", 80, 92]]], ["Obviously, since we are interested in determining the time at which the epidemic will end and the total number of infected people at the end of the epidemic, we have to correctly consider the relation of the daily cumulative number of deaths with the cumulative number of infected people.", [["deaths", "DISEASE", 235, 241], ["people", "ORGANISM", 123, 129], ["people", "ORGANISM", 281, 287], ["people", "SPECIES", 123, 129], ["people", "SPECIES", 281, 287], ["infected", "OBSERVATION", 114, 122], ["infected", "OBSERVATION", 272, 280]]], ["The number of deaths is linked to the number of infections by the IFR = D/I (D = deceased, I = infected); then, correcting the number of deaths for the constant factor represented by the inverse of IFR (I/D) gives the number of infected people.", [["deaths", "DISEASE", 14, 20], ["infections", "DISEASE", 48, 58], ["deaths", "DISEASE", 137, 143], ["people", "ORGANISM", 237, 243], ["people", "SPECIES", 237, 243], ["infections", "PROBLEM", 48, 58], ["the constant factor", "PROBLEM", 148, 167], ["infections", "OBSERVATION", 48, 58], ["infected", "OBSERVATION", 228, 236]]], ["However, we must also consider that infection and death are two temporal limits of the disease; it begins with infection, manifests symptoms, then ends with one of two possibilities: recovery or death.", [["infection", "DISEASE", 36, 45], ["death", "DISEASE", 50, 55], ["infection", "DISEASE", 111, 120], ["death", "DISEASE", 195, 200], ["infection", "PROBLEM", 36, 45], ["death", "PROBLEM", 50, 55], ["the disease", "PROBLEM", 83, 94], ["infection", "PROBLEM", 111, 120], ["symptoms", "PROBLEM", 132, 140], ["death", "PROBLEM", 195, 200], ["infection", "OBSERVATION", 36, 45], ["disease", "OBSERVATION", 87, 94], ["infection", "OBSERVATION", 111, 120]]], ["To account for this, we must consider the shift in time between infection and death.", [["infection", "DISEASE", 64, 73], ["death", "DISEASE", 78, 83], ["infection", "PROBLEM", 64, 73], ["death", "PROBLEM", 78, 83], ["infection", "OBSERVATION", 64, 73]]], ["For COVID-19, we estimate that the average time from infection to death in Italy is 16 days.", [["infection", "DISEASE", 53, 62], ["death", "DISEASE", 66, 71], ["COVID", "TEST", 4, 9], ["infection", "PROBLEM", 53, 62], ["infection", "OBSERVATION", 53, 62]]], ["This shift is computed as the sum of the median incubation time, estimated to be comprised between 4.8 and 7.1 days [26] [27] [28] , and the median time from symptoms onset to death, that is 10 days in Italy according to ISS [29] .", [["death", "DISEASE", 176, 181], ["symptoms", "PROBLEM", 158, 166], ["death", "PROBLEM", 176, 181]]], ["A similar time has also been observed in China when considering only patients over 70 years old [30] consistent with the median age of people who died in Italy due to the infection being 79 years [29] .", [["infection", "DISEASE", 171, 180], ["patients", "ORGANISM", 69, 77], ["people", "ORGANISM", 135, 141], ["patients", "SPECIES", 69, 77], ["people", "SPECIES", 135, 141], ["the infection", "PROBLEM", 167, 180], ["infection", "OBSERVATION", 171, 180]]], ["With such relations in mind between infections and deaths, we fit the cumulative number of deaths to a logistic function of the general form: y(t) = K 1+me \u2212tr 1+qe \u2212tr .", [["infections", "DISEASE", 36, 46], ["deaths", "DISEASE", 51, 57], ["deaths", "DISEASE", 91, 97], ["K", "TEST", 149, 150], ["\u2212tr", "TEST", 156, 159]]], ["To validate the use of this function, in Figure 2 , we show the fit made using a logistic function, to the epidemic curve of the cumulative daily number of cases (infections) reported in the whole China, Hubei province and China without the Hubei province [31]. consistent with the median age of people who died in Italy due to the infection being 79 years [29] .", [["infections", "DISEASE", 163, 173], ["infection", "DISEASE", 332, 341], ["people", "ORGANISM", 296, 302], ["people", "SPECIES", 296, 302], ["a logistic function", "TREATMENT", 79, 98], ["the infection", "PROBLEM", 328, 341], ["infection", "OBSERVATION", 332, 341]]], ["With such relations in mind between infections and deaths, we fit the cumulative number of deaths to a logistic function of the general form:Possible Forecast of Future Behaviour of InfectionTo validate the use of this function, in Figure 2 , we show the fit made using a logistic function, to the epidemic curve of the cumulative daily number of cases (infections) reported in the whole China, Hubei province and China without the Hubei province [31].", [["infections", "DISEASE", 36, 46], ["deaths", "DISEASE", 51, 57], ["deaths", "DISEASE", 91, 97], ["infections", "DISEASE", 354, 364]]], ["It is clear that, after the initial epidemic spread is over, the overall epidemic behaviour from the onset to end of infection can be well described by the logistic function.Possible Forecast of Future Behaviour of InfectionTo describe the evolution of the epidemic in Italy, as we explained, we decided to use the cumulative daily number of deaths to fit the logistic function because it is a much more reliable quantity when compared to the total reported cases.", [["infection", "DISEASE", 117, 126], ["deaths", "DISEASE", 342, 348], ["the initial epidemic spread", "PROBLEM", 24, 51], ["infection", "PROBLEM", 117, 126], ["clear", "OBSERVATION", 6, 11], ["infection", "OBSERVATION", 117, 126], ["epidemic", "OBSERVATION_MODIFIER", 257, 265]]], ["Figure 3a ,b shows the fits of the data for deaths reported in Italy (green), Lombardia (blue), and Italy without Lombardia (red) until 30 March 2020, with a logistic function and its derivative, respectively.", [["deaths", "DISEASE", 44, 50], ["deaths", "PROBLEM", 44, 50]]], ["After this date, the It is clear that, after the initial epidemic spread is over, the overall epidemic behaviour from the onset to end of infection can be well described by the logistic function.Possible Forecast of Future Behaviour of InfectionTo describe the evolution of the epidemic in Italy, as we explained, we decided to use the cumulative daily number of deaths to fit the logistic function because it is a much more reliable quantity when compared to the total reported cases.", [["infection", "DISEASE", 138, 147], ["deaths", "DISEASE", 363, 369], ["the initial epidemic spread", "PROBLEM", 45, 72], ["infection", "PROBLEM", 138, 147], ["clear", "OBSERVATION", 27, 32], ["infection", "OBSERVATION", 138, 147], ["epidemic", "OBSERVATION_MODIFIER", 278, 286]]], ["Figure 3a ,b shows the fits of the data for deaths reported in Italy (green), Lombardia (blue), and Italy without Lombardia (red) until 30 March 2020, with a logistic function and its derivative, respectively.", [["deaths", "DISEASE", 44, 50], ["deaths", "PROBLEM", 44, 50]]], ["After this date, the number of deaths remains high and perturbs the data near the peak and does not decrease as the curve would previously predict.", [["deaths", "DISEASE", 31, 37], ["the curve", "TEST", 112, 121], ["high", "OBSERVATION", 46, 50]]], ["If we separate the data of Lombardia from the rest of Italy, however, we see that the result is much more regular (red line, Figure 3b ).Possible Forecast of Future Behaviour of InfectionThe curves, the logistic, and the derivative are both well constrained in this case, and the peak value seems to have occurred on 27 March.", [["Infection", "DISEASE", 178, 187], ["Infection", "PROBLEM", 178, 187], ["the peak value", "TEST", 276, 290], ["Infection", "OBSERVATION", 178, 187]]], ["The anomaly of the data for Lombardia is even more evident by considering the data of Emilia Romagna Region, which is the second most affected region according to the official reports [8] .", [["Lombardia", "TEST", 28, 37], ["anomaly", "OBSERVATION", 4, 11]]], ["Figure 4a ,b shows in red the logistic fit (and its derivative) to the cumulative (and the new) number of deaths in Emila Romagna. number of deaths remains high and perturbs the data near the peak and does not decrease as the curve would previously predict.", [["deaths", "DISEASE", 106, 112], ["deaths", "DISEASE", 141, 147], ["Emila Romagna", "SPECIES", 116, 129], ["deaths", "PROBLEM", 141, 147], ["the curve", "TEST", 222, 231], ["deaths", "OBSERVATION", 141, 147], ["high", "OBSERVATION", 156, 160]]], ["The peak value occurs around 24 March 2020, consistent with this region being among the first where the infection began.", [["infection", "DISEASE", 104, 113], ["The peak value", "TEST", 0, 14], ["this region", "PROBLEM", 60, 71], ["the infection", "PROBLEM", 100, 113], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["consistent with", "UNCERTAINTY", 44, 59], ["infection", "OBSERVATION", 104, 113]]], ["Besides Emilia-Romagna, which represents a good example of a region in which the epidemic is already \"mature\" (in the sense that the peak of deaths has already passed), it is interesting to see what happens in one of the southern regions of Italy, for example, Calabria, where the infection presumibly started later.", [["deaths", "DISEASE", 141, 147], ["infection", "DISEASE", 281, 290], ["Emilia-Romagna", "ORGANISM", 8, 22], ["the infection", "PROBLEM", 277, 290], ["good", "OBSERVATION_MODIFIER", 43, 47], ["epidemic", "OBSERVATION_MODIFIER", 81, 89], ["infection", "OBSERVATION", 281, 290]]], ["It is clear that, since the epidemic here has not yet reached the peak value, the curves are poorly constrained, and the future evolution is still very uncertain.", [["clear", "OBSERVATION", 6, 11]]], ["The difference between Emilia-Romagna and Calabria curves illustrates well the different behaviours of the epidemic in the different regions and the difference between northern and southern regions.Possible Forecast of Future Behaviour of InfectionTo estimate the cumulative number of infections, we use several tentative values of IFR: the one computed from the University of Oxford, IFR = 0.2%; the one computed from the lethality on the Diamond Princess, IFR = 1.3%; and one much larger, IFR = 5.7%, in case the IFR for Italy would be much larger than in other countries due, for instance, to a rapid hospital and ICU saturation and/or high median age of people who died due to the infection (79 years) [29] .", [["infections", "DISEASE", 285, 295], ["infection", "DISEASE", 685, 694], ["Emilia-Romagna", "ORGANISM", 23, 37], ["people", "ORGANISM", 658, 664], ["people", "SPECIES", 658, 664], ["Emilia-Romagna", "TEST", 23, 37], ["Calabria curves", "TEST", 42, 57], ["infections", "PROBLEM", 285, 295], ["IFR", "TEST", 385, 388], ["IFR", "TEST", 458, 461], ["IFR", "TEST", 491, 494], ["the infection", "PROBLEM", 681, 694], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["Emilia", "OBSERVATION_MODIFIER", 23, 29], ["Calabria curves", "OBSERVATION", 42, 57], ["different", "OBSERVATION_MODIFIER", 79, 88], ["behaviours", "OBSERVATION_MODIFIER", 89, 99], ["epidemic", "OBSERVATION_MODIFIER", 107, 115], ["different", "ANATOMY_MODIFIER", 123, 132], ["regions", "ANATOMY_MODIFIER", 133, 140], ["difference", "OBSERVATION_MODIFIER", 149, 159], ["southern", "OBSERVATION_MODIFIER", 181, 189], ["infections", "OBSERVATION", 285, 295], ["larger", "OBSERVATION_MODIFIER", 483, 489], ["infection", "OBSERVATION", 685, 694]]], ["This IFR value was obtained considering the actual CFR computed by Italian authorities (11.3%) and taking into account the percentage of undiagnosed asymptomatic cases, which is found up to 50% by recent studies [9, 12, 26] .", [["This IFR value", "TEST", 0, 14], ["undiagnosed asymptomatic cases", "PROBLEM", 137, 167], ["recent studies", "TEST", 197, 211]]], ["Such a large range of IFRs for conversion is useful to check the final number of total infections but also to determine the portion of unreported cases in respect to the official numbers.Possible Forecast of Future Behaviour of InfectionIn order to estimate the total number of infected cases, we take the less-noisy data from Italy without Lombardia, but we normalize the number of deaths to be equal to the total Italian deaths (including the Lombardia data) at the last date (30 March 2020) .", [["infections", "DISEASE", 87, 97], ["deaths", "DISEASE", 383, 389], ["deaths", "DISEASE", 423, 429], ["total infections", "PROBLEM", 81, 97], ["the Lombardia data", "TEST", 441, 459], ["large", "OBSERVATION_MODIFIER", 7, 12], ["infections", "OBSERVATION", 87, 97], ["infected", "OBSERVATION", 278, 286]]], ["This procedure is used in order to remove the data scattering introduced by the Lombardia reported number of deaths without, on the other hand, underestimating the total number of infections.", [["deaths", "DISEASE", 109, 115], ["infections", "DISEASE", 180, 190], ["This procedure", "TREATMENT", 0, 14], ["infections", "PROBLEM", 180, 190], ["total", "OBSERVATION_MODIFIER", 164, 169], ["number", "OBSERVATION_MODIFIER", 170, 176], ["infections", "OBSERVATION", 180, 190]]], ["In Figure 5 , we report the fit of the estimated amount of total cases in all of Italy with the procedure that we just described.", [["the procedure", "TREATMENT", 92, 105]]], ["Logistic fit (y = K 1+me \u2212xr 1+ne \u2212xr ) parameters for the estimated (total and undetected) COVID-19 cases in Italy based on three different IFR hypotheses: 0.2% (blue and light blue dots), 1.3% (red and pink dots), and 5.7% (green and light green dots) (see Figure 5 ).", [["Logistic fit", "TEST", 0, 12], ["K", "TEST", 18, 19], ["\u2212xr", "TEST", 25, 28], ["COVID", "TEST", 92, 97], ["light blue dots", "TEST", 172, 187], ["red and pink dots", "TEST", 196, 213]]], ["In order to estimate the total number of infected cases, we take the less-noisy data from Italy without Lombardia, but we normalize the number of deaths to be equal to the total Italian deaths (including the Lombardia data) at the last date (30 March 2020) .", [["deaths", "DISEASE", 146, 152], ["deaths", "DISEASE", 186, 192], ["the Lombardia data", "TEST", 204, 222], ["infected", "OBSERVATION", 41, 49]]], ["This procedure is used in order to remove the data scattering introduced by the Lombardia reported number of deaths without, on the other hand, underestimating the total number of infections.", [["deaths", "DISEASE", 109, 115], ["infections", "DISEASE", 180, 190], ["This procedure", "TREATMENT", 0, 14], ["infections", "PROBLEM", 180, 190], ["total", "OBSERVATION_MODIFIER", 164, 169], ["number", "OBSERVATION_MODIFIER", 170, 176], ["infections", "OBSERVATION", 180, 190]]], ["In Figure 5 , we report the fit of the estimated amount of total cases in all of Italy with the procedure that we just described. (green and light green lines).", [["green and light green lines", "CELL_LINE", 131, 158], ["the procedure", "TREATMENT", 92, 105], ["light green lines", "OBSERVATION_MODIFIER", 141, 158]]], ["Blue and sky-blue solid lines represent logistic fits of total and undetected estimated cases with IFR = 0.2%, respectively.", [["solid lines", "CELL", 18, 29], ["sky-blue solid lines", "CELL_LINE", 9, 29], ["Blue and sky-blue solid lines", "PROBLEM", 0, 29], ["IFR", "TEST", 99, 102], ["blue solid lines", "OBSERVATION", 13, 29]]], ["Red and pink solid lines represent logistic fits of total and undetected estimated cases with IFR = 1.3%, respectively.", [["pink solid lines", "ANATOMY", 8, 24], ["pink solid lines", "CELL", 8, 24], ["Red and pink solid lines", "CELL_LINE", 0, 24], ["Red and pink solid lines", "PROBLEM", 0, 24], ["IFR", "TEST", 94, 97], ["pink", "OBSERVATION_MODIFIER", 8, 12], ["solid lines", "OBSERVATION", 13, 24]]], ["Green and light green solid lines represent logistic fits of total and undetected estimated cases with IFR = 5.7%, Figure 5 .", [["solid lines", "CELL", 22, 33], ["light green solid lines", "CELL_LINE", 10, 33], ["Green and light green solid lines", "PROBLEM", 0, 33], ["IFR", "TEST", 103, 106], ["light green", "OBSERVATION_MODIFIER", 10, 21], ["solid lines", "OBSERVATION", 22, 33]]], ["Estimated (total and undetected) COVID-19 cases in Italy based on three different infection fatality ratio (IFR) hypotheses: 0.2% (blue and light blue lines), 1.3% (red and pink lines), and 5.7% (green and light green lines).", [["infection", "DISEASE", 82, 91], ["COVID", "TEST", 33, 38], ["light blue lines", "TEST", 140, 156], ["pink lines", "TEST", 173, 183], ["infection", "OBSERVATION", 82, 91], ["pink lines", "OBSERVATION", 173, 183], ["green lines", "OBSERVATION", 212, 223]]], ["Blue and sky-blue solid lines represent logistic fits of total and undetected estimated cases with IFR = 0.2%, respectively.", [["solid lines", "CELL", 18, 29], ["sky-blue solid lines", "CELL_LINE", 9, 29], ["Blue and sky-blue solid lines", "PROBLEM", 0, 29], ["IFR", "TEST", 99, 102], ["blue solid lines", "OBSERVATION", 13, 29]]], ["Red and pink solid lines represent logistic fits of total and undetected estimated cases with IFR = 1.3%, respectively.", [["pink solid lines", "ANATOMY", 8, 24], ["pink solid lines", "CELL", 8, 24], ["Red and pink solid lines", "CELL_LINE", 0, 24], ["Red and pink solid lines", "PROBLEM", 0, 24], ["IFR", "TEST", 94, 97], ["pink", "OBSERVATION_MODIFIER", 8, 12], ["solid lines", "OBSERVATION", 13, 24]]], ["Green and light green solid lines represent logistic fits of total and undetected estimated cases with IFR = 5.7%, respectively.", [["solid lines", "CELL", 22, 33], ["light green solid lines", "CELL_LINE", 10, 33], ["Green and light green solid lines", "PROBLEM", 0, 33], ["IFR", "TEST", 103, 106], ["light green", "OBSERVATION_MODIFIER", 10, 21], ["solid lines", "OBSERVATION", 22, 33]]], ["Black dotted vertical lines mark the dates of Codogno area lockdown, Italian schools' lockdown, Lombardia lockdown, and Italy lockdown.", [["vertical lines", "CELL", 13, 27], ["Black dotted vertical lines", "CELL_LINE", 0, 27], ["Black dotted vertical lines", "PROBLEM", 0, 27], ["dotted", "OBSERVATION_MODIFIER", 6, 12], ["vertical lines", "OBSERVATION", 13, 27]]], ["Dark orange dashed vertical line marks the inflection points of the three curves representing the total infected estimates; magenta dotted vertical line marks the 95% of the plateau of the three curves.", [["vertical line", "CELL", 19, 32], ["Dark orange dashed vertical line", "PROBLEM", 0, 32], ["the total infected estimates", "PROBLEM", 94, 122], ["magenta", "TREATMENT", 124, 131], ["orange", "OBSERVATION_MODIFIER", 5, 11], ["dashed", "OBSERVATION_MODIFIER", 12, 18], ["vertical line", "OBSERVATION", 19, 32], ["total", "OBSERVATION_MODIFIER", 98, 103], ["infected", "OBSERVATION", 104, 112], ["vertical line", "OBSERVATION", 139, 152]]], ["Best fit parameters are listed in Table 2 .Total Estimated CasesThe different logistic curves (blue, red, and green) present in the figure are the estimated number of contagious people for the different IFR values of 0.2%, 1.3%, and 5.7%, respectively.", [["people", "ORGANISM", 178, 184], ["people", "SPECIES", 178, 184], ["the different IFR values", "TEST", 189, 213], ["contagious", "OBSERVATION_MODIFIER", 167, 177]]], ["From these values, we also subtract the number of cases reported by Italian Civil Protection to estimate the number of unreported contagious cases (light blue, pink, light green); the parameters obtained from the best fits are reported in Table 2 .Total Estimated CasesIt is evident that the number of reported infection cases is only a minor fraction of the estimated number of contagious people.", [["infection", "DISEASE", 311, 320], ["people", "ORGANISM", 390, 396], ["people", "SPECIES", 390, 396], ["the parameters", "TEST", 180, 194], ["infection", "OBSERVATION", 311, 320], ["contagious", "OBSERVATION_MODIFIER", 379, 389]]], ["In particular, for an IFR of 0.2%, 1.3%, and 5.7%, we estimate in the whole of Italy a total number of cases at 30 March 2020 (35 days from the first declared red zone) of about 8 million, 1.2 million, and 300,000, depending on the 0.2, the 1.3, and the 5.7% IFR values, respectively.", [["an IFR", "TEST", 19, 25], ["the 5.7% IFR values", "TEST", 250, 269]]], ["With a total number of reported cases of about 100,000, Italy might be strongly underestimating the total number of infected people (including asymptomatic and pauci-symptomatic persons) of 98.7%, 91.7%, or 63.7% depending on the IFR.", [["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["persons", "SPECIES", 178, 185], ["infected", "OBSERVATION", 116, 124]]], ["From the time dependence of the logistic function, we observe that the inflections of the respective curves are now exceeded by the data points no matter which conversion factor IFR is used.", [["IFR", "PROTEIN", 178, 181], ["the respective curves", "TEST", 86, 107]]], ["This probably means that Italy as a whole has already overcome the maximum number of new daily infections.", [["infections", "DISEASE", 95, 105], ["new daily infections", "PROBLEM", 85, 105], ["maximum", "OBSERVATION_MODIFIER", 67, 74], ["number", "OBSERVATION_MODIFIER", 75, 81], ["new", "OBSERVATION_MODIFIER", 85, 88], ["daily", "OBSERVATION_MODIFIER", 89, 94], ["infections", "OBSERVATION", 95, 105]]], ["In particular, the peak value of infections should have been reached around 11 March 2020, one week after the closing of schools and just after the lockdown of Italy.", [["infections", "DISEASE", 33, 43], ["the peak value of infections", "PROBLEM", 15, 43], ["peak", "OBSERVATION_MODIFIER", 19, 23], ["infections", "OBSERVATION", 33, 43]]], ["Moreover, our results predict that the 95% point of the maximum value of the best fitting logistic curves was reached in the last week of March.", [["the maximum value", "TEST", 52, 69], ["maximum", "OBSERVATION_MODIFIER", 56, 63]]], ["By the first week of April, the real number of contagious people was already well within the saturation thus ostensibly should not increase anymore.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["Finally, by tracking the dates when the logistic functions of the estimated number of contagious people have value 1, we can also obtain an estimate for the beginning of the epidemic in Italy.", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103]]], ["Depending on the used IFR, we find a starting date between 23 January and 30 January 2020, confirming the epidemiological data survey completed in Lombardia [5] .Total Estimated CasesIt is possible that, after the epidemic spread in Italy is over, growth functions different from the logistic such as Gompertz [32] , Janoschek [33] or Richards [34] sigmoids could be more suited to describe the epidemic spread because they allow their derivative to be non-symmetric and therefore can result in a more generalized integral function.", [["Janoschek", "TEST", 317, 326]]], ["A non-symmetric integral curve with a slower derivative in the descending part after the peak could result, for istance, from a differential shift of epidemic curves for different regions-particularly for the southern ones-due to the delay of the infection start in Lombardia.", [["infection", "DISEASE", 247, 256], ["A non-symmetric integral curve", "TEST", 0, 30], ["epidemic curves", "PROBLEM", 150, 165], ["different regions", "PROBLEM", 170, 187], ["the southern ones", "PROBLEM", 205, 222], ["the infection", "PROBLEM", 243, 256], ["descending", "ANATOMY_MODIFIER", 63, 73], ["infection", "OBSERVATION", 247, 256]]], ["When compared to the logistic function, a typical variation of these more generalized growth functions is the shift of the inflection point a few days later and the increase of the saturation value.", [["these more generalized growth functions", "PROBLEM", 63, 102], ["the saturation value", "TEST", 177, 197], ["generalized", "OBSERVATION_MODIFIER", 74, 85], ["growth", "OBSERVATION_MODIFIER", 86, 92], ["increase", "OBSERVATION_MODIFIER", 165, 173]]], ["It is evident nevertheless that, using such a curve to estimate the total number of infections, due to a much lower decay, the saturation would occur many days after, and the final, cumulative number of deaths (and of infected) would be much larger (more than 50% with this particular curve).DiscussionThe COVID-19 epidemic in Italy shows very abnormal features in terms of the severity of disease and its lethality rate.", [["infections", "DISEASE", 84, 94], ["deaths", "DISEASE", 203, 209], ["infections", "PROBLEM", 84, 94], ["a much lower decay", "PROBLEM", 103, 121], ["the saturation", "TEST", 123, 137], ["The COVID", "TEST", 302, 311], ["very abnormal features", "PROBLEM", 339, 361], ["disease", "PROBLEM", 390, 397], ["its lethality rate", "PROBLEM", 402, 420], ["infections", "OBSERVATION", 84, 94], ["larger", "OBSERVATION_MODIFIER", 242, 248], ["very", "OBSERVATION_MODIFIER", 339, 343], ["abnormal", "OBSERVATION", 344, 352], ["disease", "OBSERVATION", 390, 397]]], ["The CFR (defined as the ratio between the number of deceased and the number of recorded infected) in Italy reached very high values disproportional to those of other countries.", [["The CFR", "TEST", 0, 7]]], ["This CFR reached approximately 11% in the country overall with a rate of 16% in the Lombardia region, which represents half of the total recorded infections in Italy.", [["infections", "DISEASE", 146, 156], ["This CFR", "TEST", 0, 8], ["a rate", "TEST", 63, 69], ["the total recorded infections", "PROBLEM", 127, 156], ["approximately", "OBSERVATION_MODIFIER", 17, 30], ["11%", "OBSERVATION_MODIFIER", 31, 34], ["half", "OBSERVATION_MODIFIER", 119, 123], ["infections", "OBSERVATION", 146, 156]]], ["Estimating a reliable value of the IFR (the ratio between the number of deaths and the total number of infections) during the epidemic is very difficult due to the complex laboratory procedures required to diagnose it.", [["deaths", "DISEASE", 72, 78], ["infections", "DISEASE", 103, 113], ["the IFR", "TEST", 31, 38], ["infections", "PROBLEM", 103, 113], ["infections", "OBSERVATION", 103, 113]]], ["In this case, we considered three approaches: the first one, used by University of Oxford [2] , is based on the minimum reliable CFR values and assuming a 50% rate of non-recorded infections; the second one uses the unusual laboratory-like case study provided by the Diamond Princess cruise ship on which all passengers and crew (3771 people) were tested for SARS-CoV-2; a third one using the CFR computed by Italian authorities and assuming, as in the first case, that the detections have lost almost all asymptomatic and pauci-symptomatic individuals.", [["infections", "DISEASE", 180, 190], ["SARS", "DISEASE", 359, 363], ["people", "ORGANISM", 335, 341], ["people", "SPECIES", 335, 341], ["SARS-CoV", "SPECIES", 359, 367], ["non-recorded infections", "PROBLEM", 167, 190], ["SARS", "TEST", 359, 363], ["CoV", "TEST", 364, 367], ["the CFR", "TEST", 389, 396], ["infections", "OBSERVATION", 180, 190]]], ["University of Oxford computed a value of IFR = 0.2%.", [["IFR", "TEST", 41, 44]]], ["In the second approach, we considered that, on the Diamond Princess cruise ship, 712 infections were detected and 9 of them died.", [["infections", "DISEASE", 85, 95]]], ["This permits a mostly unbiased value of IFR = 1.3% to be calculated.", [["IFR", "TEST", 40, 43]]], ["In the third case, from a CFR = 11.3%, we computed an IFR = 5.7%.", [["a CFR", "TEST", 24, 29], ["an IFR", "TEST", 51, 57]]], ["We then consider these values as the limits defining the range of IFR.", [["these values", "TEST", 17, 29]]], ["If we assume that the infection number underestimation is the only reason for the large overestimation of the lethality rate, to determine the real number of infected cases and correct the apparent lethality to the true value, we should multiply the \"official\" number of recorded infections by the ratio between the CFR = 11.3% and the IFR (=0.2%, 1.3%, or 5.7%).", [["infection", "DISEASE", 22, 31], ["infections", "DISEASE", 280, 290], ["the infection number underestimation", "PROBLEM", 18, 54], ["the lethality rate", "PROBLEM", 106, 124], ["infected cases", "PROBLEM", 158, 172], ["the apparent lethality", "PROBLEM", 185, 207], ["recorded infections", "PROBLEM", 271, 290], ["the ratio", "TEST", 294, 303], ["the CFR", "TEST", 312, 319], ["the IFR", "TEST", 332, 339], ["infection", "OBSERVATION", 22, 31], ["large", "OBSERVATION_MODIFIER", 82, 87], ["overestimation", "OBSERVATION", 88, 102], ["infected", "OBSERVATION", 158, 166]]], ["In this way, we obtain a real number of infections in Italy (as of 30 March 2020) that ranges between about 0.3 and 8 million people infected ( Figure 5 ).DiscussionWhile this number appears very high in respect to the total number of reported cases of less than 90,000 in China (where, using the same assumption and the central IFR value, this amount should be multiplied by four), it is not unreasonable for several reasons.", [["infections", "DISEASE", 40, 50], ["people", "ORGANISM", 126, 132], ["people", "SPECIES", 126, 132], ["infections", "PROBLEM", 40, 50], ["infections", "OBSERVATION", 40, 50], ["very", "OBSERVATION_MODIFIER", 191, 195], ["high", "OBSERVATION", 196, 200]]], ["While a high number of tests have been completed in Italy (about 500,000), this is still only a small fraction of the total population (60 million people) and does not take into account the number of asymptomatic and pauci-symptomatic cases.", [["people", "ORGANISM", 147, 153], ["people", "SPECIES", 147, 153], ["asymptomatic and pauci-symptomatic cases", "PROBLEM", 200, 240], ["small", "OBSERVATION_MODIFIER", 96, 101], ["fraction", "OBSERVATION", 102, 110], ["total", "OBSERVATION_MODIFIER", 118, 123], ["asymptomatic", "OBSERVATION", 200, 212]]], ["This is also confirmed by observing that the CFR in Italy is very similar to the percentage of deaths detected in hospital cases [11] .", [["deaths", "DISEASE", 95, 101]]], ["The large number of potential daily infections in Italy during commutes to work or study can be also independently estimated by the statistics for the use of public transportation (the most likely to cause infection due to the high number of people assembled in small space).", [["infections", "DISEASE", 36, 46], ["infection", "DISEASE", 206, 215], ["people", "ORGANISM", 242, 248], ["people", "SPECIES", 242, 248], ["potential daily infections", "PROBLEM", 20, 46], ["public transportation", "TREATMENT", 158, 179], ["infection", "PROBLEM", 206, 215], ["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["potential", "OBSERVATION_MODIFIER", 20, 29], ["daily", "OBSERVATION_MODIFIER", 30, 35], ["infections", "OBSERVATION", 36, 46], ["infection", "OBSERVATION", 206, 215], ["small space", "OBSERVATION_MODIFIER", 262, 273]]], ["Before the epidemic spread and the lockdown measures, roughly 30 million people used to travel in Italy each day for work or study, with peak values in Lombardia [35] .", [["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["the lockdown measures", "TREATMENT", 31, 52], ["peak values", "TEST", 137, 148]]], ["Roughly 56% of these people use public transportation; two thirds of the total travel for more than 15 min.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27], ["public transportation", "TREATMENT", 32, 53]]], ["Considering only these people and not including gatherings of people in schools, work places, and occasional visits to restaurants, clubs, pubs, sport matches, theatres, supermarkets, etc., we get a minimum estimate of about 11 million people within close contact to one another each day.", [["people", "ORGANISM", 23, 29], ["people", "ORGANISM", 62, 68], ["people", "ORGANISM", 236, 242], ["people", "SPECIES", 23, 29], ["people", "SPECIES", 62, 68], ["people", "SPECIES", 236, 242]]], ["A final indication that the number of effective infected cases is not unrealistic comes from the exponential fit of the first days of infection ( Figure 1 ); by extrapolating that exponential curve to 30 March 2020, it would predict about one million infection cases.", [["infection", "DISEASE", 134, 143], ["infection", "DISEASE", 251, 260], ["effective infected cases", "PROBLEM", 38, 62], ["infection", "PROBLEM", 134, 143], ["effective", "OBSERVATION_MODIFIER", 38, 47], ["infected", "OBSERVATION", 48, 56], ["infection", "OBSERVATION", 134, 143], ["infection", "OBSERVATION", 251, 260]]], ["Obviously, such a hypothesis would assume that the exponential increase lasted until 30 March 2020 (or until a few days before) and that the real exponential curve was missed because the limited number of tests progressively sampled a smaller and smaller percentage of the true daily number.", [["the real exponential curve", "TEST", 137, 163], ["tests", "TEST", 205, 210], ["exponential", "OBSERVATION_MODIFIER", 51, 62], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["smaller", "OBSERVATION_MODIFIER", 235, 242], ["smaller", "OBSERVATION_MODIFIER", 247, 254], ["percentage", "OBSERVATION_MODIFIER", 255, 265]]], ["From any point of view, in conclusion, a real number of 0.3-8 million currently infected people does not appear unrealistic.DiscussionOther factors could also affect the very high lethality observed (as CFR); discarding the existence in Italy of a virus strain significantly different and more aggressive (a hypothesis impossible to verify because there is not yet the Italian genome available), a possible contribution could come from the relatively high air pollution (from particulate matter PM10, PM2.5, and ozone) of the area around the Po Valley, where more than 50% of counted infections are clustered.", [["PM10", "CHEMICAL", 495, 499], ["PM2.5", "CHEMICAL", 501, 506], ["ozone", "CHEMICAL", 512, 517], ["infections", "DISEASE", 584, 594], ["PM2.5", "CHEMICAL", 501, 506], ["ozone", "CHEMICAL", 512, 517], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["the very high lethality", "PROBLEM", 166, 189], ["a virus strain", "PROBLEM", 246, 260], ["the relatively high air pollution", "PROBLEM", 436, 469], ["counted infections", "PROBLEM", 576, 594], ["not appear", "UNCERTAINTY", 101, 111], ["unrealistic", "OBSERVATION", 112, 123], ["high", "OBSERVATION_MODIFIER", 451, 455], ["air pollution", "OBSERVATION", 456, 469], ["infections", "OBSERVATION", 584, 594]]], ["Among the other hypothesized causes, the high average age (however lower than Japan, which showed a much lower CFR) is not likely to play a fundamental role, nor is the number of smokers (lower than the EU average).", [["not likely", "UNCERTAINTY", 119, 129]]], ["The observed high antibiotic-resistance, the highest in Europe, has been also indicated as a possible contributing factor.", [["high", "OBSERVATION_MODIFIER", 13, 17], ["antibiotic", "OBSERVATION", 18, 28], ["resistance", "OBSERVATION_MODIFIER", 29, 39]]], ["This resistance results in the deaths in Italy of roughly one third (10,000 cases; double that of France and four times that of Germany) of the total deaths from antibiotic resistance in the entire EU (33,000 cases), yet it does not appear to significantly affect the lethality (CFR) associated with seasonal flu (the most reliable comparison we can do to infer the possible effect on COVID-19 lethality), which seems not significantly higher with respect to other European countries.DiscussionAnother issue that often comes out as a possible bias in the lethality estimates for Italy is the way of counting equally people dead \"with\" or \"by\" the infection.", [["deaths", "DISEASE", 31, 37], ["deaths", "DISEASE", 150, 156], ["infection", "DISEASE", 647, 656], ["people", "ORGANISM", 616, 622], ["people", "SPECIES", 616, 622], ["antibiotic resistance", "TREATMENT", 162, 183], ["the lethality", "PROBLEM", 264, 277], ["seasonal flu", "PROBLEM", 300, 312], ["COVID", "TEST", 385, 390], ["the infection", "PROBLEM", 643, 656], ["antibiotic resistance", "OBSERVATION", 162, 183], ["lethality", "OBSERVATION", 268, 277], ["infection", "OBSERVATION", 647, 656]]], ["We, however, do not think this question can seriously affect the data provided that only those who die for pulmonary collapse (or else for collapse of other organs following a serious pulmonary disease) are counted.", [["pulmonary", "ANATOMY", 107, 116], ["organs", "ANATOMY", 157, 163], ["pulmonary", "ANATOMY", 184, 193], ["pulmonary collapse", "DISEASE", 107, 125], ["pulmonary disease", "DISEASE", 184, 201], ["pulmonary", "ORGAN", 107, 116], ["organs", "ORGAN", 157, 163], ["pulmonary", "ORGAN", 184, 193], ["pulmonary collapse", "PROBLEM", 107, 125], ["collapse of other organs", "PROBLEM", 139, 163], ["a serious pulmonary disease", "PROBLEM", 174, 201], ["pulmonary", "ANATOMY", 107, 116], ["collapse", "OBSERVATION", 117, 125], ["serious", "OBSERVATION_MODIFIER", 176, 183], ["pulmonary", "ANATOMY", 184, 193], ["disease", "OBSERVATION", 194, 201]]], ["On the contrary, an interesting issue given the high selectivity of the disease towards older and/or multi-pathology people is to understand, at the end of the year, the total deaths caused cumulatively by all the seasonal diseases (flu, infections from antibiotic-resistant bacteria, walking pneumonia, .DiscussionA significant contribution to the increase of the \"local\" IFR could, on the contrary, have come from the saturation of the public hospitals, in particular from the limited number (as compared, for instance, to Germany) of ICU beds.", [["deaths", "DISEASE", 176, 182], ["flu", "DISEASE", 233, 236], ["infections", "DISEASE", 238, 248], ["pneumonia", "DISEASE", 293, 302], ["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123], ["the disease", "PROBLEM", 68, 79], ["the seasonal diseases", "PROBLEM", 210, 231], ["flu", "PROBLEM", 233, 236], ["infections", "PROBLEM", 238, 248], ["antibiotic", "TREATMENT", 254, 264], ["resistant bacteria", "PROBLEM", 265, 283], ["walking pneumonia", "PROBLEM", 285, 302], ["disease", "OBSERVATION", 72, 79], ["pneumonia", "OBSERVATION", 293, 302], ["increase", "OBSERVATION_MODIFIER", 349, 357]]], ["Italy before the COVID-19 epidemic had 8.4 ICU beds per 10,000 citizens (5090 ICU total), whereas Germany had 34 of them (28,000 ICU total).", [["the COVID", "TEST", 13, 22]]], ["Faulty actions taken by the public hospitals in managing the first days of infection (testified by many media and by a dramatic percentage of infected medical staff) could have significantly enhanced the infection.", [["infection", "DISEASE", 75, 84], ["infection", "DISEASE", 204, 213], ["Faulty actions", "PROBLEM", 0, 14], ["infection", "PROBLEM", 75, 84], ["the infection", "PROBLEM", 200, 213], ["infection", "OBSERVATION", 75, 84], ["infection", "OBSERVATION", 204, 213]]], ["As of 30 March 2020, 51 doctors had died and 6414 medical staff members have been infected, most of them in Lombardia (ISSb, 25 March 2020).", [["infected", "OBSERVATION", 82, 90]]], ["The anomalous behaviour of a persistently high number of deaths in Lombardia also suggests some problems in that region, which has the most critical numbers and where the infection started.", [["deaths", "DISEASE", 57, 63], ["infection", "DISEASE", 171, 180], ["some problems in that region", "PROBLEM", 91, 119], ["the infection", "PROBLEM", 167, 180], ["anomalous", "OBSERVATION_MODIFIER", 4, 13], ["behaviour", "OBSERVATION_MODIFIER", 14, 23], ["persistently", "OBSERVATION_MODIFIER", 29, 41], ["high", "OBSERVATION_MODIFIER", 42, 46], ["number", "OBSERVATION_MODIFIER", 47, 53], ["deaths", "OBSERVATION", 57, 63], ["some", "OBSERVATION_MODIFIER", 91, 95], ["problems", "OBSERVATION", 96, 104], ["infection", "OBSERVATION", 171, 180]]], ["Such problems likely include an insufficient sanitary system that was stressed above the critical point by the extreme numbers of people hospitalized (11, 883) or in ICUs (1324).", [["people", "ORGANISM", 130, 136], ["people", "SPECIES", 130, 136], ["Such problems", "PROBLEM", 0, 13], ["an insufficient sanitary system", "PROBLEM", 29, 60], ["insufficient", "OBSERVATION", 32, 44]]], ["One of the main criticisms in Lombardia, largely reported by media and also focused upon by some judicial inquiries, has been the transfer of COVID-19 patients in the RCH (Residential Care Homes, the long stay hospitals for old people, the terminally ill, and people with disabilities), which caused a large number of deaths [29, 36] .DiscussionIn this paper, we also use an indirect procedure based on the analysis of the cumulative number of deaths-the only reliable datum-to forecast the short-term evolution of the epidemic in Italy.", [["terminally ill", "DISEASE", 240, 254], ["deaths", "DISEASE", 318, 324], ["deaths", "DISEASE", 444, 450], ["patients", "ORGANISM", 151, 159], ["people", "ORGANISM", 228, 234], ["patients", "SPECIES", 151, 159], ["people", "SPECIES", 228, 234], ["people", "SPECIES", 260, 266], ["an indirect procedure", "TREATMENT", 372, 393], ["the analysis", "TEST", 403, 415], ["main", "OBSERVATION_MODIFIER", 11, 15], ["criticisms", "OBSERVATION", 16, 26], ["large", "OBSERVATION_MODIFIER", 302, 307], ["short-term", "OBSERVATION_MODIFIER", 491, 501], ["epidemic", "OBSERVATION_MODIFIER", 519, 527]]], ["As we discussed, the number of recorded infections is not statistically reliable for such analyses, as they are inhomogeneous in time and in space among different regions.", [["infections", "DISEASE", 40, 50], ["recorded infections", "PROBLEM", 31, 50], ["such analyses", "TEST", 85, 98], ["infections", "OBSERVATION", 40, 50], ["inhomogeneous", "OBSERVATION_MODIFIER", 112, 125]]], ["Considering the average time span from infection date to death (16 days), we show that lethality data converted to infection data using a large range of possible IFR are well fitted by logistic functions; this indicates that the 95% rate of total infection (i.e., the starting of the flattening of the function, which represents the end of infection) is expected near the last days of March.", [["infection", "DISEASE", 39, 48], ["death", "DISEASE", 57, 62], ["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 247, 256], ["infection", "DISEASE", 340, 349], ["IFR", "PROTEIN", 162, 165], ["infection", "PROBLEM", 39, 48], ["lethality data", "PROBLEM", 87, 101], ["infection data", "PROBLEM", 115, 129], ["total infection", "PROBLEM", 241, 256], ["infection", "PROBLEM", 340, 349], ["total", "OBSERVATION_MODIFIER", 241, 246], ["infection", "OBSERVATION", 247, 256], ["flattening", "OBSERVATION_MODIFIER", 284, 294], ["infection", "OBSERVATION", 340, 349]]], ["The point of inflection of the logistic best fitting functions, which corresponds to the peak of the infections in Italy, occurred around 11 March 2020 given the interval of confidence over the delay time from symptoms to death.", [["infections", "DISEASE", 101, 111], ["death", "DISEASE", 222, 227], ["the infections", "PROBLEM", 97, 111], ["symptoms", "PROBLEM", 210, 218], ["death", "PROBLEM", 222, 227], ["peak", "OBSERVATION_MODIFIER", 89, 93], ["infections", "OBSERVATION", 101, 111]]], ["Looking at Figure 5 , this date occurs just after the national lockdown of the Italy, and it demonstrates the successful mitigating impact of the lockdowns; however, since it also occurs only from 4 to 10 days after the closing of the schools, it probably indicates that this measure has also been effective in containing the infection.", [["infection", "DISEASE", 326, 335], ["the infection", "PROBLEM", 322, 335], ["probably indicates", "UNCERTAINTY", 247, 265], ["effective", "OBSERVATION_MODIFIER", 298, 307], ["infection", "OBSERVATION", 326, 335]]], ["Indeed, the high effectiveness of the closure of schools for containing epidemic spread has been specifically assessed by a number of epidemiologic studies (i.e., [37] ).DiscussionOur results also illustrate the shift of the infection curves between the northern regions where the infection started (i.e., Emilia-Romagna) and the southern Italian regions (i.e., Calabria) where, on 30 March 2020, the peak had not been reached yet and therefore the curves are still unconstrained and the future trends very uncertain.", [["infection", "DISEASE", 225, 234], ["infection", "DISEASE", 281, 290], ["the closure of schools", "TREATMENT", 34, 56], ["epidemic spread", "PROBLEM", 72, 87], ["epidemiologic studies", "TEST", 134, 155], ["the infection curves", "PROBLEM", 221, 241], ["the infection", "PROBLEM", 277, 290], ["the curves", "TEST", 445, 455], ["high", "OBSERVATION_MODIFIER", 12, 16], ["closure", "OBSERVATION", 38, 45], ["infection", "OBSERVATION", 225, 234], ["infection", "OBSERVATION", 281, 290]]], ["These results, based on the rate of casualties, further confirm that the infection data we record are dependent on variable and inhomogeneous sampling and not the true statistical evolution of the epidemic.", [["infection", "DISEASE", 73, 82], ["the infection data", "PROBLEM", 69, 87], ["inhomogeneous sampling", "TEST", 128, 150], ["the epidemic", "PROBLEM", 193, 205], ["infection", "OBSERVATION", 73, 82], ["epidemic", "OBSERVATION_MODIFIER", 197, 205]]], ["Looking at these very inconclusive data, it is clear that the increase or the decrease of new daily infections strongly depend on the number of tests performed.", [["infections", "DISEASE", 100, 110], ["new daily infections", "PROBLEM", 90, 110], ["tests", "TEST", 144, 149], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["decrease", "OBSERVATION_MODIFIER", 78, 86], ["new", "OBSERVATION_MODIFIER", 90, 93]]], ["This is an obvious consequence of the fact that the true number of infections is much larger than the small sample tested.", [["infections", "DISEASE", 67, 77], ["infections", "PROBLEM", 67, 77], ["true", "OBSERVATION_MODIFIER", 52, 56], ["number", "OBSERVATION_MODIFIER", 57, 63], ["infections", "OBSERVATION", 67, 77], ["much", "OBSERVATION_MODIFIER", 81, 85], ["larger", "OBSERVATION_MODIFIER", 86, 92], ["small", "OBSERVATION_MODIFIER", 102, 107]]], ["The conclusion that the epidemic in Italy is reaching saturation and is predicted to end within the first half of April, although obscured by the tested number of new infections, should be seriously considered in order to determine how and when to commence the next stages of the infection containment response.ConclusionsIn this paper, we analysed the COVID-19 epidemic in Italy, which was amongst the largest and the most lethal in the world.", [["infections", "DISEASE", 167, 177], ["infection", "DISEASE", 280, 289], ["new infections", "PROBLEM", 163, 177], ["the infection containment response", "PROBLEM", 276, 310], ["the COVID", "TEST", 349, 358], ["epidemic", "OBSERVATION_MODIFIER", 24, 32], ["new", "OBSERVATION_MODIFIER", 163, 166], ["infections", "OBSERVATION", 167, 177], ["infection", "OBSERVATION", 280, 289], ["largest", "OBSERVATION_MODIFIER", 403, 410]]], ["We discussed the causes of such anomalous behaviour of the disease in Italy, where lethality appears much higher than in other countries.", [["the disease", "PROBLEM", 55, 66], ["lethality", "PROBLEM", 83, 92], ["anomalous", "OBSERVATION", 32, 41], ["disease", "OBSERVATION", 59, 66], ["much", "OBSERVATION_MODIFIER", 101, 105], ["higher", "OBSERVATION_MODIFIER", 106, 112]]], ["Among the various hypotheses made to explain such anomalous behaviour, it appears that neither the older median age of the population nor the observed antibiotic-resistance of the population (by far the highest levels in Europe), nor even the smoking rate should have significant effects on the observed lethality.", [["smoking", "CHEMICAL", 243, 250], ["such anomalous behaviour", "PROBLEM", 45, 69], ["the observed lethality", "PROBLEM", 291, 313]]], ["The most reasonable effect would involve a strong underestimation of the extension of the infection (implying a factor 2.8 to 56.5 more cases than the tested ones).", [["infection", "DISEASE", 90, 99], ["the infection", "PROBLEM", 86, 99], ["a factor", "TEST", 110, 118], ["infection", "OBSERVATION", 90, 99]]], ["A possible further contribution could be given by the very high fine powder and ozone pollution in the Po Valley (one of the highest ones in Europe).", [["ozone", "CHEMICAL", 80, 85], ["ozone", "CHEMICAL", 80, 85], ["ozone", "SIMPLE_CHEMICAL", 80, 85], ["the very high fine powder and ozone pollution", "TREATMENT", 50, 95], ["the Po Valley", "TREATMENT", 99, 112], ["possible", "UNCERTAINTY", 2, 10]]], ["This could facilitate the virus transmission as well as make the lungs more vulnerable and stressed, causing heavier damages upon impact with the virus.", [["lungs", "ANATOMY", 65, 70], ["lungs", "ORGAN", 65, 70], ["the virus transmission", "TREATMENT", 22, 44], ["heavier damages", "PROBLEM", 109, 124], ["the virus", "PROBLEM", 142, 151], ["virus", "OBSERVATION", 26, 31], ["lungs", "ANATOMY", 65, 70]]], ["Another factor emerging from our analyses (as well as from media) that likely amplified lethality could have been the lack of preparedness and initial faults of the sanitization protocols in hospitals, particularly in Lombardia, where the epidemic first emerged.ConclusionsThe problem of underestimation of the number of infections coupled with inconsistent sampling and testing of the positive cases makes these data unreliable to use for statistics aimed to forecast the epidemic evolution.", [["infections", "DISEASE", 321, 331], ["our analyses", "TEST", 29, 41], ["the sanitization protocols", "TREATMENT", 161, 187], ["infections", "PROBLEM", 321, 331], ["testing", "TEST", 371, 378], ["the positive cases", "PROBLEM", 382, 400], ["infections", "OBSERVATION", 321, 331]]], ["Here, we use the cumulative daily number of deaths corrected for an appropriate IFR to simulate the evolution of the epidemic by a logistic function.", [["deaths", "DISEASE", 44, 50]]], ["When corrected for IFR and time shift between infection and death, these data can be well fitted by a logistic function and show that the epidemic started at the end of January, the actual peak of infection was reached around mid-March and the saturation of the curve (end of epidemic) is expected within the first week of April or a few days later.", [["infection", "DISEASE", 46, 55], ["death", "DISEASE", 60, 65], ["infection", "DISEASE", 197, 206], ["IFR", "TEST", 19, 22], ["infection", "PROBLEM", 46, 55], ["death", "PROBLEM", 60, 65], ["a logistic function", "TEST", 100, 119], ["the epidemic", "PROBLEM", 134, 146], ["infection", "PROBLEM", 197, 206], ["infection", "OBSERVATION", 46, 55], ["peak", "OBSERVATION_MODIFIER", 189, 193], ["infection", "OBSERVATION", 197, 206]]], ["The information presented here regarding the possible evolution of the epidemic and its likely end, which is not evident from the very incomplete sampling of the population, should be seriously considered in the decision-making process per measures to relax lockdown in the future.", [["the epidemic", "PROBLEM", 67, 79], ["not evident", "UNCERTAINTY", 109, 120]]], ["Equally, it is evident that a mass test campaign (for infection and for antibodies) is required to correctly understand and control the evolution of the epidemic.", [["infection", "DISEASE", 54, 63], ["antibodies", "PROTEIN", 72, 82], ["a mass test campaign", "TEST", 28, 48], ["infection", "PROBLEM", 54, 63], ["antibodies", "PROBLEM", 72, 82], ["the epidemic", "PROBLEM", 149, 161], ["mass", "OBSERVATION", 30, 34]]], ["The apparent effectiveness of school closures, probably the least invasive measure in a social and economic sense, should be further investigated by the government and considered as a primary measure.", [["school closures", "TREATMENT", 30, 45], ["invasive", "OBSERVATION_MODIFIER", 66, 74]]], ["The study of this unprecedented medical catastrophe will hopefully give robust indications to avoid, in the future, the same errors.", [["The study", "TEST", 0, 9], ["this unprecedented medical catastrophe", "PROBLEM", 13, 51]]]]}